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Having a human immune system is like having a life insurance. 
3 	
If it pays out it is too late. 
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This thesis focuses on the human immune system as the ultimate organ explaining the 
development of most, if not all, ‘typically Western’ chronic diseases. Patho-physiologically, 
the emphasis is on the development of ‘systemic low-grade inflammation’ (LGI). A red thread 
throughout this thesis is Charles Darwin’s (1809-1882) ‘adaptation to the conditions of 
existence’. We explain our physiology and functioning in the light of evolution, being the 
only approach that really ‘makes sense in biology’ (Theodosius Dobzhansky, 1900-1975). 
 
During millions years of evolution the immune system has saved simple organisms, such as 
the lamprey, and later on much more complex types of life, including humans and plants, 
although the latter make use of a much less complicated innate-like immune system that e.g. 
does not rely on mobile defence cells. Analogous to all other systems, the immune system has 
been adapted by evolutionary pressure to the benefit of survival and reproduction. There is 
good evidence to show that infection should be considered as the ‘roller coaster’ of evolution 
that shaped all forms of life, and humans in particular. Even today it are still infections by 
parasites, bacteria, fungi and viruses causing the most devastating conditions in humans. 
Contemporary examples are Zika in the America’s, ebola outbreak in Africa, HIV affecting 
millions of humans, salmonella infections worldwide and Aspergillus in intensive care units 
(Bellet 2013, Tyghe 2011, Wingard 2008).  
 
For example, about half of the world’s population is at risk of malaria infection, causing about 
438,000 deaths on a yearly basis (WHO http://www.who.int/features/factfiles/malaria/en/). 
The malaria parasite might be at least 200 million years old, as compared to the about 160,000 
years of homo sapiens. The battle between the two species has become intensified from 
about 80,000 years ago, i.e. long after homo sapiens started to leave Africa some 100,000 
years ago (Cserti 2007). According to Darwin’s ‘adaptation to the conditions of existence’ this 
battle has shaped both the genomes of Plasmodium and modern humans. Some examples of 
human adaptations by positive selection of polymorphisms are given in the Table 1 
(Kwiatkowsi 2005). At least some of these adaptations, like sickle haemoglobin, confer 
heterozygote advantage, also named balancing selection, with homozygotes exhibiting 
(serious) disease, while heterozygotes are not even fully protected. The existence of 
haplotypes witness the independence of the occurrence and preservation of the sickle 
haemoglobin mutation in at least 4 malaria-endemic regions in the world, adding to the 
notion of the very strong selective pressure that has and is still exerted by Plasmodium.  
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Table 1. Anti-malarial strategies related to malaria survival.  
Membrane proteins Duffy antigen (chemokine receptor functioning as 
recognition site, confers resistance to P. vivax). Glycophorin. 
Chloride/HCO3- exchanger (ovalocytosis). 
Blood group resistance: 0>B>A (South America 100% type 0). 
(Energy) metabolism Glucose-6-phosphate dehydrogenase (G6PD; higher RBC 
oxidative stress). 
Hemoglobin Hb structural variants (examples HbS, HbC, HbE). 
Thalassemias (notably alpha, beta). 
Haptoglobulin Binding of free Hb. 
Immunity, 
inflammation, adhesion 
Ag presentation (HLA), cytokines (ILs, interferon, TNF-
alpha), NO-synthase, adhesion molecules (ICAM1). 
 
Humans have conquered the world and survived their continuing search of novelty 
(Pruimboom 2015). Encountered challenges included e.g. climate, famine, thirst, but most of 
all infections (Nunn 2014). The corresponding evolutionary pressure triggered many 
phenotypic adjustments by either genetic or epigenetic modifications. As an example we 
mention 3 major strategies: 
 
1. A shift from strong to smart (Watve 2007), needed to ‘outthink’ much stronger animals 
and to guarantee food, water, shelter from cold and heat, protection from violence, and 
solutions for infections (Nunn 2014) 
 
2. A shift from strong to smart leading to the highest encephalization quotient among all 
animals (Roth 2005) and a change from present to future thinking through the 
development of a more dopamine-oriented neuroanatomy (Vernier 2004) 
 
3. A highly adequate-functioning immune system, though expensive, needed to survive 
pathogenic load and novel environmental challenges, prior to the institution of hygiene 
and modern medicine (e.g. antibiotics).  
 
A highly effective ‘somatic immune system’ has provided humans with many fitness benefits 
that are nevertheless endowed with important limitations and costs. A reactive pro-
inflammatory immune response is metabolically expensive; not only from a caloric point of 
view, but also from the view of nutrients, such as calcium and magnesium. Calcium, as signal 
transducer, is essential for adequate functioning of the immune system, muscles, brain and 
others. The immune system’s activation in general (Vig 2009), and more specifically of T-
cells, induces profound increases of intracellular calcium, needed to initiate the production of 
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cytotoxic substances and T-cell antigen receptor ligation. Sickness syndrome may 
accompany infection and the concomitant lack of mobilization causes loss of calcium from 
bones and augmented urinary calcium excretion, illustrating ‘use it or lose it’. The 
concomitant anorexia of severe infection causes long-term reduced intestinal calcium and 
magnesium intakes, and may, aggravated by vitamin D and K deficiencies, add to the 
negative calcium balance that ultimately results in osteopenia (Straub, J Intern Med 2010). 
 
Thus, the immune system’s actions can be highly debilitating and damaging in the face of its 
causation of sickness behaviour, cytotoxicity, fever, fatigue and micronutrient depletion, all 
of which may ultimately lead to multiple organ failure, including damage to the immune 
system itself. Prevention of immune responses are therefore of paramount importance. A 
unique part of the human immune system is the ‘behavioural immune system’ (Schaller 2011), 
since it aims at the predictable benefits of prevention. This system developed to avoid 
pathogen contact, thereby preventing an energy-costly reactive response and saving energy 
and resources for other essential organs, including the brain and the heart (Schaller 2011, Park 
2007).  
 
The human brain and the immune system have become so important for human physiology 
and evolutionary fitness that both systems have developed selfish behaviours by their 
capabilities to pull on energy and other resources, with the solemn purpose to maintain their 
own anatomies and optimal functioning (see for the selfish brain concept: Kubera 2012, 
Peters 2011, Peters 2009, Peters 2007, Peters 2004 and for the selfish immune system: Straub 
2014, Pruimboom 2015). Upon challenge, an optimal human response therefore depends on 
the flexibility to (re)distribute energy, and thereby in first instance prevent energy conflicts 
between the brain and the immune system. The circadian rhythm (Figure 1), allowing the 
brain to dominate daytimes and the immune system to exploit night times, illustrates how 
evolution shaped collaboration between these two highly selfish systems, while avoiding 
conflict (Straub 2011; Pacheco-Lopez 2011). The selfish behaviour of the immune system may, 
from a pathophysiological point of view, explain why LGI disturbs the functioning of many 
other organs, including the brain. LGI puts the immune system on top of hierarchic priorities 
as e.g. evidenced by the observation that the system even endorses breakdown of an essential 




Figure 1. Circadian fuel allocation.  
At daytime (A): the immunosuppressive stress hormones, cortisol and adrenalin, together with anti-inflammatory myokines, 
shut-off the immune system. At night (B): growth hormone, prolactin and melatonin,  secreted shortly after sleep onset, 
activate the immune system. Modified from Pacheco-Lopez (Philos Trans R Soc Lond Sci 2011). 
 
Known risk factors for LGI and chronic disease are age, smoking, socioeconomic status, 
obesity, chronic psychosocial stress, sedentary lifestyle, toxins, insufficient sleep, nutritional 
factors (nutrient composition, time, frequency) and abuse of legal and illegal drugs, alcohol 
included (Schmid 2015, Henson 2015, Ruiz 2014, Ruiz 2013, Egger 2012a, Egger 2012b, Egger 
2011). These, mostly environmentally-driven, risk factors seem inevitable in current Western 
societies and their shares and intensities are most likely destined to further increase in the 
future. Importantly, many of these risk factors exhibit interaction, while contemporary 
humans are likely to suffer from them in concert. This current ‘condition of existence’, occurs 
as opposed to the stress factors experienced by humans living in the environment of our 
ancestors. In that environment, they had to cope with short-term mono-metabolic danger 
factors (e.g. hunger, thirst, cold, heat), whereas modern humans are exposed to multi-
metabolic risk factors that stimulate an energy conflict between organs and major systems 
(Wells 2012). The ensuing conflict between what we currently experience and to what our 
genes are adapted is the basis of the so-called ‘mismatch hypothesis’ of ‘typically Western’ 
diseases. 
 
Mono-metabolic stress factors have shaped mechanisms for survival and reproduction, such 
as short-lasting infections, insulin resistance, activation of the sympathetic nervous system 
and others. All of these responses emerged with the purpose to first protect the brain from 
damage and energy deficits (Pruimboom 2011). Mono-metabolic challenge increases basal 
metabolic rate and frequent challenges in a resource-restricted (thrifty) environment prevent 
a pathological increase of adipose tissue size. A sizeable fat-mass in concert with other risk 
factors, is not unlikely to become an inflammatory compartment (Exley 2015). Multi-
metabolic risk factors may, on the other hand, cause LGI and a hypo-metabolic state (Wells 
2012).  The latter is probably the main reason for the deleterious effects of LGI, since a hypo-
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metabolic state causes energy deficits in multiple organs, and consequently multi-organ 
damage (Straub 2010).  
 
While among our ancestors, cold, heat, starvation and repetitive infections were major causes 
of death, exposure to mild cold, mild heat, short fasting periods and the regular consumption 
of small amounts of ‘toxic’ nutrients provided hormetic triggers. Mildly toxic insults, for 
example, derive from plant secondary metabolites, many with bitter tastes. The discovery of 
the nrf2 receptor has revolutionized toxicology by unveiling the benefits of low amounts of 
toxins (Bryan 2013, Hayes 2014; Forman 2014). Ultimately, it is all about hormesis: every dose-
response curve is U-shaped (Calabrese 2014), as opposed to the saturation curves that are 
usually depicted in textbooks and lectures, and is the first to pop-up when entered into 
Google-pictures. Establishment of ‘dietary reference intakes’ (e.g. AIs, RDAs, ULs) have for 
long used dose-response curves showing a range starting from deficiency, via adequacy, to 
toxicity, but the step to ‘what does not kill you makes you stronger’ has only recently become 
appreciated. This notion deserves rethinking of the definition of ‘essential nutrients’.  
 
Mild triggers might at least in part recover physiologic and metabolic dysfunctioning in 
patients suffering from ‘typically Western’ diseases (Mattson 2015). In other words: they may 
provide low-cost opportunities for secondary prevention. Conversely, the chronic absence of 
mild stress factors may have rendered modern 21st century humans less resistant to major 
toxic insults and susceptible to the development of many, ‘typically Western’, chronic 
diseases of affluence, including metabolic disorders, some types of cancer, depression and 
cardiovascular diseases (Mattson 2015, Calabrese 2015, Mattson 2014). Re-introduction of 
exposure provides low-cost opportunities for primary prevention with huge favourable 
potential for the society as a whole. Many changes in lifestyle are involved and their adoption 
is not necessarily unpleasant, as is frequently claimed. For instance, a recent study suggested 
that men taking sauna bathing sessions at a frequency of 4-7 times/week have 63% lower risk 
of all-cause and CVD mortality, compared with those having one sauna session/week. There 
was also a significant trend of lower fatal CVD mortality of 19 minutes sessions, compared 
with sessions lasting less than 11 minutes (Laukkanen 2015). A sauna session may be regarded 
as a mild, heat-based, stress factor with hormetic actions and broad protecting ability from 
the insults of the 21st century environment (Sarup 2014, Rattan 2009).  
 
Aim of the thesis 
The purpose of this thesis was to contribute to the notion that the human immune system 
may be selfish and perhaps even more selfish than the human brain. The exploitable part of 
this knowledge is that the triggering of the immune system’s selfish behaviour might be 
responsible for most, if not all, current chronic non-communicable diseases (CNCD), and that 
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a chronically activated immune system produces a long-term hypo-metabolic state.  
 
Along these lines, the aim of our field study (Chapter 3) was to show that metabolism and 
normal immunological functioning of contemporary humans can be recovered by ‘suffering’ 
from ancient mild stress factors, analogous to what our ancestors have experienced in the 
past, and as opposed to the LGI ensuing from modern life. We definitely do not propose to 
return to the ‘caveman’s life’, like popular ‘counterarguments’ tend to posit, but to exploit the 
positive effects of evolutionary-based lifestyle challenges to the benefit of our current health. 
The only realistic and affordable road to ‘healthy aging’ is comprised in the ‘adaptations to the 
past conditions of existence’ according to culture of the 21st century (Cordain 2005). For this 
we hypothesize that living a life with short-term mild stress factors could prevent metabolic 
diseases and LGI (primary prevention) and even cure patients suffering from CNCD, at least to 
some extent (secondary prevention). In other words: short-term mild stress factors may 
protect and even cure modern humans from the deleterious effects of Western lifestyle. 
 
Chapter 1 reviews LGI as the major cause of most, if not all, CNCD. Paragraph 1.1 describes the 
‘selfish immune system’ concept, as compiled from the existing scientific literature. 
Paragraphs 1.2 and 1.3 review the current lifestyle factors held responsible for the 
development of LGI and CNCD, respectively. In paragraph 1.4 we describe several pathways 
leading to LGI and ensuing from modern lifestyle factors. Paragraph 1.5 discusses the gluten 
in grains as a specific, uniformly present, nutritional factor that is likely to be involved in the 
development of LGI. Paragraph 1.6 discusses the background of genetic adaptations triggered 
by the consumption of non-human milk and starchy-rich foods, which are two recently 
introduced foods into homo sapiens’ diet. Our hypothesis in this paragraph may illustrate the 
widely misunderstood distinction between ultimate and proximate explanations of our 
physiology, that nevertheless in both explanations ensue from evolutionary pressure with the 
aim to survive and reproduce. The question here is not ‘how’ we adapted (proximate 
explanation) but ‘to what’ and ‘why’ (evolutionary approach). Chapter 2 deals with physical 
activity. Paragraphs 2.1 and 2.2 discuss the impact of sedentary lifestyle and a lack of physical 
activity on the developments of LGI and CNCD. Finally, in Chapter 3, we present our field 
study aiming to show that a concerted lifestyle ‘intervention’, based on what made us 
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Chapter 1. Chronic systemic low-grade inflammation 
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Abstract 
The brain and the immune system are the only two systems of the human body that can 
dominate all others by extracting resources, including glucose. The brain dominates during 
daytime hours and stressful situations, whereas the immune system protects us principally at 
night, during periods of infection and when wounds are healing. Both systems are similarly 
capable of drawing on energy and other essential resources using strategies beneficial to their 
own function and anatomy. Human evolution has made the brain the most important of the 
body’s systems, resulting in a shift from strong to smart. However, the immune system is very 
old and robust; when necessary it is activated by a variety of non-specific immune challenges 
such as psychoemotional stress and most often when immune activating risk factors 
(including endotoxemia) are not solved in an appropriate timeframe. When chronically 
activated, the immune system demonstrates even more selfish behaviour than the selfish 
brain, inducing chronic low-grade inflammation and multiple related diseases. But before 
castigating the immune system for this behaviour, it is crucial to recognise that it is only 
doing what it is made for: trying to protect us. 
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immune system; selfish brain; inflammation; evolution; stress; chronic disease; Alzheimer; 





1.1. The selfish brain and immune system in evolution 
Low-grade inflammation; the cause of causes 
Chronic inflammatory diseases (CID) are increasing in frequency, while treatments for these 
conditions are still in their infancy (1). Many of these diseases hardly existed 200 years ago (2) 
and proximate interventions addressing their genuine aetiologies have not been very 
successful (3). Chronic inflammation involves the innate and adaptive immune system (4), 
which can be considered very costly at the level of the use of resources, including energy (5), 
proteins and certain minerals, such as calcium (6) and magnesium (7-9). Long-term 
activation of the innate and adaptive immune system causes further maturation of antigen 
presenting cells (10). It is therefore plausible that low-grade inflammation is a direct cause of 
multiple diseases related with increased activity of the innate and adapted immune system 
including multiple autoimmune disorders and cancer. A recent meta analysis showed a linear 
association between C reactive protein (CRP), a marker for low grade inflammation and risk 
for breast cancer (11)). 
 
Physiological processes in all living organisms are direct consequences of evolutionary 
pressure promoting overall evolutionary fitness, defined as survival taking precedence over 
reproduction and direct survival/reproduction taking precedence over long-term 
survival/growth (12). Because of this precedence being set, injuries or atrophy of tissues such 
as skin, bone and tendons occur when resources needed for survival are scarce, including 
situations of starvation (13), and in times of energy depletion due to acute and even chronic 
inflammation (1). Many CIDs manifest at older age and therefore exert little selection pressure. 
Our ancestors had much lower life expectancies and rarely suffered from CIDs or the 
resulting adverse health consequences, and when they did this would hardly have affected 
survival and reproduction (14). Nevertheless, although inflammation can affect important 
organs such as the liver and liver inflammatory mechanisms are essential for the 
maintenance of liver health, it is important to note that even in these situations, hepatic 
gluconeogenesis is maintained during immune activation, providing the energy required for 
survival and reproduction (15, 16).  
 
During the preparation of this review, which started in 2008, other authors published the term 
“selfish immune system” and so we refere to those publications (17, 18). Nevertheless this 
paper has been written as original and focuses on total different insides of the selfish 
character of the immune system. The purpose of this review is to give evidence that the 
immune system overrides the brain in situations of low grade inflammation and that the 
dominance of the immune system is the major reason for the development of most if nota ll 
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chronic diseases. It is obvious that the comparance between a solid organ such as the brain 
and a circulatory organ such as the immune system is difficult. Nevertheless, if we do not 
consider anatomy, both Systems are perfectly comparable at the level of behaviour, health and 
disease  
 
1.2. Protective role of the immune system during human evolution 
Robust adaption to new environmental challenges involves epigenetic changes that 
influence rapid (epigenetic; individuals, some generations) and long-term (genetic; 
generations) adjustment of the phenotype, for instance by epimutation, single nucleotide 
polymorphisms and gene copy number variation (19, 20). Numerous environmental factors 
have shaped the human genome, including climate, food and microbial load (21). Although 
the first two challenges certainly show selective pressure in humans, the main selective 
pressure seems to derive from pathogens because of their high degree of potential lethality 
(22).  
 
When hominins began exploring new environments looking for food and scavenging, they 
were exposed to new pathogens. For example, dead meat, when spoiled, is a perfect source of 
pathogens such as Escherichia coli, Salmonella and other possible lethal microbes (23). The 
struggle to survive in new situations led to the development of an incredibly effective and 
robust immune system. The survival mechanisms evolved at least four times and entailed: 
upregulation of anti-inflammatory and anti-pathogenic strategies (24), spontaneous physical 
activity (25, 26), the development of a highly sophisticated behavioural immune system (27), 
and higher immunological reactivity, when compared with our evolutionary closest 
counterpart, the chimpanzee (28, 29).  
 
The higher reactivity of the immune system enabled the exploration of new environments 
and, when necessary, the ability to mount a massive innate immune response to prevent 
lethal infection (30). This response is extremely costly and would have hardly permitted the 
further brain growth observed in later hominins if the pro-inflammatory reaction to 
pathogens had prevailed over the needs of the brain on a chronic basis. The use of the first 
three strategies might have been necessary because of a much lower energetic cost, thus 
protecting against pathogenic load, without suffering from the possible secondary damaging 
effects of a pro-inflammatory strategy (31). It is therefore conceivable that the combination of 
these three strategies ‘liberated’ energy for larger brains and an expansion of brain functions.  
 
Failure of these three strategies (i.e. upregulation of anti-inflammatory and anti-pathogenic 
strategies, spontaneous physical activity and the development of a highly sophisticated 
behavioural immune system) necessitates a protective high-cost pro-inflammatory response 
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and the entire body is then at the disposal of the immune system; “prima vivere e dopo 
filosofare” (first live and then philosophise). This selfish behaviour of the immune system is 
observed not only in acute inflammation but also in chronic inflammation, the major 
difference between these two states being a shift from a hypermetabolic state to a 
hypometabolic state. Figures 1 and 2 show how the immune system puts the body at its 
disposal in acute inflammatory (Figure 1) and chronic inflammatory (Figure 2) states. 
Observing the actual pandemic increase of non-communicable diseases, we consider that it 
is this selfish behaviour of the immune system that causes the majority, if not all, of these 
diseases. Although the selfish immune system gave humans the ability to explore the entire 
world, it now seems to be responsible for most modern diseases, including cardiovascular 
disorders, autoimmune and neurodegenerative diseases.  
 
 
Figure 1. The immune/metabolic response during acute inflammation.   
The increased need for energy during acute inflammation causes a hypermetabolic state and allocation of resources, 
including proteins and minerals, to the immune system. Insulin levels are down-regulated by inhibition of pancreatic B-cells 
and glucose can be used by the immune system through development of adaptive insulin resistance of competing organs 
such as muscles, fat and liver. Short-term use of neurotransmitters by the immune system increases the activity level of the 
innate immune inflammatory response, ‘helping’ the need to mount an intense but optimal reaction that will resolve in a 
maximum of 4 to 7 days. Sickness behaviour induced by hyperleptinaemia and pro-inflammatory cytokines further saves 
energy, induces sleep and adaptive cachexia. The optimal IIS response is short-term and will moderately activate antigen-
presenting cells. The adaptive immune system will produce anti-inflammatory memory cells that can be recruited when the 
host encounters a different immune challenge of the same type. This adaptive immune response generally ends after a 
maximum of 27 days, leaving sufficient energy to maintain health of the organs disposed of during the start of the immune 
response. Resolving substances such as protectins and resolvins finish immune activation and homeostasis of the whole 




Figure 2. Chronic low-grade inflammation and hypometabolism.  
In the modern world, long-term pro-inflammatory activity of the immune system is frequently caused by anthropogenic 
factors and other conditions that challenge the immune system only weakly, but chronically. In normal situations any 
inflammation would produce a compensatory immune suppression, which is why low-grade inflammation needs a logical 
explanation. To maintain pro-inflammatory activity, the immune system itself puts the entire body at its disposal, but at the 
same time protects the body against multiple organ failure by inducing a hypometabolic state. Cortisol and noradrenaline 
induce gluconeogenesis and this extra glucose is allocated to the immune system by increasing insulin resistance of 
competing organs. At the same time, leptin reactivates the immune system, whereas brain regions associated with satiety 
develop leptin resistance, inducing increased food craving. Low thyroid hormone (rT3>T3) decreases total energy 
expenditure (protective hypometabolism) and rT3 is needed to fight pathogens. Nerve-driven immunity provides the 
immune system software (serotonin and dopamine) to maintain pro-inflammatory activity, whereas immune-suppressive 
mediators are down-regulated (cannabinoids and acetylcholine). Retraction of sympathetic fibres of inflamed/immune 
tissue and increase of sensory fibres are hardware strategies of nerve-driven immunity. Chronic pro-inflammatory activity is 
further maintained by a shift from an anti-inflammatory androgenic to a pro-inflammatory oestrogenic state in both males 
and females. The total picture of this ‘selfish immune system behaviour’ might be considered protective when it does not 
last too long; it is however highly deleterious when the human body starts developing all kinds of modern disorders such as 
autoimmune diseases, neurodegeneration and other maladies. Nevertheless, even today it is usually better to develop a 
CNCD than to die of cancer or infection.  
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1.3. Acute inflammation resolves itself; controlled resolution 
The immune system is self-regulating through negative biofeedback mechanisms, just like 
any other system in the human body. Acute inflammation induces the production of several 
substances responsible for finishing the immune reaction, including arachidonic acid 
derived lipoxins, EPA-derived protectins and DHA-derived resolvins (1), but only if the 
aforementioned fatty acids, notably the fish-derived fatty acids EPA and DHA,  are available in 
sufficient amounts (32-34). These substances decrease the activity of pro-inflammatory cells 
of the innate immune system and, at the same time, stimulate migration of phagocytizing 
macrophages to the danger zone/battlefield (35-37) 
 
Another more intrinsic negative biofeedback signal is lactic acid. The activated immune 
system uses (cytoplasmic) glycolysis as energy metabolism, in which 90% of glucose 
molecules are converted into lactic acid, a metabolic shift from mitochondrial oxidative 
phosphorylation (MOP) to cytoplasmic substrate level phosphorylation (SLP) (38). This 
metabolic shift seems counterintuitive when considering that only 2 molecules of ATP are 
generated from 1 molecule of glucose during SLP, whereas MOP yields 36 molecules of ATP. 
This is, however, conceivable in the light of the velocity of SLP, which is a hundred times 
faster than MOP (38, 39). 
 
A second benefit of SLP is that the glucose molecule is only partially used for ATP generation. 
Lactic acid and other macromolecules are metabolites of SLP that confer several favourable 
positive conditions during acute inflammation that guarantee cell division and cytokine 
production and render the immune system to a state independent of food and oxygen. The 
immune system’s capacity to engage in SLP is also known as the ‘Warburg effect’, which not 
only provides the immune system with fast energy, but also the precursor (glucose) needed 
for the synthesis of structural elements for the production of all DNA, RNA, organelles and the 
majority of cell membranes (for an excellent review, see 40). The oxygen-independent 
fermentation of glucose in the cytoplasm thus leads to the production of amino acids as 
precursors of proteins, (deoxy)ribose for DNA and RNA, glycerol for lipids and NADPH 
through the pentose phosphate pathway, needed for the production of phospholipids and 
glutathione (40). The activated immune system is now capable of growth and proliferation, 
largely without the need to uptake oxygen and building blocks. Considering the sickness 
behaviour associated with acute infectious disorders, characterised by cachexia {food 
absence} and even diaphragmatic breakdown {low oxygen} (41, 42), this makes sense.  
 
Lactic acid supports the role of lipoxins, resolvins and protectins in finishing the 
inflammatory response in a maximum of 4 to 7 days. Finishing the inflammatory response in 
time protects the body against possible deleterious secondary effects caused by the immune 
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system itself. Not only have intrinsic mechanisms emerged to end an acute inflammatory 
response, but brain-coordinated strategies, including the production of substances such as 
cortisol (43), certain cannabinoids (44), acetylcholine (45) and catecholamines (46, 47), are able 
to switch off the immune system. These inhibiting mechanisms are activated through 
coordinated processes during acute inflammation and the same holds true for the serotonin 
and dopamine pathways (see chapter ‘behaviour at the disposal of the immune system’). 
Observing the multiple mechanisms responsible for inhibiting the pro-inflammatory activity 
of the immune system, it can only be concluded that the inflammatory response should be 
finalised in time, leading to controlled resolution even after infection (48). 
 
Therefore, why is immune-inhibition absent when people suffer from weak inflammation 
caused by anthropogenic factors (AF)? AF activate the immune system through indirect 
pathways and causes a weak, ‘cold’ inflammation, without any of the typical signs of ‘hot’ 
inflammation (49). Usually adipocytes are activated by AF, such as high caloric food intake 
and psycho-emotional stress. Although this type of inflammation is not as strong, it still 
produces a metabolic shift of the immune system, giving rise to the production of substantial 
amounts of lactic acid, which serves as a potent immune suppressor through the creation of 
significant acidosis (50, 51). The question therefore remains how the immune system 
‘manages’ its activity for years and years, in spite of intrinsic and extrinsic mechanisms that 
inhibit the immune system and generally protect the body, but especially the selfish brain, 
against secondary damaging effects.   
 
We suggest that the immune system manages long-term activity by pursuing at least two 
strategies, firstly to achieve energy (glucose) and secondly to reactivate itself. The first strategy 
has to induce constant gluconeogenesis and energy allocation to the immune system and the 
second strategy has to reactivate the immune system. Pro-inflammatory immune system 
activity depends on several conditions. 1. Pro-inflammatory cytokines have to be produced 
through activation of the key regulator of the immune system being nuclear factor-κB (NFkB), 
2. Immune cell growth and cell proliferation depends on activation of the mammalian target 
of rhapamacin (mTOR), 3. cytoplasmic glycolysis is needed for the production of 
macromolecules and energy during immune activation and this requires the activation of 
hypoxia-induced factor-1 (HIF-1) and 4. The activated immune system demands large 
amounts of glucose and therefore a higher number of glucose transporters type 1, achieved 
by upregulation of c-myc (52-54).  
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Strategies used by the immune system to reactivate itself include: 
• Insulin resistance and high insulin levels 
• Leptin resistance and hyperleptinaemia 
• Low thyroid hormone syndrome 
• Catecholamine resistance of the immune system 
• Cortisol resistance of the immune system 
• Systemic androgens to oestrogens shift 
• Peripheral serotonin recruitment 
• Peripheral dopamine recruitment 
 
The majority of these different strategies are associated with sickness behaviour exhibited 
during acute infection (55). This behaviour is characterised by symptoms such as cachexia, 
fatigue, increased sleep and fever. It suggests that the activated immune system itself is 
responsible for fasting during infection and ‘senses’ that food will not be available under these 
conditions. The outcome is the mentioned shift from MOP to SLP, resulting in immune cell 
proliferation and activity becoming independent from food intake, all to enable the infection 
to be cured (56). Chronic activity of the immune system, during which the same metabolic 
shift occurs, would require a large amount of glucose, which is the basic energy fuel of the 
activated immune system and, of which, the limited availability constitutes the basic problem 
in chronic non-communicable diseases (CNCD) (56). This ‘nutrition-independent’ state may 
be responsible for the recently evidenced decrease in basal metabolic rate in chronic 
inflammatory disorders, rendering the subject vulnerable to the development of multiple 
metabolic disorders, including metabolic syndrome and diabetes mellitus type 2 (57). 
 
In summary, the metabolic shift observed in conditions of an activated immune system 
renders the system glucose-dependent and will therefore activate all strategies to maintain 
glucose homeostasis through systemic gluconeogenesis (43). The immune system can apply 
multiple strategies to maintain activity, although at a low level and puts the whole body at its 
disposal, including the brain, if necessary. This selfish behaviour has a protective effect 
during acute infection, but may have a dramatically deleterious effect in the long run, 
evidenced by the number of people suffering from CNCD in our society (58, 59). Low-grade 
inflammation should therefore be regarded as the cause for the majority, if not all, cases of 
CNCD. Treatment should therefore target the strategies used by the immune system to 
maintain its activity over a prolonged period of time. The only way to provide the correct 
treatment is to understand the ways the immune system puts the whole body at its disposal, 
which is the aim of this review. 
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1.4. The selfish immune system; brain damage leads to more brain damage 
caused by the immune system and overriding the brain as most dominant 
organ 
The immune system is one of the systems with a high level of biological robustness (60). 
Some diseases and their effects produced by the robust character of the immune system will 
not necessarily benefit the host, but that is the price to pay. We provide evidence that the 
mechanisms leading to pathologies affecting the whole body, including the brain, should be 
considered robust and part of the survival strategies developed during hominin evolution (61). 
 
The interactive neuro-endocrine-immune system evolved to cope with acute immunological 
challenges such as infection and wound healing, but is also activated by non-immunological 
danger for which it was not designed (2, 62). Theories explaining biological priorities 
consistently put the human brain in first place (63, 64). However, brain functions, blood 
circulation and anatomy are disrupted in those suffering from Alzheimer’s disease, 
Parkinson’s disease, fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS) and 
depression  (65-68), which suggests that certain pathophysiological processes override the 
protective behaviour of the selfish brain.   
 
FMS depression and Alzheimer’s disease (AD) are obviously not diseases of choice, but may 
rather reflect the involuntary alternative of suffering from a low energetic state leading to a 
non-permissive brain disorder (e.g. AD, depression and FMS), rather than dying from multiple 
organ failure (69-71) caused by a chronic activated pro-inflammatory immune system.   
 
Rogers (72) stated that “Inflammation seems useful when controlled, but deadly when it is not. 
For example, ‘head trauma may kill hundreds of thousands of neurons, but the secondary 
inflammatory response to head trauma may kill millions of neurons or the patient” and the 
same holds true for people who suffer a stroke (73, 74). The inflammatory response of the 
immune system causing severe secondary damage to the brain after traumatic brain injury or 
ischaemic stroke seems maladaptive in the face of the ‘selfish’ brain hypothesis. It would, 
however, correspond with the ‘selfish’ immune system hypothesis, which states that danger 
gives precedence to the immune system, and thereby overriding the selfish brain.  
 
It may even be the case that dramatic inflammatory response following brain injury is not 
caused by the injury itself, but by the presence of infectious pathogens. Pre-existing infection 
is present in one third of clinical ischaemic stroke patients  (75). Clinical data suggest that 
stroke risk peaks at three days after infection onset and that this risk remains high for three 
months (76). Almost three out of every four people in the world who suffer a fatal stroke live in 
developing countries and malaria, Chagas disease and Gnathostomiasis seem to be the major 
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causes for this surprising fact (77). Children and young adults are less susceptible to all-cause 
strokes with the exception of infectious stroke and diseases such as sickle cell disease. A 
recent case-control study revealed that pre-existing infection is an independent risk factor for 
stroke in 33% of affected children also in developed countries, such as the USA where 2,400 
children suffer from strokes every year (78). These data suggest that a possible pathogenic 
presence ‘programmed’ a severe pro-inflammatory immune response when the brain or the 
heart muscle are damaged. The selfish behaviour of the immune in these cases should be 
considered as adaptive but also possibly deleterious. Nevertheless the fact that people 
suffering from immune suppression after stroke are highly susceptible for sepsis and dead 
(79) suggests that the selfish behaviour of the immune system should be considered as 
needed when damage to the heart or the brain has been done. 
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2. It’s all about energy – The selfish immune system 
 
2.1. Robustness and energy reallocation between visceral organs, muscles, 
the immune system and the brain 
The immune system is one of the energetically most costly systems in humans when 
‘activated’. Consequently, immune metabolism has a profound effect on the functioning of 
the body. Metabolic conflicts between organs seem to explain the emergence of several 
disorders and, more specifically, modern non-communicable diseases such as autoimmune 
disorders (80).  
 
Anthropogenic danger signals, such as psychoemotional stress and sleep deprivation,  are 
capable of activating the immune system and a chronically activated immune system 
demands high energy, protein and immune-specific minerals such as calcium (2). Such high 
costs would never have permitted the development of the phylogenetic newer metabolic 
expensive brain in general and, more specifically, the neocortex during evolution. A recent 
review describes how exercise (searching for food, water and shelter) in primates and early 
hominids produced a shift from a pro-inflammatory immune reaction with a high metabolic 
demand to an anti-inflammatory response with a low metabolic demand (31). This shift made 
it possible to allocate energy to other organs e.g. the brain without large amounts of energy, 
proteins and minerals having to be invested in the immune system, whilst at the same time 
maintaining protection against microbes.  
 
2.2. Energy and energetic conflict as the driving force behind evolution 
Changes in energy allocation between organs are a consequence of energy conflicts that 
affect all animals, but non-human primates and humans in particular  (81, 82). Several 
scenarios have been proposed, with the brain being the organ to benefit from loss of colon 
length and high caloric dense food [the expensive tissue hypothesis] (81, 82)], a decrease in 
muscle mass, an increase in fat mass (49), cooking (83), human locomotion costing less 
energy (84) and, very recently, a change in the expression of glucose transporters beneficial to 
the brain (85). To our knowledge, as yet it has not been suggested that immune function may 
also have benefitted from a smaller gut, a lower energy demand for locomotion, an increase 
in fat mass and tissue-specific differences in the expression of glucose transporters. The latter 
entails a higher expression of GLUT1 in activated immune cells, when energy is needed to 
protect against pathogens and other immune challenges (86), at the expense of GLUT4 
expression in muscles and adipocytes (87-90).  
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The work of Fedrigo et al. (85) shows that glucose transport capacity has been essential for 
brain growth and function during human evolution. They demonstrated that human brain 
cells express more activity of the SLC2A1 gene, which is the genetic code for the production 
of GLUT-1 glucose transporters compared with the chimpanzee and macaque (human > 
chimpanzee > macaque). At the same time, SLC2A4 expression in muscle is significantly 
higher in chimpanzee > human > macaque.  
 
Logical reasoning makes it plausible that a concomitant per gram tissue reduction of SLC2A4 
in skeletal muscle and an increase of SLC2A1 in the brain will lead to higher glucose uptake by 
the brain at a given plasma glucose concentration. This would result in a shift of glucose 
allocation away from the body (strong) and towards the brain (smart).   
 
2.3. Glucose to the immune system – prioritising energy guidance 
Along a similar vein, the same holds true for glucose allocation to the immune system. The 
energy demand of lymphocytes and leukocytes increases dramatically upon activation (2, 4) 
and all activated immune cells express GLUT1 glucose transporters (86, 91). Higher expression 
of GLUT1 will promote energy allocation to the immune system, which could be considered 
to be an ‘energy demand reaction’ (92). Glucose allocation to the immune system maintains 
its function even under strong energy restriction (80).   
 
The foregoing demonstrates that activation of the immune system through danger signs will 
attract and redistribute energy, favouring the brain and the immune system.  Prolonged 
activation of the immune system (as has been observed in people with CIDs) would allocate 
glucose chronically to the immune system through immune-controlled down-regulation of 
GLUT1 transporters at the level of the blood-brain barrier and would decrease GLUT4 
transporters at the level of muscle and adipose tissue (93-96). 
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3. Evolution shaped the selfish immune system 
 
3.1. Evolution and the human selfish immune system - over-reactivity of the 
human immune system when compared with chimpanzees 
It has been shown that the human immune system is relatively over-reactive when compared 
with our closest evolutionary relative, the chimpanzee (97). The increased activity of the 
human immune system holds true for both the innate and the adaptive immune systems (98). 
It seems that all major cell groups of the human immune system show lower levels of 
mediators capable of down-regulation of the immune response against pathogens and 
phytohaemagglutinin (28). These mediators, called inhibitory sialic acid-recognising Ig-
superfamily lectins (SIGLEC), are expressed on most immune cells including B lymphocytes 
(99). The difference between chimpanzees and humans is three-fold. Firstly, humans express 
different SIGLECs; secondly, humans exhibit lower SIGLEC numbers and little or none are 
present on T lymphocytes, and thirdly, they show a lower production rate of inhibitory 
SIGLECs when challenged with pathogens or other immune stimuli (99, 100).  
 
The observed development of a more reactive immune response in humans is probably a 
consequence of being faced by unique immune challenges to numerous pathogens through 
scavenging, increased population density, hunting and migration (101, 102).  
 
3.2. The selfish brain is less selfish than the much more ancient immune 
system 
The brain is selfish in almost every situation, including mild and severe stress (103) and 
multiple studies support the ‘selfish brain’ hypothesis. Acute mild mental stress requires 12% 
additional energy from the human brain (104) and the same holds when humans are 
challenged by intense exercise (105). The group of Peters showed that social stress also 
augments the brain’s energy need  (106) and that the brain switches to the use of ketone 
bodies (107) and lactic acid (107) when glucose is unavailable. Therefore, several lines of 
research give evidence for the ‘selfish brain’ hypothesis in which it is stated that brain energy 
is maintained through multiple pathways, including activation of central stress axes and the 
use of multiple energy sources (glucose, ketone bodies, lactic acid). Immune activation also 
produces activity of central stress axes and a state of high arousal of the central nervous 
system, the purpose being to sense and avoid further danger (108). An acute inflammatory 
response produces energy allocation to the immune system until this is resolved, and only 
when the system is challenged by mono-metabolic danger signals (108). However, multi-
metabolic risk factors produce an energetic conflict between the immune system and the 
brain. The combined need for resources (energy-producing macronutrients, blood, oxygen) 
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of the stressed brain, of the activated immune system and of other organs responsible for 
maintaining organ functions during multiple metabolic signalling challenges, caused by 
psychogenic, psychosocial and physical factors at the same time, would probably override the 
maximum capacity of energy uptake by the gut and, although speculative, would demand a 
maintained heart rate of around 180/minute and a chronically increased blood pressure at 
around 160/120 mm Hg. This would lead to severe damage to the heart and probably the 
brain, which is contrary to the evolutionary drive of maintaining brain function and anatomy 
against at any cost (106). The only feasible response to maintain life throughout chronic 
situations of high energy demands of ‘conflicting’ organs, is the ‘creation’ of an organ-
specific low thyroid hormone syndrome and other adaptations with the purpose of lowering 
the activity of all organs and puts the body at the disposal of the immune system. This is 
evidenced by the development of immunological sickness behaviour, immunologically 
induced secondary damage of vital organs, protective depression, gluconeogenesis by the 
liver and kidneys, and the use of metabolic hormones and neurotransmitters by the immune 
system to benefit its pro-inflammatory activity and thereby protect against possible lethal 
pathogens (109, 110, 111, 112).  
 
It is definitely true that the brain ‘behaves’ selfishly in almost every situation, including an 
energy deficient intra-uterine environment. Nevertheless, although it seems that one of the 
most fundamental biological drivers in humans is supplying the brain with nutrients and 
energy, how is it possible for people to suffer from diseases related with lack of brain energy?’ 
Something has to be so wrong that it may even cause a reaction that overrides this interest 
and ‘accept’ the collateral damage to the selfish brain. Acute sepsis, severe burn wounds, 
multiple traumata and major surgery are known to allocate up to 100% of resting energy 
expenditure to the immune system, but these are acute situations which often lead to instant 
death, even in children (3, 4, 113-116). Neurodegenerative disease, fibromyalgia, and chronic 
fatigue disorders develop slowly and should therefore be caused by factors that demand long-
term energy allocation to systems other than the brain, e.g. the immune system, ultimately 
affecting the transport of resources to the selfish brain. Sedentary lifestyle, overeating, 
childhood abuse, oral sepsis, chronic life stress, leaky barriers, perceived social stress, 
environmental toxins, social jetlag, meal frequency and even father-daughter conflict all 
activate the immune system and an energy demand response based on activation of the SAM 
and HPA axes (117-121). This latter response should provide energy for, primarily, the brain 
and secondarily, the immune system. When brain allocation fails, brain functions and 
possibly anatomy will be disturbed. The latter occurs in people suffering from acute infection, 
but also in those suffering from Alzheimer’s disease, FMS, CFS, depression and other diseases 
affecting the central nervous system. It seems that multiple metabolic danger signals produce 
a state mimicking acute life threatening danger, allocating energy to the immune system and 
disposing of energy from the rest of the body, including the brain.  
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4. Genetic and environmental evidence supporting the 
hypothesis 
 
4.1. Genetic evidence for the selfish immune system hypothesis 
Depression and other maladies, including FMS and neurodegenerative disorders, such as 
Parkinson’s and Alzheimer’s diseases, are related to increased immune activity (122, 123, 124). 
All of these disorders seem to have a genetic predisposition and the majority of the genes 
related with neuro-degenerative disorders and depression influence the immune system. 
Raison hypothesised that if depression is related to certain polymorphisms, then these genes 
are primarily protective in the face of infection (for review see 125). The same holds for genes 
related to Alzheimer’s disease and FMS.  
 
The gene most widely accepted to be associated with Alzheimer’s disease susceptibility is 
ApoE 4 (apolipoprotein E4), although many others have been proposed as Alzgenes (126). 
Classical functions of apolipoprotein E relate to metabolism (transporter of lipids in the 
periphery and in the central nervous system (127)). More recently, it was found that ApoE 
influences the innate and adaptive immune systems (128). The overall influence of ApoE on 
the innate immune system is complex and depends on ApoE polymorphism. ApoE4 induces 
an inflammatory response, whereas ApoE3 inhibits inflammation and enhances repair (see 
references in 128). The pro-inflammatory activity of ApoE4 is classically seen as deleterious, 
but can also be considered protective in the light of the pathogen-host defence (PATHOS-D) 
hypothesis proposed by Raison and Miller (125). In our recent evolution, the share of the 
ApoE3 allele appears to have increased at the expense of the ancestral ApoE4 (129). ApoE3 has 
spread significantly in first world populations, whereas the prevalence of ApoE4 is still very 
high in cultures historically exposed to disease-causing pathogens (116, 130-132). The 
observation seems consistent with the protective role of ApoE4 against infection. The 
Yoruban population in Nigeria has a 70% lower incidence of dementia when compared to 
African Americans. This difference is probably caused by the lifelong low-fat diet of the 
Yorubans  (133).  
 
Candidate genes possibly associated with increased susceptibility to fibromyalgia syndrome 
have been reported, but no definite conclusions can be drawn as yet (134). The serotonin 
transporter gene SLC6A4 is perhaps the strongest candidate in terms of its relation to FMS (51, 
135, 136). Two major SLC6A4 polymorphisms have been identified. The short allele carrier 
produces a protein, which is less efficient in the reuptake of serotonin and carriers show an 
increased risk for the development of depression when facing psychosocial challenges. 
Carriers of the short allele further show higher levels of circulating pro-inflammatory 
cytokines compared with anti-inflammatory cytokines (IL-6/IL-10 rate) when challenged 
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with a psychosocial stressor (137).  
Another disease with an immunological genetic background is celiac disease. Celiac disease 
is caused by the intake of gluten and it’s interaction with a great number of genes, of which 
most are related with an increased reactivity of the immune system (138). More specific, it are 
alleles related with IL18, IL23, IL2 and IL12 that increase the susceptibility for celiac disease, 
but at the same time people expressing these genes are probably better protected against 
pathogens, including virus and bacteria (139) 
 
4.2. Pathogens shaped genetics to the benefit of the immune system and 
pathogen load prioritises the immune system over the brain 
If the PATHOS-D hypothesis is correct, that the microbial world is co-responsible for the 
chronically increased activity of the immune system and disposal of expensive brain 
functions, then pathogenic load should not only affect brain function and anatomy of older 
people, but also younger individuals. Evidence for this supporting the PATHOS-D hypothesis 
comes from studies investigating the development of intelligence during human evolution in 
general and, more recently, the past two hundred years. A recent study of Eppig (140) showed 
that infectious disease and the consequent immune activity is the most important predictor 
of lower intelligence in almost every population on earth. Nutrition was also correlated with 
IQ, but became insignificant when corrected for infection. The connection between 
pathogen load, infection and intelligence seems plausible considering the high energetic cost 
of infectious disease. (141).  
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5. Long -term immune activity: the need for reactivation and 
fuelling strategies 
 
5.1. Evolutionary stored energy limits the timescale of immune activity 
Both the innate and adaptive immune responses are normally self-limiting (142). The self-
limiting timeframe of 28 days is probably based on the energy-resource model. A (much) 
longer massive activity of both systems would lead to severe secondary damage and even 
death because of sustained energy deficit of vital organs including the liver, kidneys and heart 
muscle (143). Recruitment of the adaptive immune system, although very expensive at first 
exposure time (141), and the generation of immune memory, should be considered beneficial 
from an evolutionary point of view, because of the shortening of the immune response and 
protection against energy depletion, when the host is newly exposed to the pathogen (64). 
Chronic low-grade inflammation literally means long-term low activity of the innate immune 
system and lack of the production of self-limiting substances, such as resolvins and 
protectins (142). Chronic low-grade inflammation probably starts after a non-optimal acute 
inflammatory response (supranormal or subnormal) and when self-limiting mechanisms or 
strategies fail (143). Sterile wounds, low pathogenic load and non-specific immunological 
challenges such as psychogenic stress activate the immune system, but lack the strength of 
optimal immune activation which would normally lead to complete resolution (144). 
Nevertheless if the factors that activate the immune system in a subnormal manner are not 
resolved, the capacity to maintain immune activity is essential for survival, as evidenced in 
people suffering from inflammation-associated immune suppression. People suffering from 
inflammation-associated immune suppression (IAIS) are highly susceptible for the 
development of different types of cancer and secondary infections, and IAIS significantly 
increases the mortality rate (145, 146). IAIS is induced by immunological intrinsic (e.g lactic 
acid)., but also multiple brain derived strategies including the activation of the 
parasympathetic nervous system. This is where the immune system has to put the body at its 
disposal, thereby overriding the selfish brain. 
 
5.2. The consequence: the whole body at the disposal of the selfish immune 
system 
The way in which the immune system puts the body at its disposal might follow a 
coordinated sequence. The initial activation of energy demanding central stress axes allocates 
resources to the immune system through induction of gluconeogenesis and insulin 
resistance of competing organs, such as, bone, muscle, adipose tissue and the liver (1, 40). 
Once the innate immune system (maximum 4-7 days) and, when necessary, the adaptive 
immune system (27–42 days) has/have triggered the immune response, problems should 
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have been resolved. If immune activation is required for a longer period of time, this induces 
further insulin resistance/hyperinsulinemia, hyperleptinaemia/leptin resistance, and 
hypercortisolism/glucocorticoid resistance. The possible hypermetabolic state produced by 
the constantly activated immune system could cause multiple organ disorders, failure and 
even death (MODFD). The development of a low thyroid hormone state (rT3>T3) protects the 
body against MODFD, putting homeostatic regulation at the disposal of the immune system. 
The pro-inflammatory activity can also be maintained by higher aromatase activity and the 
production of pro-inflammatory oestrogens (see below): a further step in putting the whole 
body, including the reproductive system, at the disposal of the immune system.  
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6. Fuelling and reactivation strategies of the immune system 
 
6.1. Thyroid hormone prevents multiple organ failure during 
hypermetabolism and maintains immune homeostasis; thyroid hormone 
at the disposal of the selfish immune system 
Immune activity depends on aerobic glycolysis (147). It is only possible to maintain aerobic 
glycolysis when the intrinsic inhibitory pathways of the immune system can be overruled. 
Low T3 and high rT3 can maintain aerobic glycolysis in immune cells. Thyroid hormone T3 
induces mitochondrial activity in all kinds of cells, including immune cells (148). T3 can even 
strongly activate mitochondrial oxidation in cancer cells and render them more sensitive for 
chemotherapy (149). Intracellular T3 would therefore inhibit the inflammatory activity of the 
immune system, which would be highly deleterious during severe infection or other 
immunological challenges. Extracellular T4 and T3 are necessary for immune activation (150), 
but intracellular T4 is converted by deiodinase 3 (D3) into rT3 and T3 is rapidly downregulated 
by the same enzyme, preventing mitochondrial activation and maintenance of cytoplasmic 
substrate level phosphorylation through upregulation of D3 by the pro-inflammatory 
cytokine IL-6 (151). The final state is that of a low thyroid hormone syndrome (LTHS). 
 
LTHS does not only benefit the immune system, but is also protective against the possible 
secondary damage of chronic immune system activation. These rather deleterious effects of 
immune activation on other organs and tissues is prevented by down-regulation of the 
conversion of T4 into T3 both systemically and tissue specifically, causing the reduction of 
overall metabolic rate, but especially the activity of organs less important for direct survival 
during immune activity, such as muscle tissue, liver, kidneys, the heart muscle and the 
digestive system (152-154). The lower activity of these organs protects them against acute 
organ failure and sudden death of the host. The protection and lower metabolic rate is a 
product of low thyroid syndrome and high reverse T3 (rT3) (151). This state is protective 
initially, but can be deleterious in the long run (155).   
 
A recent discovery by the group of Klein and Schaefer has shed new light on the interaction 
between the immune system and metabolism. Their group proposed a new model of 
controlled metabolic regulation by an activated immune system (156-158). They showed that 
TSH can be produced by several tissues other than the thyroid gland. Dendritic cells (DCs) and 
several cells from the small intestine are capable of producing TSH and this happens mostly 
during bacterial or viral infection (159). Certain leukocytes also produce TSH, but with a 
slightly different structure and this hormone has been named TSHbeta splice variant (160). 
The TSHbeta splice variant seems to change the thyroid phenotype inducing a shift from T3 
to rT3. This shift decreases total body metabolism because of lower systemic T3 (159) and 
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initially saves the brain by continued conversion of T4 to T3 in the brain itself (161).  
 
The possible function of D3 expression in activated innate immune cells is intriguing. 
Thyroid hormones (TH) play a role in differentiation and proliferation of cells, with high T3 
inducing cell differentiation and low T3 inducing cell proliferation. Granulocytes are short-
lived, fully differentiated cells that migrate to the site of infection and do not proliferate, 
which may argue against a role for D3 induction in differentiation or proliferation of activated 
granulocytes. Studies in the 1960s suggested a role for thyroid hormone in the bacterial killing 
capacity of leukocytes. Iodide in combination with hydrogen peroxide (H2O2) provides one 
of the most effective antibacterial substances of the immune system. Thyroid hormones are 
an important source of iodide, and leukocytes generate inorganic iodide by the uptake of 
iodide and by de-iodinating T4, (162). In combination with the recent demonstration of D3 
induction in infiltrating leukocytes during infection, we suggest that D3 induction helps to 
generate iodide as part of the innate immune response (150). Studies in S. pneumonia-
infected D3 knockout mice indeed showed a defective bacterial clearance compared with 
wild-type mice, which supports this hypothesis (163). Further evidence is given by the work of 
Kwakkel et al, showing a dramatic increase of D3 production by neutrophils when challenged 
with bacterial LPS (164).  
 
The resulting state of immune activation, low T3, high rT3, combined with the energy 
demand reaction of the HPA axis and the sympathetic nervous system maintains 
immunological homeostasis during prolonged stress. The brain will maintain anatomy and 
function as long as brain metabolism can be guaranteed. The same holds for the immune 
system, although long-term stress and inflammation suppress immune activity (46). The 
latter situation could expose the host to possible infection and death. Protection of the host 
integrity will now depend on the use of alternative mechanisms to postpone this dangerous 
state whilst maintaining pro-inflammatory immune activity. This would be the time at which 
the immune system 1. puts every possible organ at its disposal to guarantee its own metabolic 
homeostasis, 2. induces resistance to hormones with pleiotropic immunological functions 
(leptin, insulin, cortisol) and 3. produces a state of nerve-driven immunity, putting almost all 
neurotransmitters, including dopamine, serotonin, acetylcholine, glutamate and GABA at its 
disposal (165-169). 
 
6.2. Gluconeogenesis and glucocorticoid resistance at the disposal of the 
immune system 
Endogenous cortisol has several effects on the immune system, including suppression 
through activation of the inhibiting factor kappa B (IkB) (170), apoptosis of immune cells that 
are no longer needed (171) and migration of immune cells to the so-called ‘battlefield’ 
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(dangerous zone) or back into the ‘barracks’ (lymph knots, bone marrow, thymus) (172) and 
through activation of macrophage migration activating factor (173). Intact cortisol signalling 
in the immune system would lead to suppression of the immune system, which is why 
immune cells show an intrinsic mechanism to develop cortisol resistance, which is essential 
during acute infection but at the same time co-responsible for low-grade inflammation (174). 
Glucocorticoid resistance (GR) of the immune system leads to hypercortisolaemia and 
constant gluconeogenesis. The glucose produced by GR-gluconeogenesis can cover the 
energetic needs of the selfish immune system. GR-gluconeogenesis can be induced in 
muscle, the liver, kidneys and perhaps even the pancreas (175-178). So GR serves two basic 
strategies to maintain immune activity: immunological GR prevents inhibition of the 
immune system and GR-induced hypercortisolaemia increases glucose production, 
necessary for the constant nourishment of chronic active selfish immune cells.  
 
Glucocorticoid resistance itself seems to protect the host against possible viral infection, 
including HIV, by maintaining high activity of the anti-viral Th1 component of the adapted 
immune system (179, 180), although GR can be highly deleterious (181). The GR observed 
during chronic inflammation is universal and mostly occurs along with another ancient 
protective mechanism: insulin resistance (182). Cells of the immune system show inherent 
genetically imprinted resistance mechanisms, which protect the body against the immune-
suppressive effects of glucocorticoids, although side-effects can be severe, including chronic 
leukaemia (174).  
 
GR is observed in rheumatoid arthritis, inflammatory bowel disease and COPD and is mostly 
considered deleterious (183). Treatment of these diseases normally focuses on increasing 
cortisol sensitivity (184) with contrasting results (1). Increasing GC-sensitivity can even lead to 
higher mortality when animals are challenged with pathogens such as E. Coli (185). If intrinsic 
or acquired GR conveys protection against pathogenic load, than asthma, rheumatoid 
arthritis and inflammatory bowel disease should be associated with increased pathogenic 
microbial load. Indeed, the group of Siala showed that reactive and undifferentiated 
oligoarthritis is associated with the presence of a high number of bacteria in the synovial fluid 
(186, 187). Patients with arthritis also show a high incidence of glucocorticoid resistance (188). 
Those with chronic asthma present higher bacterial colonisation of the lower airways, linked 
to the severity and duration of asthma (189), whilst GR is also a characteristic of asthmatic 
patients (190). Inflammatory bowel disease (IBD) normally evolves with pathogenic bacteria 




It therefore appears that GR prevents suppression of the innate immune system and the 
glucocorticoids-induced shift from Th1 to Th2 activity of the adapted immune system (192), 
thus maintaining protection against microbial infiltration and infection. GR serves the selfish 
immune system to maintain activity, nourish itself with glucose, but with just one purpose, 
which is to protect the individual from lethal infection. 
 
6.3. Leptin and insulin at the disposal of the selfish immune system 
Leptin and insulin are needed to maintain long-term activity of the immune system and the 
immune system itself increases the production of leptin by adipocytes via TNFα signalling 
(193). Leptin is highly inflammogenic (194) and hyperleptinaemia, together with central leptin 
resistance, maintains pro-inflammatory activity and energy allocation to the immune system 
(195, 196). Proinflammatory cytokines induce leptin production by adipocytes, as does food 
intake.  
 
Adipose tissue is present in immune-cell-harbouring tissues, such as lymphoid organs, bone 
marrow and adipocytes that infiltrate wounds (34) and so adipocyte derived leptin can have 
direct influence on immune cell functioning.  
 
Leptin activates all types of immune cells and increases glucose uptake during 
immunological activity. The principal target of leptin-induced immune cell reactivation is the 
key immune response regulator nuclear factor-κB, responsible for transcription of genes 
encoding for IL1, IL6 and TNFα (197). In summary, leptin activates the immune system 
through different pathways with a focus on the innate immune system and Th1. Under 
physiological circumstances, this leads to increased protection against infection and 
pathogenic growth. During low-grade inflammation, leptin should be considered to be a re-
activator, which can perpetuate immune activity. 
 
The strategies used by the immune system to maintain its activity and guarantee glucose 
availability could merely have evolved for their beneficial effects; a basic rule in evolutionary 
biology. This also holds true for the leptin and insulin responses observed during acute and 
chronic inflammation. The leptin response during inflammation supports different protective 
traits. Hyperleptinaemia during immune activity informs the brain about the adequacy of 
long-term energy stores in adipose tissue, asking for/demanding permission to produce a 
costly fever reaction and a short-term hypermetabolic state, following immune activation 
(198, 91). The hyper-leptinaemic state will also produce inflammatory cachexic behaviour, 
which is protective at the start when facing an acute inflammatory response, but could be 
deleterious when chronic, as is observed in patients and animals with chronic kidney 
inflammation (199).  
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Long-term hyperleptinaemia leads to central leptin resistance. Several researchers noted that 
hyperleptinaemia is required for the development of leptin resistance (200). Central leptin 
resistance is responsible for an increased risk of overeating (201) and overeating rapidly 
produces leptin resistance (202). Central leptin resistance can be considered to be an 
evolutionary advantage when energy availability is low, or when the need for energy is 
chronically increased as observed during prolonged immune activity (203). The beneficial 
effect of hyperleptinaemia and LR is observed in different situations. Hyperleptinaemia and 
LR protect against cardiovascular disorders by preventing lipid deposition in the heart muscle 
itself (204, 205), although recent publications have challenged this view (206). The influence 
of leptin on the anti-pathogenic function of the immune system has recently been 
demonstrated in two new studies from the same group (207, 208). Children with low leptin 
levels are more susceptible to infection (209). The required pro-inflammatory effect of leptin 
to fight against pathogens has also been demonstrated in a recent in vitro study (210). The 
overall effect of leptin on the immune system seems to be permissive, which implies that 
intact leptin-signalling towards the immune system maintains Th1-Th2 functioning and, if 
necessary, ‘permits’ pro-inflammatory activity (211).  
 
Like leptin, insulin is also recognised as a pleiotropic hormone. Energy demands of the brain, 
or the immune system during starvation, infection or stress are covered by gluconeogenesis 
and the temporary development of insulin resistance of various organs, caused by 
proinflammatory cytokines and stress hormones (212, 213). Energy allocation to the immune 
system is achieved by activating the energy-demand stress systems (sympatho-
adrenomedullary, axis, SAM and hypothalamic-pituitary-adrenocortical axis, HPA) and stress 
systems-induced gluconeogenesis. Hyperinsulinaemia precedes stress-induced and 
inflammation-induced insulin resistance (214). Hyperinsulinaemia is seen immediately after 
a stress challenge and/or direct immunological activators, such as injuries and pathogen 
invasion (215). Low insulin levels increase the susceptibility to develop infections, suggesting 
that insulin protects against pathogens (216). Acute inflammation produces down-regulation 
of insulin levels through inhibition of pancreatic β-cells (217) and also insulin resistance in 
competing organs for glucose uptake (such as liver, muscles and adipose tissue (212). In this 
way, glucose becomes available for the energy-demanding immune system. Chronic 
inflammation maintains the state of insulin resistance and enhances insulin production, 
leading to hyperinsulinemia (218). In the latter situation, glucose remains available for the 
immune system and insulin can now be used as reactivator through the mTOR pathway in 
immune cells, protecting against possible infections which is, however, deleterious in the 
long run (219). Insulin can also upregulate the specific glucose transporters on immune cells, 
including GLUT1, GLUT3 and GLUT4, thereby increasing glucose uptake by leukocytes and 
lymphocytes (220). Insulin signalling through insulin receptors on immune cells stimulate 
the IRS-1/PI3K/AKT pathway that activates mTOR1 and mTOR2 (221). mTOR signalling 
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recruits c-myc, NFkB and HIF1, facilitating further glucose uptake, production of pro-
inflammatory cytokines and maintenance of cytoplasmic aerobic glycolysis, respectively 
(222-224).  
 
It seems clear that leptin and insulin pathways are capable of fuelling and reactivating the 
immune system, not only during acute infection, but also to maintain long-term activation. 
The capacity of redistributing glucose to the immune system and away from peripheral 
tissues mediates the immune response and has been crucial to human survival. In other 
words: leptin and insulin signalling beneficial to immune system activity are vital for survival, 
and are  meanwhile also responsible for chronic low-grade inflammation and its associated 
diseases. 
 
6.4. The reproductive system at the disposal of the selfish immune system 
The combined metabolic shift produced at the disposal of the pro-inflammatory activity of 
the immune system is directly responsible for the pro-inflammatory systemic 
hypoandrogenic state observed in individuals suffering from low- grade inflammatory 
disorders (225). This systemic hypoandrogenic state is not produced because of lower 
testosterone production in the sex organs. To the contrary, obese males, characterised by 
increased plasma leptin and low-grade inflammation, exhibit a higher testosterone-
dependent risk of prostate cancer (226), while the same holds true for the polycystic ovaria 
syndrome in females (227).  
 
The testosterone boost produced by metabolic hormones precedes the increased systemic 
and tissue-specific conversion of testosterone into pro-inflammatory oestrogens. This shift 
has been observed in different diseases, including obesity and inflammation-related breast 
cancer (228).  
 
The systemic shift from testosterone to oestrogens could benefit the anti-pathogenic pro-
inflammatory activity of the immune system. Males with higher testosterone levels are more 
susceptible to parasite infection, microbial transmission (229) and have decreased resistance 
against tick infection (230). Conversely, low testosterone protects against bacterial infection 
in general and specifically against prostate infection (231). It is therefore conceivable, but at 
the same time striking, that both males and females exhibit higher aromatase activities during 
inflammation as evidenced in patients with rheumatic diseases, characterised by high pro-
inflammatory oestrogens and low testosterone levels (232). The protective effect of oestrogens 
against microbial infiltration and infection is supported by epidemiological data showing that 
postmenopausal women are disproportionately susceptible to recurrent urinary tract 
infections  (233). Urinary tract infections (UTI) in elderly patients are more treatment resistant 
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and oestrogen replacement diminishes UTI frequency (234). Chronic inflammation and stress 
lead to low testosterone and high oestrogens in men (235) and high oestrogen levels protect 
against possible infection.  
 
A possible negative effect of this shift from testosterone to oestrogen is the loss of fertility (41). 
Obese men, characterised by high aromatase activity in adipocytes (236) and low-grade 
inflammation (237), have lower fertility (238). Individuals engaged in a chronic struggle 
against pathogens rather not reproduce, preventing damage to offspring, which is beneficial 
to overall reproductive success (125). The septic danger posed by non-sterile wounds is 
included in the selective pressure factors shaping human behaviour (phenotype) and genome 
(genotype). It has been shown that the shift from testosterone to oestrogen in the skin is 
highly protective against pathogenic infection, prolonged infection, wound healing and 
overall cutaneous repair (239). It is consequently conceivable that the immune system also 
puts the reproductive system at its disposal. Immediate survival overrules reproduction. Once 
again, the immune system dominates the whole body, including the timing of reproduction 
and, if necessary, protecting genetically-related individuals against possible pathogenic 
damage, or damage to the immune system itself (240). Oestrogens activate the immune 
system through several mechanisms including stimulation of NFkB, c-myc and mTOR, 
facilitating immune cell proliferation and inflammatory activity (241). 
 
6.5. Behaviour at the disposal of the immune system: serotonin-dependent 
reactivation of the immune system 
The observed changes in behaviour during inflammation suggest that the immune system 
actively affects neurophysiological function, putting behaviour at its own disposal. Pro-
inflammatory cytokines such as TNFα, IL-1 beta, and IL-6 produce adaptive behavioural 
effects when entering the brain (55). Sickness behaviour includes social withdrawal, increased 
sleeping time, fatigue and exercise avoidance.  This reduces energy uptake by muscles and 
the brain and this is reallocated to the immune response. 
 
Several pathways explaining inflammation-induced sickness behaviour have been proposed 
and all of them probably contribute to this state (120). Sickness behaviour not only benefits 
the host’s immune system in terms of energy/resource reallocation, but also helps the 
immune system to fight pathogens and restore homeostasis when immune activity is no 
longer needed (55). Pro-inflammatory cytokines (IL1β, IL6, TNF-α and IFNy) and stress 
hormones, produced during inflammation, activate tryptophan 2,3-dioxygenase (TDO) and 
indoleamine 2,3-dioxygenase (IDO), affecting serotonin production from its precursor 
tryptophan and favouring the production of kynurenine and quinolinic acid (242) The 
resulting serotonin depletion is considered to be one of the factors causing sickness 
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behaviour (243), which, when considered from a proximate prospective, could be considered 
a maladaptive response. The latter is supported by showing that quinolinic acid, produced by 
cells in the central nervous system, is highly neurotoxic and associated with the development 
of numerous neurodegenerative conditions, including Parkinson’s and Alzheimer’s diseases 
(215).  
 
An evolutionary explanation for the underlying mechanism considers that upregulation of 
IDO and TDO during acute inflammation protects the host significantly by depleting 
tryptophan and efficiently suppressing the growth of pathogens and malignant cells (120). 
Serotonin further inhibits activation of the sympathetic nervous system (244), while SNS is 
needed for energy production and its allocation to the brain and the immune system during 
inflammation. Inhibition of serotonin production during inflammation will therefore favour 
SNS activity and energy production/allocation to the immune system.  
 
Serotonin is present in high concentrations at the sites of inflammation and is used by 
activated immune cells as co-stimulator through reuptake via the serotonin transporter 
protein (245). This is beneficial, considering the need to mount an optimal immune response 
during inflammation, but could be deleterious in the long run and cause several disorders 
including autoimmune diseases (245). IDO will not only deplete tryptophan but also serotonin 
and both pathways will inhibit the immune system activity when it is no longer needed, 
thereby recovering tissue homeostasis and facilitating tissue repair. A feeling of sickness and 
even pain are common consequences of this highly effective neuroimmunological reaction 
but that is the price to be paid (246). 
 
The total picture of inflammation-caused sickness behaviour should be considered beneficial 
to the host. Only when inflammation is supramaximal, such as in sepsis, or when 
inflammation lasts too long, sickness behaviour has more of a negative impact because of the 
possible damage caused by immune system dependent pathways. These deleterious effects to 
the brain show that, if necessary, the immune system will take over and override the interests 
of the selfish brain, supporting the ‘selfish immune system’ hypothesis. 
 
6.6. Behaviour and immune system co-evolution: dopamine-dependent 
reactivation of the immune system  
The use of dopamine as an immunological co-stimulator has been studied extensively and is 
of high clinical importance (247). Dopamine recruitment by the immune system has 
profound effects on inflammatory behaviour. Humans have engaged in exploring new 
environments and this demands several traits, including curiosity (25), a large brain and 
immune protection.  
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Dopamine is considered to be the main neurotransmitter responsible for curiosity (248), 
novelty seeking (249), motivation and aggressiveness (250). A polymorphism of the dopamine 
receptor D4 (DRD4) is associated with novelty seeking, risk-taking and increased exploratory 
behaviour (251). Novel environments produce new immunological challenges, including 
climate, food availability and pathogens (252). The long allele of the DRD4 receptor is related 
to the migratory distance from Africa. Matthews and Butler (251) suggested that this allele 
been positively selected, as opposed to genetic drift.  
 
Other behavioural traits, in addition to the association of 7R DRD4 polymorphism with 
environmental exploration and novelty seeking, are increased anger and a decreased feeling 
of disgust (253). Disgust is amongst the most intensively investigated emotions belonging to 
the behavioural immune system (248). Immune defence is usually a reaction following tissue 
damage or some pathogenic infection. It is highly costly and intense and long-term activity 
could result in secondary lesions and even multiple organ failure. Humans have explored 
new environments with constant new immunological challenges throughout evolution. The 
development of a pro-reactive behavioural immune system, preventing contact with possible 
pathogens could have been beneficial to save energy and guide them to important other 
physiological functions, including those of the brain and skeletal muscles (254, 27). Disgust as 
a proactive strategy to avoid disease, produces aversion to a wide range of factors. High levels 
of disgust, i.e. increased activity of the behavioural immune system, produce neophobia (255), 
rejection of other individuals, decrease in mating behaviour (256), food neophobia (257), 
prejudicial attitudes to old people (258) and even discrimination (259).  
 
The behavioural immune system (BIS) can be very sensitive and dominate free will. However, 
individuals, carrying the longer allele of the DRD4 gene exhibit a higher level of novelty 
seeking, less disgust and more spontaneous activity (236). This implies that people with 
increased exploratory behaviour through DRD4 polymorphism would be at a higher risk of 
pathogenic infection, because of less aversion and disgust. This combination argues against 
the current opinion about pathogens dominating selective pressure in human evolution 
(260). The only feasible explanation would be that the longer allele of the DRD4 gene should 
have some immune function, protecting the ‘seeking’ carrier against pathogens.  
 
The evidence for an immune function of the long allele of the DRD4 comes from different 
investigations studying the influence of the expression of dopamine receptors on innate 
immune cells and lymphocytes of the adaptive immune system. The various immune cells 
express different dopamine receptors (DRD1-DRD5) (165). The net function of dopamine 
receptor activation is an increase in the pro-inflammatory activity of the immune system, 
with the exception of the wild type DRD4 (the short allele’) (261). Activation of the wild type 
DRD4 receptor leads to the production of the immune-suppressing cytokine IL10 (247, 254). 
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The long 7R allele, on the contrary, is associated with diminished cAMP production and 
reduced intracellular response (262). Reduced response will lead to lower immune quiescence 
(the normal function of wild type DRD4 (247, 263) and increase the pro-inflammatory effects 
of dopamine by activating other dopamine receptors (165). It is therefore conceivable that 
migration out of Africa selected the longer allele of the D4 dopamine receptor by inducing 
novelty seeking, while increasing protective inflammatory activity. Dopamine can stimulate 
the production of NFkB and pro-inflammatory cytokines such as TNFα and IL1, although the 
opposite, production of anti-inflammatory IL10, is also possible (165). This probably depends 
on the individual’s genotype, implying that not every individual will be capable of using the 
dopamine mechanism as reactivation strategy. 
 
It seems clear that dopamine (DA) plays an important role in the immune system. Dopamine 
is not only produced in neurons, but also in several immune cells, including T lymphocytes 
(247). Dopamine seems to be recruited by the immune system to protect the host against 
acute infiltration by pathogens. The protective effect of dopamine signalling in the immune 
system against new infections is evidenced by the fact that dopamine activates resting T cells, 
but inhibits activated T cells (165) even in the absence of other danger signals (261). This is in 
line with the effects of other neurotransmitters on the immune system, increasing protection 
against new invaders (evolutionary beneficial) but having a negative effect on the 
immunological memory (264). The immunological ‘use’ of the whole body to fight infection 
makes sense in an evolutionary framework, considering that humans have had to fight 
infections as the main cause of death for thousands of generations and, as stated before, 
almost all humans died because of infection before the start of the 20th century.  
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7. Summary and conclusion 
It can be concluded that the activated immune system puts the whole body at its disposal, by 
reversing the functions of metabolic hormones, organs, and even the nervous system to the 
energetic and pro-inflammatory benefit of the immune system (Figure 3). This response is 
highly protective during acute inflammation/infection and even at the start of a chronic 
process. The longer the inflammatory response lasts, the more it contributes to (severe) loss of 
lean body mass (265, 266), organ dysfunction (4), brain damage and neurodegenerative 
diseases (77). The protective pro-inflammatory activity of the selfish immune system is no 
longer beneficial once severe secondary damage to organs has been caused by the immune 
system.  
 
Life would not have been possible without an immune system, and the development of 
complex organisms needed an even more complex immune system. The human immune 
system belongs to the most complex among all living organisms and serves as the blueprint 
for the development of antivirus software in computer programming (267). Newer systems 
and organs normally dominate older systems as the most basic phylogenetical law in 
evolution. However, this sequence may change in the face of severe or long-term danger, 
known as evo-devo1 mechanisms (268, 269). Evo-devo1 can reach so far back in time that 
inflamed lung and kidney tissue literally resembles a swim bladder (270). Chronic disease is 
characterised by chronic inflammation (and vice versa) and gradual loss of functions and 
even anatomy. It affects the whole body, including the brain. The evidence brought together 
in this review shows that the immune system captures a major part of energy and resources 
during acute inflammation, putting the whole body at its disposal. This state relates to 
disposal of muscles (muscle wasting), the cardiovascular system (high blood pressure, 
atherosclerosis), the gut (digestive problems and food intolerance) and even the brain (loss of 
memory and concentration in, for instance, individuals suffering from FMS). Long-term pro-
inflammatory activation of the immune system would not be possible without putting the 
whole body at the disposal of the immune system. Because of the immune system’s capability 
of recruiting metabolic hormones and neurotransmitters and using them for its own benefit, 
it is the most selfish organ in human beings. The body at the disposal of the immune system 
protects the host during acute inflammation by mounting an optimal response and during 
chronic stress to maintain pro-inflammatory activity and to protect against possible 
infectious pathogens. This situation is initially protective, but becomes severely deleterious 
when the secondary damage to organs and tissues overrides the benefit of infectious 
protection. The environment in which current human beings live constantly challenges the 
body with multiple new metabolic signalling factors. The only organ capable of 
                                                
 
1 Evolutionary developmental biology, or evo-devo, broadly investigates how body plan diversity and morphological novelties have arisen and persisted in nature  
(132). 
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communicating with all organs involved in the energetic conflict because of these multiple 
metabolic signalling is the immune system. To prevent further conflict, the immune system 
takes over, using its robust power to put the whole body at its disposal and showing its selfish 
behaviour. This selfish behaviour of the immune system has saved hominins for millions of 
years. A slow-changing environment to which the immune system could gradually adapt, 
characterised these years. This selfish behaviour of the immune system has to be considered 
to be the main cause of the majority, if not all, modern diseases. The reason lies in the 
interaction between the evolutionary background of immune function, genetic development 
and notably, the current environment as the primary cause. Genes and functions are old; the 
environment is brand new and this conflict underlies modern disease. It should, however, be 
noted that the immune system is only doing what it is made for: trying to protect us. 
 
 
Figure 3. The total picture of the body at the disposal of the selfish immune system. 
If the immune system succeeds in doing so, the host is protected against inflammation-induced immune suppression, 
which would lead to cancer and possibly lethal infections (bottom right), but at the expense of the development of modern 
low-grade inflammatory diseases (bottom left). GLUT 1, glucose transporter 1: GLUT 4, glucose transporter 4; IS, immune 
system; SAM, sympathetic adrenal medular system; HPA, hypothalamus-pituitary-adrenal axis; GR, glucocorticoid receptor; 
BH4, tetrahydrobiopterin; IDO, indoleamine 2,3-deoxigenase: TDO, tryptophan 2,3-deoxigenase; CVD, cardiovascular 
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In this review, we focus on lifestyle changes, especially dietary habits, that are at the basis of 
chronic systemic low grade inflammation, insulin resistance and Western diseases. Our 
sensitivity to develop insulin resistance traces back to our rapid brain growth in the past 2.5 
million years. An inflammatory reaction jeopardices the high glucose needs of our brain, 
causing various adaptations, including insulin resistance, functional reallocation of energy-
rich nutrients and changing serum lipoprotein composition. The latter aims at redistribution 
of lipids, modulation of the immune reaction, and active inhibition of reverse cholesterol 
transport for damage repair. With the advent of the agricultural and industrial revolutions, we 
have introduced numerous false inflammatory triggers in our lifestyle, driving us to a state of 
chronic systemic low grade inflammation that eventually leads to typically Western diseases 
via an evolutionary conserved interaction between our immune system and metabolism. The 
underlying triggers are an abnormal dietary composition and microbial flora, insufficient 
physical activity and sleep, chronic stress and environmental pollution. The disturbance of 
our inflammatory/anti-inflammatory balance is illustrated by dietary fatty acids and 
antioxidants. The current decrease in years without chronic disease is rather due to ‘nurture’ 
than ‘nature’, since less than 5% of the typically Western diseases are primary attributable to 
genetic factors. Resolution of the conflict between environment and our ancient genome 
might be the only effective manner for ‘healthy aging’, and to achieve this we might have to 
return to the lifestyle of the Paleolithic era as translated to the 21st century culture. 
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Introduction 
In recent years, it has become clear that chronic systemic low grade inflammation is at the 
basis of many, if not all, typically Western diseases centered on the metabolic syndrome. The 
latter is the combination of an excessive body weight, impaired glucose homeostasis, 
hypertension and atherogenic dyslipidemia (the ‘deadly quartet’), that constitutes a risk for 
diabetes mellitus type 2, cardiovascular disease (CVD), certain cancers (breast, colorectal, 
pancreas), neurodegenerative diseases (e.g. Alzheimer's disease), pregnancy complications 
(gestational diabetes, preeclampsia), fertility problems (polycystic ovarian syndrome) and 
other diseases (1). Systemic inflammation causes insulin resistance and a compensatory 
hyperinsulinemia that strives to keep glucose homeostasis in balance. Our glucose 
homeostasis ranks high in the hierarchy of energy equilibrium, but becomes ultimately 
compromised under continuous inflammatory conditions via glucotoxicity, lipotoxicity, or 
both, leading to the development of beta-cell dysfunction and eventually type 2 diabetes 
mellitus (2).  
 
Insulin resistance has a bad name. The ultimate aim of this survival strategy is, however, 
deeply anchored in our evolution, during which our brain has grown tremendously. The goal 
of reduced insulin sensitivity is, among others, the reallocation of energy-rich nutrients 
because of an activated immune system (3, 4), limitation of the immune response, and the 
repair of the inflicted damage. To that end, serum lipoproteins adopt a pattern that bears 
resemblance with the ‘hyperlipidemia of sepsis’, accompanied by seemingly inconsistent 
changes in serum cholesterol, increased triglycerides, decreased HDL-cholesterol, and an 
increase of ‘small dense’ LDL-particles, of which the latter three constitute the triad of 
atherogenic dyslipidemia that is part of the metabolic syndrome (5-10). 
 
From the perspective of our brain growth during evolution, we address the question of why 
homo sapiens is so sensitive to the development of insulin resistance. The purpose and the 
underlying mechanisms leading to insulin resistance and the associated dyslipidemia are 
subsequently discussed in more detail. We argue that our current Western lifestyle is the 
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cause of many false inflammatory triggers which successively lead to a state of chronic 
systemic low grade inflammation, insulin resistance, the metabolic syndrome, and eventually 
to the development of the above mentioned typically Western diseases of affluence. To find a 
solution for the underlying conflict between our environment and our ancient genome, we 
also go back in time. With the reconstruction of our Paleolithic diet, we might be able to 
obtain information on the nutritional balance that was at the basis of our genome. We argue 
that insight into this balance bears greater potential for healthy aging than the information 
from the currently reigning paradigm of ‘Evidence Based Medicine’ (EBM) and ‘randomized 
controlled trials’ (RCTs) with single nutrients.  
 
Our brain growth rendered us sensitive to glucose deficits 
Homo sapiens and the current chimpanzees and bonobos share a common ancestor, who 
lived in Africa around 6 million years ago. Since about 2.5 million years ago, our brain has 
strongly grown from an estimated volume of 400 mL to the current volume of approximately 
1,400 mL (Figure 1). This growth was enabled by the finding of a high-quality dietary source2, 
that was easy to digest and contained an ample amount of nutrients, necessary for the 
building and maintenance of a larger brain. The nutritional quality of primate food correlates 
positively with relative brain size and inversely with body weight, suggesting that a larger 
brain requires a higher dietary quality (11). The necessary so-called ‘brain selective nutrients’ 
include, among others, iodine, selenium, iron, vitamins A and D, and the fish oil fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), that jointly are abundantly 
available in the land-water ecosystem. There are compelling arguments that a sizeable part of 
our evolution occurred at places where the land meets the water (12-15), but also that we have 
changed our lifestyle in a too short period of time. These changes started from the 
agricultural revolution (around 10,000 years ago) and became accelerated since the industrial 
revolution (about 100-200 years ago). They created a conflict between our current lifestyle, 
including our diet, and our ancient genome, that, with an average effective mutation rate of 
0.5% per million years, still resides for the greater part in the Paleolithic era (16, 17). It is not by 
chance that the above mentioned brain selective nutrients are among those of which we 
currently exhibit the largest deficits worldwide. These deficits are masked by enrichment and 
fortification of our current diet with iodine (in salt), vitamins A and D (e.g. in margarines and 
milk) and iron (flour, cereals). 
                                                
 
2 Food quality refers to the energy content and/or the nutrient content of a diet. An increase in food quality may derive from the consumption of a diet with another 
composition or the modification of the diet by e.g. cooking or genetic manipulation (11). 
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Figure 1. Evolution of our brain size within the past 3.5 million years. 
Our brain has grown fast since the homo erectus (1.7-2.0 million years ago). The newborn homo sapiens, the adult 
chimpanzee and the homo floresiensis (18) have brain volumes of around 400 mL. Adapted from Aiello and Wheeler (19) 
with permission from The University of Chicago Press. 
 
 
Figure 2. Relationship between body weight and basal metabolism in 51 land mammals (20 non-
primates, 30 primates, and humans).   
Adapted from Leonard et al.(11) with permission from Elsevier. 
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Our brain consumes 20-25%3 of our basal metabolism (11-17, 20) and is thereby together with 
the liver (19%2), our gastrointestinal tract (15%2), and skeletal musculature (15%2) among the 
quantitatively most important organs in energy consumption (19). The infant brain consumes 
as much as 74% of the basal metabolism (11, 21). In contrast to most other organs, the brain 
uses mostly glucose as an energy source. There is no other primate equipped with such a 
large, glucose-consuming, luxury organ as our brain. For example, our closest relative, the 
chimpanzee, has a brain volume of 400 mL, which consumes about 8-9% of the basal 
metabolism. Because of the high energy expenditure of a large brain, it was necessary to 
make various adjustments in the sizes of some other organs. There is a linear relationship 
between body weight and basal metabolism among terrestrial mammals (Figure 2). This 
apparently dogmatic relationship predicts that, due to the growth of our brain, other organs 
with high energy consumption had to be reduced in size, what in evolution is known as a 
‘trade-off’4. As a consequence of this ‘expensive tissue hypothesis’ of Aiello and Wheeler (19) 
our intestines, amongst others, had to become reduced in size. However, this exchange of 
expensive tissue probably occurred prior to, or simultaneous with, our brain growth, in which 
the trigger was the consumption of the easily digestible high-quality food (20) that contains 
the above-mentioned ‘brain selective nutrients’ from the land-water ecosystem. Under these 
‘conditions of existence’ (Darwin), a single mutation in a growth regulatory gene is likely to 
have been sufficient for the brain to grow. This notion derives from the existence of 
genetically-determined micro- (22) and macrocephaly (23) and it is as a ‘proof of principle’ 
demonstrated by the differences in the beak lengths of Darwins’ legendary Galapagos finches 
(24-26). Compared with our close (vegetarian) relatives in the primate world, we possess a 
relatively long small intestine and a relatively short large intestine, which corresponds with 
the digestion of high quality food (such as meat and fish) in the small intestine, and the lesser 
need of a long colon for the digestion of complex carbohydrates (e.g. fiber) from a typically 
vegetarian diet (19). Unlike our near primates, such as the gorilla, our teeth and the 
attachments of our jaw muscles are not specialized for the processing of tough vegetarian 
food. Also our muscle mass became adapted, since its current size is relatively small 
compared to our body weight. For instance, when compared with the chimpanzee, we are 
definitely weak. On the other hand, we have a relatively sizeable fat mass, which probably 
serves as a guarantee for the high energy requirement of our brain. 
 
Our brain’s energy consumption is quite stable. Unlike other organs, the energy consumption 
of the brain can not be downregulated at times of a negative energy balance or fasting (11, 20). 
Our brain also gets spared during prolonged fasting, while other organs such as the liver, 
spleen, kidneys and even the heart, are sacrificed for energy generation (27). This hierarchy 
                                                
 
3 These estimates derive from various publications and therefore do not add to 100%. They should be regarded as indications. 
4 The beneficial exchange of a certain property into another one  
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also applies to the prenatal brain, whose development is conserved during intrauterine 
growth restriction (28). An example is the Indian 'thin fat baby’, with a birth weight of 2,700 g. 
Compared with its 3,500 g counterpart from the UK, this infant has a similar brain size and a 
relatively large fat compartment, at the expense of the somatic growth of the skeletal muscle, 
kidneys, liver and the pancreas (28). Our brain ranks high in the functional hierarchy and 
should be provided with the necessary energy at all times. 
 
Apart from its large size, there is nothing special about our brain within the primate world. 
Compared with other species, primates have a very economical space-saving brain, but 
among the primates, brain weight correlates with the number of neurons (29-32) and 
intelligence (33). Actually, our brain is no more than an oversized primate brain (29). What 
does distinguish us from other species is the high ratio between our brain size and our body 
weight, which is also named encephalization quotient (EQ) (Figure 3). Toothed whales (brain 
weight 9,000 g) and African elephants (4,200 g) have much larger brains than humans, but 
they have lower EQs (34). Among the primates, EQ does not correlate with intelligence (33). 
Our high EQ has major implications for our energy management, particularly at times of 
‘glucose shortage’. Under normal circumstances, our brain functions almost entirely on 
glucose, consuming up to 130 g/day (27). Compared with the apparently unlimited storage 
capacity for fat, we only dispose of a small reserve of glucose that is stored as glycogen in the 
liver (up to 100-120 g; mobilizable) and muscles (360 g; for local usage), while some glycogen 
can even be found in brain’s astrocytes (35). With the exception of the glycerol moiety, we can 
not convert fat into glucose. The reduced carbohydrate intake that came along during 
evolution with the transition from vegetarians to omnivores rendered us strongly dependent 
on gluconeogenesis from (glucogenic) amino acids. This was possible because we 
simultaneously consumed more protein from meat and fish, which is also referred to as the 
‘carnivore connection’ (36). After the depletion of our glycogen reserves, for instance after an 
overnight fast, we obtain the necessary glucose for our brain via gluconeogenesis from 
glycerol and amino acids. Under normal conditions, these amino acids derive from our 
dietary proteins after a meal, but during starvation, they become extracted from our tissues by 
catabolism of functional proteins, at the expense of our lean body mass. Under such 
circumstances of severe glucose deficit, the energetic need of our brain becomes increasingly 
covered by ketone bodies from fat (37, 38). 
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Figure 3. Encephalization quotient (EQ) of selected mammals.  
The EQ has been normalized with the cat as a reference. Data adapted from Roth and Dicke (34).  
 
A glucose deficit leads to competition between organs for the available glucose. As previously 
mentioned, this occurs during fasting, but also during pregnancy and 
infection/inflammation. Fasting is characterized by a generalized shortage of glucose (and 
other macronutrients), but in case of pregnancy and inflammation we deal with active 
compartments competing with the brain for the available glucose, i.e. the growing child and 
the activated immune system, respectively. During competition between organs for glucose, 
we fulfill the high glucose needs of the brain by a reallocation of the energy-rich nutrients, 
and to that end, we need to become insulin resistant. 
 
Reallocation of energy-rich nutrients by insulin resistance 
The developing child grows fast in the third trimester of pregnancy. In this period, the supply 
of the necessary building blocks like glucose and fatty acids should be independent of the 
maternal metabolic status, which is known as the state of ‘accelerated starvation’ and 
‘facilitated anabolism’ (38). Glucose crosses the placenta without restriction. Fetal needs are 
directive, since the developing fetus is high in the evolutionary hierarchy. If necessary, the 
fetal needs become covered at the expense of the mother, which is known as the ‘depletion 
syndrome’.  
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During infection/inflammation we deal with the metabolic needs of an activated immune 
system for acute survival. The inactive immune system consumes about 23%2 of our basal 
metabolism, of which as much as 69% derives from glucose (47%) and the glycogenic amino 
acid glutamine (22%). Upon activation, the energy requirement of our immune system may 
increase with about 9-30% of our basal metabolic rate. In multiple fractures, sepsis and 
extensive burns, we deal with increases up to 15-30, 50, and 100% of our basal metabolism, 
respectively (3, 4, 39). 
 
The way we save glucose for our brain during starvation, for the brain and the fetus during 
pregnancy, and for the brain and immune system during infection/inflammation, is by 
causing insulin resistance in selected insulin-dependent tissues. These tissues are thereby 
forced to switch to the burning of fat. Due to insulin resistance, the adipose tissue 
compartment will be encouraged to distribute free fatty acids, while the liver will be 
encouraged to produce glucose via gluconeogenesis and to distribute triglycerides via VLDL. 
The aforementioned (asymmetric) ‘thin fat baby’ with its spared brain, relatively high adipose 
tissue compartment, and the growth restricted body (islets of Langerhans included), has 
relatively high cord plasma insulin and glucose concentrations at birth (28). These 
characteristics of insulin resistance and diabetes mellitus are probably necessary for the 
postpartum, saving of as much as possible of the available glucose for the brain, whereas the 
other organs are provided with fatty acids from the sizeable adipose tissue stores. This 
intrauterine 'programming', that follows the prediction of a thrifty postnatal life comes along 
with health risks, notably when the prediction proves false (40, 41). According to the ‘Barker 
hypothesis’, at adult age, these children have a higher chance of diseases related to the 
metabolic syndrome, especially when they are raised in our current obesogenic society. The 
unfavorable interaction of their high EQ with a high body weight is already demonstrable at 
the age of 8 years (42). Essentially, their postnatal risk is attributable to a (probably epigenetic) 
‘intrauterine programming’, that traces back to the high hierarchical ranking of our brain in 
both growth and energy needs, also referred to as ‘the selfish brain’ (43). 
 
Glucose intolerance (26) and insulin resistance have been reported in calorie restriction, 
extreme fasting and anorexia nervosa, and may even cause, under these circumstances, 
diabetes mellitus type 2, notably in those subjects sensitive to its development (44). According 
to textbooks, insulin resistance during the third trimester of pregnancy is caused by the 
hormonal environment, among which HPL, progesterone, estrogens, prolactin and cortisol 
are mentioned. However, placental tumor necrosis factor alpha (TNFα) correlates best with 
measures of maternal insulin resistance (45, 46). Pregnancy is therefore sometimes referred to 
as a physiological state of systemic low grade inflammation (47). As a consequence of 
reduced insulin sensitivity, maternal circulating concentrations of energy-rich nutrients, 
such as glucose and fat, tend to increase, promoting their transport across the placenta. 
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Under non-pregnant conditions, this situation would resemble pathology, but is tolerable 
during the 9 months of a pregnancy, while the largest changes occur during the third 
trimester. 
 
Figure 4. Mechanistic connection between inflammation and insulin resistance.  
The NFκB and AP-1 Fos/June inflammatory pathways inhibit the PI3K/AKT signal transduction pathway for nutrient 
metabolism and the Ras/MAPK pathway for gene expression, both part of the insulin signaling. CAP, Cbl associated protein; 
Cbl, Proto-oncogene product; ER, endoplasmic reticulum;  FFAs, Free fatty acids; Gqα/11, heterotrimeric G protein; Ikkb, I 
kappa B kinase Beta; IRS, insulin receptor substrate; JNK, C-jun N-terminal kinase; NFkB, nuclear factor kappa B; NO, nitric 
oxide; Ras/MAPK; PI3K, phosphatidylinositol 3-kinase;  Ras-mitogen activated protein kinase; Shc, Src homology 2 
containing protein; SOCS, supressor of citokyne signaling; TLRs, Toll-like receptors. Adapted from de Luca and Olefsky (48) 
with permission from Elsevier. 
 
During infection and inflammation, the signals for metabolic adaptation become transmitted 
by pro-inflammatory cytokines. The resulting insulin resistance causes reallocation of energy 
(i.e. the aim of the process; see above), which illustrates that inflammation and metabolism 
are highly integrated (49-51). At the molecular level, the interaction takes place through the 
influences of the nuclear factor kappa B (NFκB) and the AP-1 Fos/June inflammatory 
pathways on the PI3K/Akt signal transduction pathway for nutrient metabolism and the 
Ras/MAPK pathway for gene expression, which are both part of the insulin signal 
transduction (48, 52). To put it simply: the activated inflammatory signal transduction 
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pathway causes inhibition of the postreceptor insulin signaling pathway, which becomes 
noticeable by what we know as insulin resistance (Figure 4). Insulin resistance especially 
refers to a grossly diminished reduction of the circulating glucose concentration by insulin. 
However, insulin has many functions, and thereby exerts different effects in the various 
organs carrying the insulin receptor. Consequently, the ‘resistance’ affects the many insulin 
signal transduction pathways at various degrees, and thereby works out differently with 
respect to the various insulin functions (1, 53). Some processes are impaired (i.e. are genuinely 
‘resistant’), while others remain intact and become excessively stimulated by the 
compensatory hyperinsulinemia. This compensatory increase of the circulating insulin levels 
aims at the prevention of a disturbed glucose homeostasis and thereby the onset of type 2 
diabetes mellitus. The persistence of compensatory hyperinsulinism is responsible for most, if 
not all, of the abnormalities that belong to the metabolic syndrome (1). 
 
In muscle and fat cells, insulin resistance induces a diminished glucose uptake and therefore 
a reduced storage of glucose as glycogen and triglycerides. In fat cells, it causes decreased 
uptake of circulating lipids, increased hydrolysis of stored triglycerides and their mobilization 
as free fatty acids and glycerol. In liver cells, insulin resistance induces the inability to 
suppress glucose production and secretion, in addition to decreased glycogen synthesis and 
storage. The hereby promoted reallocation of energy-rich substrates (glucose to the brain, 
fetus and immune system; fat to the fetus and the organs that became insulin resistant) and 
the compensatory hyperinsulinemia, are meant for short-term survival, and their persistence 
as a chronic state are at the basis of the ultimate changes that we recognize as the symptoms 
of the metabolic syndrome, including the changes in glucose and lipid homeostasis (3, 4) and 
the increasing blood pressure. For example, the concomitant hypertension has been 
explained by a disbalance between the effects of insulin on renal sodium reabsorption and 
NO-mediated vasodilatation, in which the latter effect, but not the first, becomes 
compromised by insulin resistance, causing salt sensitivity and hypertension (54). 
 
Reaven coined the term ‘metabolic syndrome’ and subsequently renamed it the ‘insulin 
resistance syndrome’ (1). However, it becomes increasingly clear that we could better refer to 
it as the ‘chronic systemic low-grade inflammation induced energy reallocation syndrome’. 
The reason for this broader name derives from the recognition that insulin resistance is only 
part of the many simultaneously occurring adaptations. To their currently known extent, 
these adaptations and consequences are composed of: i) reduced insulin sensitivity (glucose 
and lipid redistribution, hypertension), ii) increased sympathetic nervous system activity 
(stimulation of lipolysis, gluconeogenesis and glycogenolysis), iii) increased activity of the 
HPA-axis [hypothalamus-pituitary-adrenal gland (stress) axis, mild cortisol increase, 
gluconeogenesis, with cortisol resistance in the immune system], iv) decreased activity of the 
HPG-axis (hypothalamus-pituitary-gonadal gland axis; decreased androgens for 
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gluconeogenesis from muscle proteins, sarcopenia, androgen/estrogen disbalance, inhibition 
of sexual activity and reproduction), v) IGF-1 resistance (insulin-like growth factor-1; no 
investment in growth) and vi) the occurrence of ‘sickness behavior’ (energy-saving, sleep, 
anorexia, minimal activity of muscles, brain, and gut) (3).  
 
The HPT-axis (hypothalamic-pituitary-thyroid axis) has a central role in our energy 
management. The adaptation of thyroid function in subjects with the metabolic syndrome is 
yet unclear, possibly due to the many concerted changes, such as an altered thyroid hormone 
binding capacity, tissue uptake, conversion of T4 into T3, and tissue-specific receptor 
expression and function. For example, T4 may become converted into the highly active T3 
within the target cell and thereby, without visible changes of circulating hormone 
concentrations, bind to the intracellular thyroid hormone receptor (55). Whether intracellular 
T4 is converted into T3 or the inactive reverse T3 (rT3), or is used as a source of iodine to kill 
bacteria, depends on several factors, including cytokines, that determine the expression 
pattern of the three involved deiodinases (55-57). In euthyroid subjects, free T4 (FT4) is 
associated with insulin resistance, inversely related to total- and LDL-cholesterol, while also a 
positive relationship between TSH and triglycerides has been documented (58). The reported 
changes during metabolic syndrome (59), low-grade inflammation and insulin resistance (60) 
are inconsistent, but do bear great resemblance with subclinical hypothyroidism, with high-
normal or slightly elevated TSH, and normal FT4 concentrations (61, 62). Insulin resistance has 
recently been associated with an increased T3/rT3 ratio, which is a measure of peripheral 
thyroid hormone metabolism and suggests increased thyroid hormone activity (63). In 
contrast, during fasting, energy expenditure becomes downregulated, resulting in a normal 
or decreased TSH and decreased serum thyroid hormone concentrations (64). 
Downregulation of the HPT-axis with reductions of T3, T4 and TSH, and an increase of rT3 
(and thus a decrease of the T3/rT3 ratio) occurs progressively with the severity of the ‘non-
thyroidal illness syndrome’ (NTIS, also called the ‘Low T3 syndrome’ and ‘euthyroid sick 
syndrome’) (55) which is explained as an adaptation of the body to prevent  excessive (protein) 
catabolism as part of the acute phase response (56). 
 
All of the above mentioned adaptations of our metabolism are associated with changes in the 
serum lipoprotein profile, which are part of the metabolic syndrome. The purpose of these 
changes will be explored in more detail below. 
 
Changes in serum lipoproteins 
The quantitative and qualitative changes in the composition of serum lipoproteins resulting 
from an inflammatory trigger have, in addition to the reallocation of energy-rich nutrients 
(fatty acids to the insulin resistant organs), at least two other goals (5-10, 65). These are: i) the 
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modulation of the immune response by which we protect ourselves from the harmful effects 
of invading bacteria, viruses and parasites, and ii) the restoration of the hereby inflicted 
damage. However, if the subsequent changes in structure and function of lipoproteins persist, 
they contribute to the development of atherosclerosis (66). These long term complications 
have not exerted selection pressure during evolution and, consequently, no solution has 
come into existence via the habitual process of spontaneous mutation and natural selection. 
 
The inflammatory trigger during an infection with Gram-negative bacteria is initiated by 
lipopolysaccharides (LPS). Circulating lipoproteins aid in the clearance of this LPS. Hence, 
lipoproteins do not only have functions in transporting lipids to and from tissues, but also 
play important roles in limiting the inflammatory response (67). The ability of lipoproteins to 
bind LPS is proportional to the cholesterol content of the lipoprotein (68), but the 
phospholipids/cholesterol ratio of the lipoprotein is the principal determinant of the LPS-
binding capacity (69). The available phospholipid surface is thus of special importance and is, 
under normal circumstances, the largest for the circulating HDL. However, critically ill 
patients exhibit decreases of both esterified cholesterol and HDL (see below) and in those 
patients, LPS is mainly taken up in the phospholipid layers of LDL and VLDL. Binding of LPS 
to lipoproteins prevents activation of LPS-responsive cells and encourages LPS clearance via 
the liver to the bile. In line with this mechanism, it has been observed that a decrease in 
plasma lipoproteins in experimental models increases LPS-induced lethality (69). 
 
The protective role of LDL is already known for some time, and this process has probably 
been exploited during evolution. Currently, there are over one thousand LDL-receptor 
mutations, many of which lead to a reduced or absent hepatic uptake of LDL particles, and 
consequently, to an elevated serum LDL-cholesterol (70). The carriers of these mutations have 
‘familial hypercholesterolemia’ (FH; incidence about 1/400 in The Netherlands) or ‘defective 
apo-B100’ (FDB), if the mutation is located in the LDL-receptor ligand. They constitute 
autosomal dominant disorders with a high risk of premature atherosclerosis and mortality 
from CVD (71). The arising question is why evolution has preserved so many apparently 
detrimental mutations in the LDL-receptor. Research with data from the population registry 
office in The Netherlands showed that subjects with FH lived longer until 1800, which turned 
into a shorter lifespan than the general population after 1800 (72). Important support for an 
explanation came from studies with LDL-receptor knockout mice, and also with transgenic 
mice overexpressing apo-A1, the structural protein of HDL. These mutants have a high LDL- 
and HDL-cholesterol, respectively, are resistant to LPS-induced mortality, and have better 
survival of severe Gram-negative infection compared with the wild type (66, 73). In other 
words, FH might have become widespread during evolution due to the modulating effect of a 
high LDL (i.e. ‘a high cholesterol’) during Gram-negative infections, that were much more 
common in the past. This benefit might have become a risk following the introduction of a 
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typically Western lifestyle (see below), to which subjects with FH seem particularly sensitive 
(72). 
 
Figure 5. Changes in reverse cholesterol transport during the acute phase response. 
Lipopolysaccharides (LPS) and cytokines reduce the ABCA1 (ATP binding cassette transporter A1) and the cholesterol efflux 
from peripheral cells to HDL. LPS reduces the activities of various proteins involved in HDL metabolism, such as lecithin-
cholesterol acyltransferarse (LCAT), cholesterol ester transfer protein (CETP) and hepatic lipase (HL). LPS and cytokines also 
down-regulate hepatic scavenger receptor class B type 1 (SRB1), resulting in a decreased cholesterol ester (CE) uptake in 
the liver. FC, free cholesterol; LDL-R, LDL receptor; LRP, LDL receptor-related protein; PLTP, phospholipid transfer protein. 
Adapted from Khovidhunkit et al. (66) with permission from The American Society for Biochemistry and Molecular Biology. 
 
As mentioned above, among the lipoproteins, notably HDL has the capacity to bind LPS and 
thereby to prevent an LPS-induced activation of monocytes and the subsequent secretion of 
proinflammatory cytokines (5). However, during the ‘lipidemia of sepsis’, the HDL 
concentration decreases while also the HDL particles decrease in size (6). Their function 
changes as part of the acute phase response: the immunomodulatory properties vanish to a 
high extent and HDL even becomes proinflammatory. The apo-A1 and cholesterol esters are 
lost from the HDL particle, the activities of HDL-associated enzymes and exchange proteins 
decrease, and these proteins are, among others, replaced by serum amyloid A (SAA) (5, 6). Like 
CRP, SAA is produced in the liver as part of the acute phase response. SAA is 90% located in 
HDL, prevents the uptake of cholesterol by the liver and directs it to other cells such as 
macrophages (8, 66). Both the decreasing HDL-cholesterol and the concomitantly reduced 
‘cholesterol reverse transport’, promote the accumulation of cholesterol in the tissues, where 
it is needed for the synthesis of steroid hormones (e.g. cortisol) in the adrenal glands, the 
immune system and for the synthesis of cellular membranes that became damaged by the 
infection (66). Also the formation of small dense LDL (74) might be functional because these 
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particles are poorly cleared by the LDL-receptor, easily penetrate the subendothelial space 
and by their binding to the subendothelial matrix, take their cholesterol cargo to the sites of 
damage in a highly efficient manner. It appears that there are numerous mechanisms that 
jointly cause the active inhibition of the reverse cholesterol transport in response to an acute 
phase response (Figure 5) (66, 75). 
 
Summarizing thus far, we humans are extremely sensitive to glucose deficits, because our 
large brain functions mainly on glucose. During starvation, pregnancy and 
infection/inflammation, we become insulin resistant, along with many other adaptations. 
The goal is the reallocation of energy-rich substrates to spare glucose for the brain, the 
rapidly growing infant during the third trimester of pregnancy, and our activated immune 
system that also functions mainly on glucose. Under these conditions, the insulin resistant 
tissues are supplied with fatty acids. Other goals of the changes in the serum lipoprotein 
composition are their role in the modulation of the immune response by the clearance of LPS 
during infection/inflammation and the redirection of cholesterol to tissues for local damage 
repair. The metabolic adaptations caused by inflammation illustrate the intimate relationship 
between our immune system and metabolism. This relation is designed for the short term. In 
a chronic state it eventually causes the metabolic syndrome and its sequelae. We are 
ourselves the cause of the chronicity. Our current Western lifestyle contains many false 
inflammatory triggers and is also characterized by a lack of inflammation suppressing factors. 
These will be described in more detail below. 
 
Lifestyle-induced chronic systemic low grade inflammation  
An inflammatory reaction is the reflection of an activated immune system that aims to 
protect us from invading pathogens or reacts to a sterile infection. If an activated immune 
system is uncontrolled, the resulting secondary reactions have the ability to kill us. Rogers (76) 
expresses it as follows: ‘...inflammation may be useful when controlled, but deadly when it is 
not. For example, head trauma may kill hundreds of thousands of neurons, but the secondary 
inflammatory response to head trauma may kill millions of neurons or the patient’. It is clear 
that an inflammatory reaction that has started should subsequently be ended.  
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Table 1. Environmental factors that may cause chronic systemic low grade inflammation.  
 
 
Adapted from Egger and Dixon (77). 
 
There are many factors in our current Western lifestyle that jointly cause a state of chronic 
systemic low grade inflammation, which in turn leads to chronically compromised insulin 
sensitivity, compensatory hyperinsulinemia and, eventually, the diseases related to the 
metabolic syndrome. Lifestyle factors that cause inflammation can be subdivided into an 
unbalanced composition of the diet (usually referred to as ‘malnutrition’) (78-80) and non-
food related factors (77), which partly exert their influence via obesity (81) (Table 1). Among the 
pro-inflammatory factors in our current diet, we find: the consumption of saturated fatty 
acids (82) and industrially produced trans fatty acids (83, 84), a high ω6/ω3 fatty acid ratio (85-
87), a low intake of long-chain polyunsaturated fatty acids (LCP) of the ω3 series (LCPω3) 
from fish (88, 89), a low status of vitamin D (90-92), vitamin K (93) and magnesium (94-96), 
the ‘endotoxemia’ of a high-fat low-fiber diet (97, 98), the consumption of carbohydrates with 
a high glycemic index and a diet with a high glycemic load (99, 100), a disbalance between the 
many micronutrients that make up our antioxidant/pro-oxidant network (101-103), and a low 
intake of fruit and vegetables (103, 104). The ‘dietary inflammation index’ of the University of 
North Carolina is composed of 42 anti- and proinflammatory food products and nutrients. In 
Lifestyle Exercise too little (inactivity) Lifestyle Exercise/physical activity/fitness
too much
Nutrition alcohol (excessive) Nutrition alcohol
excessive energy intake energy intake (restricted)
starvation
 'fast food'/ Western style diet Mediterranean diet
fat high-fat diet fat fish/fish oil
saturated fats mono-unsaturated fats
trans fatty acids olive oil
high ω6/ω3 ratio low ω6/ω3 ratio
fiber (low intake) fiber (high intake)
fructose nuts
glucose high glucose/GI foods low GI foods
glycemic load grapes/raisins
glycemic status dairy calcium 
sugar-sweetened drinks eggs









Obesity  'Healthy obesity'
Weight gain Weight loss
Smoking Smoking cessation












this index, a magnesium deficit scores high in the list of pro-inflammatory stimuli (105). 
Magnesium has many functions, some of them, not surprisingly, related to our energy 
metabolism and immune system, e.g., it is the cation most intimately connected to ATP (95). 
Indirect diet-related factors are an abnormal composition of the bacterial flora in the mouth 
(106), gut (106, 107), and gingivae (108-110). Chronic stress (111, 112), (passive) smoking and 
environmental pollution (77), insufficient physical activity (113-118) and insufficient sleep 
(119-123) are also involved.  
 
All of the above listed lifestyle factors exhibit interaction and are therefore difficult to study in 
isolation. As an example, the bacterial flora may change secondary to the composition of our 
diet. An inflammatory reaction might be at the basis of the observed relation between the 
abnormal bacterial species in both our oral cavity and intestine and our serum HDL- and 
LDL-cholesterol (106). Saturated fats may cause an inflammatory reaction especially when 
they are combined with a carbohydrate-rich diet, notably carbohydrates with a high glycemic 
index, and especially in subjects with the insulin resistance syndrome (124-128). 
 
Mechanisms of lifestyle-induced inflammation  
Diets high in refined starches, sugar, saturated and trans fats, and low in LCPω3, natural 
antioxidants, and fiber from fruits and vegetables, have been shown to promote inflammation 
(82-84, 129-131) (Table 1). As most chronic (inflammatory) diseases have been linked to diet, 
modifying it could prevent, delay or even heal these diseases. Obviously. inflammation is an 
essential process for survival, but our immune system should be carefully controlled to limit 
the unavoidably associated collateral damage (132). For instance, wound healing and other 
immune challenges become controlled in our body by a process coined by Serhan et al. (133-
135) as resoleomics, using metabolites produced from the LCP arachidonic acid (AA), EPA and 
DHA (85, 133-136). However, our inflammatory and resolution genes operate nowadays in a 
completely different environment than the one to which they became adapted through 
mutation and natural selection. In most (if not all) chronic diseases typical of Western 
societies, the inflammatory response is not concluded because of suboptimal or 
supramaximal responses (137, 138).  
 
It has been estimated that 10% of all deaths in the Netherlands are attributable to unfavorable 
dietary composition and 5% to overweight. In this scenario, the major contributors to diet-
associated death were insufficient intakes of fish, vegetables and fruits, with less important 
roles for too high intakes of saturated and trans fatty acids (139). The consumption of fish, 
fruit and vegetables is considered too low in most Western countries (139-143). In the USA, 
low dietary ω3 fatty acids and high dietary trans fatty acids may have accounted for up to 
84,000 and 82,000 deaths, respectively, in 2005, while a low intake of fruit and vegetables 
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might have been responsible for 58,000 deaths (144). The Dutch (145) and the American Heart 
Association (AHA) (146) dietary guidelines recommend to consume at least two servings of 
fish per week (particularly fatty fish), but in 1998, the average fish consumption in The 
Netherlands amounted to hardly 3 times per month (139). Only about 7% of the 9-13 year-old 
Dutch children eat fish twice or more per week and 10% never eat fish (147). In the USA, the 
estimated intake of fish in 2007 was about 0.7 kg per month, per person. More preoccupying 
is the fact that the USA is considered the third largest consumer of seafood in the world (148, 
149). Despite improvements of the fatty acid contents of food products, only 5% of the Dutch 
population follows a diet with the recommended fatty acid pattern (139). Eating fish once 
weekly was associated with a 15% lower risk of CVD death compared with a consumption of 
less than once per month (150), while each 20 g/day increase in fish consumption was related 
to a 7% lower risk of CVD mortality (151).  
 
The current Dutch recommendation for adults is 200 g fruits and 200 g vegetables per day 
(139), while in the USA, 4-5 servings of fruits and 4-5 servings of vegetables are recommended 
in a 2,000 kcal diet (152). Between 1988 and 1998, the consumption of fruit and vegetables in 
The Netherlands declined 15-20% and currently, less than 25% of the Dutch population follows 
the recommendations regarding the consumption of fruit, vegetables and dietary fiber (139). 
As an example, currently 99% and 95% of the 9-13 year old Dutch do not adhere to the advice 
of consuming 150 g/day vegetables and 200 g/day fruits, respectively (147).  Meta analyses of 
prospective studies indicated that <3 vs. >5 servings of fruits and vegetable per day 
correspond with a 17% reduction in coronary heart disease (153) and 26% reduction in stroke 
(154), while the relation of low intakes with mouth, pharynx, esophagus, lung, stomach, colon 
and rectum cancer is considered substantially convincing (155).  
 
In view of the numerous nutrients present in our food and their many mechanisms of action 
in the inflammatory response, we selected two nutrient classes, i.e. the LCP from fish (LCPω3; 
notably EPA and DHA), and the antioxidants in fruit and vegetables, to illustrate the many 
dietary components involved in our pro-inflammatory/anti-inflammatory balance. However, 
before embarking into these nutrient classes, it should be emphasized that our food is in 
reality composed of biological systems, such as meat, fish, vegetables and fruits, in which 
nutrients obey to the balance that comes along with living material. Therefore, focusing on 
specific, presently known mechanisms without sufficient knowledge of the many possible 
interactions between the numerous nutrients in our food should be regarded as a serious 
limitation. This is a reductionist approach, whereas system dynamics and holistic 




Fatty acids and inflammation  
The media are consistently reporting on advises to reduce fat consumption to avoid risks 
associated with obesity, CVD, diabetes and other chronic diseases and conditions. Among the 
macronutrients, fat does indeed contain the highest amount of energy per gram. However, 
from a thermodynamic point of view, a ‘calorie is a calorie’ (156), implying that any 
macronutrient consumed in disbalance with energy expenditure and thermogenesis might 
cause obesity. A recent in-depth study revealed that ‘a calorie is not a calorie’ in a metabolic 
sense, showing that isocaloric diets with different macronutrient compositions have different 
effects on resting and total energy expenditure with decreasing energy expenditures in the 
sequence low-fat diet<low-glycemic diet<very low-carbohydrate diet (157), and thereby 
suggesting that the diet with the highest protein and fat content gives rise to the lowest 
weight gain. However, whether the intake of fat per se and, as a matter of fact, any isolated 
nutrient (158), can be held responsible for the epidemics of obesity, remains controversial and 
counter intuitive (159-161). Moreover, it is becoming increasingly clear that about 10-25% of 
obese subjects have little CVD and type 2 diabetes mellitus risk (a condition coined ‘healthy 
obesity’) (162, 163), that lean physically unfit subjects have higher risk of CVD mortality than 
obese, but fit, subjects (164), and that it is the quality and not the quantity of fat that conveys a 
major health hazard (165). The type of dietary fat affects vital functions of the cell and its 
ability to resist disfunction e.g. by influencing the interaction with receptors, by determining 
basic membrane characteristics and by producing highly active lipid mediators (166, 167).  
 
Saturated fat intake has been associated with inflammation (168, 169). However, the widely 
promoted reduction of saturated fatty acids is increasingly criticized (170) and also the AHA 
advisory to replace saturated fatty acids in favor of linoleic acid (LA) to 5-10 en% (171). 
Insufficient intake of particular fatty acids is, on the other hand, likely to contribute to health 
hazards, including increased risk of infection (172), dysregulated chronobiological activity 
and impaired cognitive and sensory functions (especially in infants) (173). Among these 
important fatty acids are the LCPω3 derived from fish, of which EPA and DHA are the most 
important members. In 2003, the intake of EPA+DHA by adults in The Netherlands amounted 
to approximately 90 mg/day (women 84 mg/day and men 103 mg/day) (174), while the 
recommendation is 450 mg/day (175). This recommendation is based on an optimal effect in 
preventing CVD (anti-arrhythmic effect), but there is good evidence that higher intakes may 
convey additional favorable effects because of their anti-thrombotic properties and their 
ability to reduce blood pressure, heart rate and triglyceride levels (131). It was calculated that 
our Paleolithic ancestors living in the water-land ecosystem had daily intakes of 6-14 g 
EPA+DHA (176), which correspond with the intakes by traditionally living Greenland Eskimos 
(177), who, because of their low incidence of CVD, were at the basis of the research on the 
beneficial effects of fish oil that started in the seventies (178-180). 
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Both EPA and DHA must be in balance with AA, which is the major LCPω6 derived from 
meat, poultry, eggs (181-183) and also lean fish (184, 185). Each of these LCP may be 
synthesized by desaturation, chain elongation and chain shortening from the parent 
‘essential fatty acids’ LA (converted to AA) and alpha-linolenic acid (ALA) (converted to EPA 
and DHA) (186), even though the production of EPA, and notably DHA, occurs with difficulty 
in humans (187). Included among the symptoms of LA, LCPω3 and LCPω6 deficiencies are 
fatigue, dermatological problems, immune problems, weakness, gastrointestinal disorders, 
heart and circulatory problems, growth retardation, development or aggravation of breast and 
prostate cancer, rheumatoid arthritis, asthma, preeclampsia, depression, schizophrenia and 
ADHD (173, 188-190). 
 
LCPω3 are implicated in many diseases and conditions, including CVD, psychiatric diseases, 
pregnancy complications and suboptimal (neuro) development (86, 191-196). Moreover, a 
growing number of studies indicate the protective effects of dietary LCPω3 on mood 
symptoms, cognitive decline, depression (197, 198), Alzheimer’s disease (199) and, more 
generally, impaired quality of life both in the elderly (200, 201) and younger (202) populations. 
LCPω3 are involved in numerous processes including energy generation, growth, cell 
division, transfer of oxygen from the air to the bloodstream, hemoglobin synthesis, normal 
nerve impulse transmission and brain function. Many different mechanisms are operational: 
LCPω3 mediate potent anti-inflammatory and insulin sensitizing effects through their 
interaction with a membrane receptor named G-protein-coupled receptor 120 (GPR120) (203, 
204); they act at the gene expressional level by binding to nuclear receptors, such as the 
peroxisome proliferator activated receptors (PPARs) (205-207); and they modulate physical 
and metabolic properties of membranes through their incorporation into phospholipids and 
thereby impact on the formation of lipid rafts (134, 208, 209). Important common 
denominators in each of these interactions seem to be their anti-inflammatory and metabolic 
effects, again illustrating the intimate connection between the immune system and 
metabolism (50, 51).  
 
The modernization of food manufacturing, preservation processes and food choices have 
dramatically altered the balance between LCPω3 and LCPω6 in the Western diet, notably by 
increasing the intake of LA from refined vegetable oils and a concomitant decrease in the 
intake of LCPω3 from fish (210, 211). It is gaining acceptance that it is not the amount of fat 
but the balance between the different types of fatty acids that is important (211, 212). A high 
ω6/ω3 fatty acid ratio has been demonstrated to have an inflammatory effect (86, 212, 213), 
while a higher intake of LCPω3 in the form of EPA and DHA regulates the production of 
inflammatory and resolving cytokines and decreases LA levels in both plasma phospholipids 
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and cell membranes (183, 214). The conversions of LA and ALA to AA and to EPA+DHA, 
respectively, depend on the same enzymes in the desaturase and elongase cascade, with Δ6-
desaturase (FADS2) as a rate-limiting enzyme (215) that functions twice in the biosynthesis of 
DHA (216). Increased consumption of ALA gives rise to an increased ALA/LA ratio and 
EPA+DHA content in cell membranes that comes together with a reduction of the AA content 
(216, 217), and thereby influences the balance between inflammation and its subsequent 
resolution (Figure 6) (218-220). Conversely, a higher LA level in plasma phospholipids and cell 
membranes emerges as a major factor responsible for incomplete resoleomics reactions and 
the associated immune paralysis (214, 220, 221) (Figure 6), which is attributed to the 
competitive inhibition of LA in the conversion of ALA to EPA and DHA and also to the 
competition of LA in the incorporation of EPA and DHA into cellular phospholipids (183, 214, 
216).  
 
Figure 6. LCPω6 and LCPω3 postulated involvement in the inflammatory reaction in sepsis and 
its subsequent resolution. 
 
Sepsis causes a systemic inflammatory response giving rise to the ‘systemic inflammatory 
response syndrome’ (SIRS). The inflammatory response is followed by a compensatory anti-
inflammatory response, which results in the ‘e’ (CARS), characterized by a weakened host 
defense and augmented susceptibility to secondary infections. An inflammatory response 
should not only be initiated, but also stopped to limit collateral damage produced by the 
immune system and to prevent immune paralysis. LCPω6 (AA) are involved in the initiation 
of the inflammatory reaction, while LCPω3 (EPA and DHA) are involved in its resolution (see 
also Figure 7). a) A high LCPω6/LCPω3 ratio, e.g. low fish intake, intensifies the SIRS reaching 
a state of hyper-inflammation, while the CARS leads to a state of immune paralysis. b) A low 
LCPω6/LCPω3 ratio dampens both the SIRS and CARS, resulting in a more balanced immune 
response and preventing hyper-inflammation and immune-paralysis. SIRS, systemic 
inflammatory response syndrome; CARS, compensatory anti-inflammatory response 
syndrome. Adapted from Mayer et al. (220) with permission from Wolters Kluwer Health. 
 
LCPω3 and LCPω6 have distinct functions in the inflammatory reaction and its resolution. In 
the first phase of the inflammatory process, the pro-inflammatory eicosanoids leukotrienes-
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B4 (LTB4) and prostagladins-E2 and D2 (PGE2 and PGD2) (222, 223) are generated by 
macrophages from their precursor AA with the help of the lipid-oxidizing enzyme 
lipoxygenase-5 (LOX-5) and cyclo-oxygenase-2 (COX-2) (224-226). At the same time, PGE2 
and/or PGD2, although initially pro-inflammatory, determine the switch to the next phase: the 
resolution of the inflammation (227) via the so-called ‘eicosanoid-switch’. The production of 
the LOX-5 enzyme becomes limited, while anti-inflammatory lipoxins (LXs) are produced 
from AA through the activation of lipoxygenase-12 (LOX-12), lipoxygenase-15 (LOX-15) and 
acetylated COX-2 (228). At the site of inflammation, LOX-12 produced by platelets converts 
LTA4 to LXA4 and LXB4. Along with AA, both LOX-12 and -15 are involved in the biosynthesis 
of specialized bioactive lipid mediators, coined resolvins, (neuro)protectins (135) and 
maresins (229), which derive from EPA and DHA (Figure 7) (85, 134, 172). Several studies have 
illustrated the involvement of these lipid mediators in vascular inflammation and 
atherosclerosis (85, 228, 230, 231). They possess potent anti-inflammatory and pro-resolving 
actions that stimulate the resolution of acute inflammation by reducing and/or limiting the 
production of a large proportion of the pro-inflammatory cytokines produced by 
macrophages. Furthermore, LXA4, protectin D1 and resolvin D1 stimulate the phagocytic 
activity of macrophages toward apoptotic cells and inhibit inflammatory cell recruitment 
(232, 233) thereby protecting tissues from excessive damage by the oxidative stress that 
comes along with immune defense mechanisms and others. By their inhibitory actions on 
the recruitment of inflammatory cells, they allow the resolution phase to set in (234) and 
finish the inflammatory process with the return to homeostasis (136, 227).  
 
Accordingly, LCPω3 given at doses of hundreds of milligrams to grams per day, exhibits 
beneficial actions in many inflammatory diseases (88, 190, 194, 235, 236). For example, DHA 
has been shown to suppress NFκB activation and COX-2 expression in a macrophage cell line 
(168, 237). Different studies demonstrated the nutrigenetic modulation of the 12/15-LOX by 
providing endogenous anti-inflammatory signals and protection during the progression of 
atherogenesis (231, 238, 239), which seem to be totally annulled in the presence of Western 
diet induced hyperlipidemia. As some eicosanoids regulate the production of inflammatory 
cytokines (85, 134, 135) an LCPω3-induced decrease in pro-inflammatory eicosanoid 
production might affect the production of pro-inflammatory cytokines. Equally important is 
the observation that LCPω3 also modulate the activation of transcription factors involved in 
the expression of inflammatory genes (e.g. NFκB, phosphatidylinositol 3-kinase (PI3K)) (240). 
Hence, a high fish consumption, and especially fatty fish, rich in EPA and DHA, seems of 
crucial importance in the primary and secondary prevention of (Western) chronic diseases 
(241, 242), although it should be emphasized that fish is not a synonym of fish oil and also that 
insufficient fish consumption is certainly not the only factor involved in the pro-
inflammatory Western lifestyle (Table 1).  
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Figure 7. Biosynthesis of inflammatory and resolving lipid mediators.  
AA is released from membrane phospholipids by phospholipase A2 (PLA2) and metabolized by COXs or 5-LO to form 
inflammatory mediators, such as prostaglandins and leukotrienes. During the process of resolution, there is a ‘switch’ from 
the biosynthesis of inflammatory mediators to the formation of lipid derivatives with anti-inflammatory and pro-resolving 
properties, including lipoxins and 15-d-PGJ2. EPA and DHA are converted to potent anti-inflammatory and pro-resolving 
lipid mediators like resolvins (E1 and D1) and protectins. ASA, acetylsalicylic acid, CYP450, cytochrome P450, COX-1, cyclo-
oxygenasa-1, COX-2, cyclo-oxygenasa-2; 5-LO, 5-lipo-oxygenase; 12-LO, 12-lipo-oxygenase; 15-LO, 15-lipo-oxygenase; 
PGE2, prostagladin-E2; PGD2, prostaglandin-D2; LTs, leukotrienes; 15d-PGJ2,15-deoxy-delta-12,14-prostaglandin J2; 15-epi-
LXA4 , 15-epi-lipoxin A4 ; LXA4 , lipoxin A4. Adapted from González-Périz and Clària (243) with permission.  
 
Role of the antioxidant network  
The largest contributor to mortality and morbidity worldwide is age-related, non 
communicable disease, including cancer, CVD, neurodegenerative diseases and diabetes 
(244). Even though these are multi-factorial diseases with many pathophysiological 
mechanisms, a common finding is oxidation-induced damage through oxidative stress (245, 
246). Appropriate antioxidant intake has been proposed as a solution to counteract the 
deleterious effects of reactive oxygen species (ROS; e.g. hydrogen peroxide, hypochlorite 
anion, superoxide anion and hydroxyl radical), with substantial evidence upholding the 
contention that: a diet rich in natural antioxidants supports health (104, 246), is associated 
with lower oxidative stress and inflammation (77, 103, 140), and is therefore associated with 
lower risk of cancer, CVD, Alzheimer’s disease, cataracts, and some of the functional declines 
associated with aging (247-251).  
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Molecular oxygen is essential to aerobic life and, at the same time, an oxidizing agent, 
meaning that it can gain electrons from various sources that thereby become ‘oxidized’, while 
oxygen itself becomes ‘reduced’ (252, 253). In general terms, an antioxidant is ‘anything that 
can prevent or inhibit oxidation’ and these are therefore needed in all biological systems 
exposed to oxygen (252). The emergence of oxygenic photosynthesis and subsequent 
changes in atmospheric environment (254) forced organisms to develop protective 
mechanisms against oxygen’s toxic effects (255). Change is implicit to evolution and 
evolution results in adaptation to change (256). As a result, many enzymatic reactions central 
to anoxic metabolism were effectively replaced in aerobic organisms and antioxidant defense 
mechanisms evolved (257, 258). The continuous exposure to free radicals from a variety of 
sources led organisms to develop a series of systems (259) acting as a balanced and 
coordinated network where each one relies on the action of the others (260, 261).  
 
Oxidative stress occurs when there is a change in this balance in favor of ROS (262) that may 
occur under several circumstances, ranging from malnutrition to disease (263, 264). Damage 
by oxidation of lipids (262, 265, 266), nucleic acids and proteins changes the structure and 
function of key cellular constituents resulting in the activation of the NFκB pathway, 
promoting inflammation, mutation, cell damage and even death (252, 260, 267), and is 
thereby believed to underlie the deleterious changes in aging and age-related diseases (102, 
244). The prevention and/or inhibition of oxidation can be achieved by several types of 
specialized antioxidant mechanisms depicted in Table 2 (260). Our antioxidant system is 
composed of two networks (Figure 8), namely, the antioxidant network of non-enzymatic 
antioxidants that we obtain mostly via the diet (268), and the antioxidant enzymes that we 
synthesize ourselves and that carry metal ions for their appropriate functioning in ROS 
clearance. Members of the non-enzymatic antioxidants are e.g. ascorbic acid (vitamin C), 
alpha-tocopherol (vitamin E), carotenoids, and the polyphenols (269, 270). For instance, 
quercetin, one of the most common flavonoids in the human diet, and resveratrol, a well-
known stilbenoid present mostly in berries and the skin of red grapes, have demonstrated 
favorable effects on glucose metabolism by attenuating TNFα-mediated inflammation and 
insulin resistance in primary human adipocytes (271). Typical examples of the antioxidant 




Table 2. Types of antioxidant action. 
  Action Examples 
Prevention 
 








Specific channelling of ROS into 
harmless products 
 







Sacrificial interaction with ROS by 
expendable (recyclable or replaceble) 
substrates 
 
Ascorbic acid, alpha 




 Absorption of electrons and/or energy 
α-tocopherol, β-carotene, 
astaxanthin 
ROS, reactive oxygen species; SOD, superoxide dismutase. Adapted from Benzie (260). 
 
While the prevention of oxidative stress by enhancing the antioxidant defense mechanisms 
may diminish the production of inflammatory mediators and thereby slow aging and lower 
risk of certain diseases (102, 245, 249), it should at the same time be appreciated that ROS also 
exert essential metabolic and immune functions. For example, oxidative phosphorylation is 
based on electron transport (272), which renders free radicals’ inevitable byproducts of 
mitochondrial metabolism (273). Mitochondrial oxidants may function as signaling molecules 
in the communication between the mitochondria and the cytosol (273), while TNFα-induced 
apoptosis may involve mitochondria-derived ROS (274). The innate immune system kills 
microbes by means of the respiratory burst (275). A certain level of ROS may also be essential 
to trigger antioxidant responses (276). Repeated exposure to sublethal stress has been 
proposed to result in enhanced stress resistance and increased survival rates, which in the 
dose-response curve is better known as hormesis (277). Intracellular ROS may stimulate gene 
expression of antioxidant and immunoreactive proteins (278), while SOD may become 
upregulated in chronic exercise through the binding of NFκB to the SOD promoter (279, 280).  
 
Consequently, certain antioxidants may inhibit mitochondrial biogenesis, interfere with the 
hormetic effects of ROS (281, 282) or have other adverse effects. Effective prevention of ROS 
formation and their removal may therefore upset energy metabolism, cell signaling pathways 
and the immune system, and thereby paradoxically increase the risk of chronic disease (283). 
Moreover, any antioxidant is also a potential pro-oxidant because in its scavenging action it 
gains an extra electron that can initiate a new radical reaction when transferred to an 
acceptor, either spontaneously or upon decomposition (284, 285). Possibly through its 
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prooxidant action or other mechanisms (286), meta-analyses of studies with β-carotene 
dosages above 20 mg/day have shown increased risk of lung cancer in the total population, 
smokers and asbestos workers; and of stomach cancer in smokers and asbestos workers (287). 
Analogously, oral antioxidants to limit muscle damage following exercise training may be 
detrimental to health and performance (288), while β-carotene, vitamin A and vitamin E 
supplements have been connected with higher risk of all-cause mortality (289), although the 
outcome of the latter meta-analysis has been contested (290). Moreover, not all antioxidants 
are created equal. Astaxanthin, a carotenoid from the land-water ecosystem, does not appear 
to exhibit pro-oxidant properties (291) when supplemented alone, even at high doses (292), 
and has been shown to decrease oxidative stress and inflammation in various circumstances 
(266, 293).  
 
Chronic inflammation results in the chronic generation of free radicals, which may cause 
collateral damage and stimulate signaling and transcription factors associated with chronic 
diseases (294, 295). The hypothesis that dietary antioxidants lower the risk of chronic diseases 
has been developed from epidemiological studies consistently showing that consumption of 
fruit and vegetables is strongly associated with a reduced risk of these diseases (104, 248, 250). 
Regular consumption of green tea (296) and red wine (103, 297), both rich in polyphenols, 
decreases DNA damage, and the same holds for the kiwifruit (298) and watercress (299), both 
harboring high amounts of carotenoids and vitamin C. On a calorie basis, fruits and 
vegetables are not only richer in many vitamins and minerals, when compared with cereals, 
meat or fish, but also in antioxidants (300). These may collectively be responsible of the 
aforementioned protection of fruits and vegetables in chronic diseases, including CVD (248) 
and cancer (249). Plants harbor similar defense mechanisms as animals for protection against 
ROS (301). Some of their antioxidants are part of their arsenal of ‘secondary metabolites’, 
defined as those organic compounds that are not directly involved in normal growth, 
development and reproduction, but in long term survival and fecundity (302). The plant 
secondary metabolites are largely involved in the chemical defense against herbivores, 
microbes, viruses and competing plants, in signaling and in nitrogen storage (303); and some 
(e.g. polyphenols, carotenoids) also serve functions in the protection against ROS. The 
underlying metabolic pathways towards secondary metabolites lead to a series of related 
compounds that are usually composed of few major metabolites and several minor 
components differing in the position of their functional groups (303). Animals consuming 
fruits and vegetables may employ these plant secondary metabolite networks for their own 
purposes, including maintenance of inflammatory/anti-inflammatory balance, cancer 
chemoprevention and protection against ROS (303). 
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Figure 8. Antioxidant defense mechanisms. 
An overview of the antioxidant system present in the human body. Various types of antioxidant systems have developed 
through time, reflecting different selection pressures. Different forms have developed for the same purpose, for example, 
SODs, peroxidases and GPx are important members of the antioxidant enzyme capacity group. Tocopherols and ascorbic 
acid, as representatives of the antioxidant network, are manufactured only in plants, but are needed by animals. Ascorbic 
acid is an essential antioxidant, but cannot be synthesized by homo sapiens. In humans, therefore, antioxidant defense 
against toxic oxygen intermediates comprises an intricate network which is heavily influenced by nutrition. GR, glutathione 
reductase; GSG, reduced glutathione; GSH-Px, glutathione peroxidase; GSSG, oxidized glutathione; GST, glutathione-S-
transferase; MSR, methionine sulphoxide reductase; PUFA, polyunsaturated fatty acids; S-AA, sulphur amino-acids; SH-
proteins, sulphydryl proteins; SOD, superoxide dismutase; Fe Cu, transition metal-catalysed oxidant damage to 
biomolecules. Adapted from Strain (304) with permission from Cambridge University Press. 
 
In view of the yet poorly understood complex antioxidant networks composed of many 
compounds, it seems improbable to find a single ‘magic bullet’ to prevent and treat chronic 
diseases associated with ROS. Protective effects of fruits and vegetables may originate from 
their numerous phytochemicals working in concert (305) and from many different 
mechanisms of action that are not solely related to ROS. A purified phytochemical may not 
have the same health benefit as that phytochemical present in whole foods or a mixture of 
foods (250, 306). In biological systems, toxins may become nutrients, while nutrients may 
become toxic in other situations (268), for example when disbalanced with other nutrients. 
Rather than translating our food into an assembly of nutrients where each has to prove its 
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health benefits by scientific means, the objective should be to embrace a eucaloric diet that 
provides the adequate amount of nutrients from whole foods to maintain our body 
homeostasis. ‘Adequacy’ may in this sense be translated into causing an optimal interaction 
between our diet (and our lifestyle in general) with our genome, that is: nurture in balance 
with nature. 
 
Evolutionary nutrition vs. randomized controlled trials 
Coherence between lifestyle factors, including the composition of our diet, is quite obvious 
from an evolutionary point of view. After all, there was first an environment, and from this 
environment originated a genome that was adapted to that environment: it is the substrate 
(environment) that selects the organism, not viceversa. This is exactly what Darwin meant 
with ‘conditions of existence’, as the most important driving force in evolution. In other 
words, our only slowly changing genome is indissolubly linked to a certain environment and 
lifestyle. However, we have changed this environment since the agricultural revolution and 
continue to do so with still increasing paste. The resulting conflict does not generate acute 
toxicity, but acts as an assassin in the long term. Probably, the conflict does not exert much 
selection pressure either, because its associated mortality occurs mainly after reproductive 
age.  
 
To solve the conflict, it is virtually impossible to study all of the introduced errors in our 
lifestyle (Table 1) in isolation, according to the reigning paradigm of EBM (307). EBM is widely 
confused with the results of RCTs and preferably the meta-analysis thereof (308, 309). This 
paradigm, originally designed for objective evaluation of medical treatments and drugs in 
particular, and named in nutrition research ‘Evidence Based Nutrition’ (EBN); is at present 
misused by food scientists and Health and Nutrition advisory boards. In contrast to drugs, this 
(expensive) RCT paradigm usually lends itself poorly for the study of single nutrients with 
meaningful outcomes (308). For each nutrient, we are dealing with poorly researched dose-
response relationships, multiple mechanisms of action, small effects causing pathology in the 
long-term, numerous interactions, ethical limitations regarding the choice of intervention 
and control groups, and the inability to patent its outcomes (309). The RCT criteria are 
moreover inconsistently applied in the current development of nutritional recommendations. 
For example, there is no RCT-supported evidence for the saturated fat hypothesis (170), and 
also not for the trans fatty acids, while such an approach is considered mandatory for the 
adjustment of the vitamin D nutritional standards (310-312). Incidentally, there was also no 
RCT prior to the introduction of trans fatty acids showing that they could be consumed 
without adverse effects on the long term. However, there is an RCT on the effects of smoking 
cessation, which showed an equal mortality among the quitters (313, 314). The meta-analyses 
of RCTs studying the influence of LCP on brain development are negative (315-318). However, 
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recommendations for their addition to infant formulas have been issued (196), probably 
because nobody wants to take chances with the brains of our offspring. By applying EBM in a 
rigorous manner and by merely taking a view from the ‘precautionary principle’ (i.e. zero risk 
5) this well meant concept has become a burden in the nutritional science, that calls for 
replacement by appropriate risk-cost-benefit analyses such as e.g. performed for vitamin D 
(319). 
 
Our diet is composed of millions of substances that are part of a biological network. In fact, 
we eat ‘biological systems’ like a banana, a fish or a piece of meat. There is a connection 
between the various nutrients in these systems. In other words,, there is a balance and an 
interaction that is part of a living organism. This balance can be found in the reconstruction 
of our Paleolithic diet, and various attempts for this reconstruction have already been made 
(28, 131, 320-322). Preliminary results of interventions with a Paleolithic diet are utterly 
positive (for a review see (323)). For example, in an indeed uncontrolled study with non-obese 
sedentary healthy subjects, an eucaloric Paleolithic diet resulted within 10 days in beneficial 
effects on three out of the four symptoms of the metabolic syndrome, i.e. blood pressure, 
dyslipidemia and glucose homeostasis. The fourth symptom, overweight/obesity, was 
deliberately not changed to prevent the attribution of any beneficial changes to weight loss 
(324). 
 
Nurture, not nature 
Less than 5% of our diseases can primarily be ascribed to heritable genetic factors (325, 326). 
‘Genome wide association studies’ (GWAS) will not make this figure change; not even if the 
number of patients and controls are further increased. As it could have been predicted from 
evolution, these GWAS identify only a few genes that are associated with typically Western 
diseases. Moreover, the so far identified genes merely convey low risks. In one of these 
disappointing GWAS, where 14,000 patients with seven major typically Western diseases and 
3.000 controls were studied, it was concluded that: ‘... for any given trait, there will be few (if 
any) large effects, a handful of modest effects and a substantial number of genes generating 
small or very small increases in disease risk‘ (327). The differences in genetic susceptibility to 
environmental factors is widely confused with a primary genetic origin of Western disease. 
Environmental factors may mimic genetic heritability, especially when the exposure has 
become widespread, As clearly explained by Rose (328): "If everyone smoked 20 cigarettes a 
day, then clinical, case-control and cohort studies alike would lead us to conclude that lung 
cancer was a genetic disease; and in one sense that would be true, since if everyone is 
                                                
 
5 The precautionary principle is a moral and political principle stating that, if an intervention or policy 
may cause serious or irreversible damage to society or the environment, the burden of proof lies with the 
proponents of the intervention or the measure if there is no scientific consensus on the future damage. The precautionary principle is particularly applicable in health 
care and environment; in both cases we deal with complex systems in which interventions result in unpredictable effects (source: Wikipedia). 
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exposed to the necessary agent, then the distribution of cases is wholly determined by 
individual susceptibility”. In other words: ‘disease susceptibility genes’ is a misnomer from an 
evolutionary point of view. 
 
Most of the currently demonstrated polymorphisms associated with typically Western 
diseases already existed when homo sapiens emerged about 160,000 years ago in East-Africa. 
After all, the largest inter-individual genetic variation can be found between individuals 
belonging to a single population (93-95% of the total genetic variation), and only little genetic 
variation is on the account of differences between populations belonging to a single race (2%) 
and between the 5 races (3-5%) (329). The allele that, according to current knowledge, is linked 
with the highest penetrance of type 2 diabetes mellitus in the general population (with 
Western lifestyle!) conveys 46% higher relative risk (RR=1.46) (330). In contrast, a woman with 
a body mass index (BMI) of 35+ kg/m2 has a one hundred-fold higher risk (RR=100) of diabetes 
mellitus type 2 (331), which translates into a 9,900% higher relative risk. ‘Genetic’ diseases with 
relative risks below 1.5 have no practical value in Public Health. They are only important to 
our understanding of the etiology of the concerning disease and for drug development (326), 
which is part of Health Care.   
 
Between 70 and 90% of the cases of type 2 diabetes mellitus, CVD and colon cancer can be 
prevented by paying more attention to nutrition, smoking, overweight and lack of physical 
activity (325). Hemminki et al. (326) stated that ‘if the Western population was to live in the 
same conditions as the populations of developing countries, the risk of cancer would 
decrease by 90%, provided that viral infections and mycotoxin exposures could be avoided’. 
The popular counter argument that people in developing countries have (on average!) shorter 
life spans is not valid. The reason that we (on average!) live longer in Western societies, is 
mainly due to the strong reduction of infectious diseases (particularly in childhood), famine 
and violence (332, 333), and also in part on the account of Health Care. However, together 
with our increasing life expectancy, there is a decrease in the number of years without 
chronic disease (334). 
 
Conclusions 
It has become clear that most, if not all, typically Western chronic illnesses find their primary 
cause in an unhealthy lifestyle and that systemic low grade inflammation is a common 
denominator. From an evolutionary point of view, the current conflict between environment 
and our Paleolithic genome traces back to our brain growth and the ensuing intimate 
relationship between inflammation and metabolism. The present disbalance between 
inflammatory and anti-inflammatory stimuli does not originate from a single cause and can 
consequently also not be solved by a single ‘magic bullet’. Resolution of the conflict between 
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environment and our ancient genome might be the only effective manner to arrive at 
‘healthy aging’ and to achieve this objective we might have to return to the lifestyle of the 
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Serhan and colleagues introduced the term “Resoleomics” in 1996 as the process of 
inflammation resolution. The major discovery of Serhan´s work is that onset to conclusion of 
an inflammation is a controlled process of the immune system (IS) and not simply the 
consequence of an extinguished or “exhausted” immune reaction. Resoleomics can be 
considered as the evolutionary mechanism of restoring homeostatic balances after injury, 
inflammation and infection. Under normal circumstances, Resoleomics should be able to 
conclude inflammatory responses. Considering the modern pandemic increase of chronic 
medical and psychiatric illnesses involving chronic inflammation, it has become apparent 
that Resoleomics is not fulfilling its potential resolving capacity. We suggest that recent 
drastic changes in lifestyle, including diet and psycho-emotional stress, are responsible for 
inflammation and for disturbances in Resoleomics. In addition, current interventions, like 
chronic use of anti-inflammatory medication, suppress Resoleomics. These new lifestyle 
factors, including the use of medication, should be considered health hazards, as they are 
capable of long-term or chronic activation of the central stress axes. The IS is designed to 
produce solutions for fast, intensive hazards, not to cope with long-term, chronic stimulation. 
The never-ending stress factors of recent lifestyle changes have pushed the IS and the central 
stress system into a constant state of activity, leading to chronically unresolved inflammation 
and increased vulnerability for chronic disease. Our hypothesis is that modern diet, increased 
psycho-emotional stress and chronic use of anti-inflammatory medication disrupt the 
natural process of inflammation resolution ie Resoleomics. 
 
Keywords 
Chronic inflammation, Central stress system, Nutrition, Resoleomics, Sympathetic-adrenal-
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The number of people suffering from chronic diseases such as cardiovascular diseases (CVD), 
diabetes, respiratory diseases, mental disorders, autoimmune diseases (AID) and cancers has 
increased dramatically over the last three decades. The increasing rates of these chronic 
systemic illnesses suggest that inflammation [1,2], caused by excessive and inappropriate 
innate immune system (IIS) activity, is unable to respond appropriately to danger signals that 
are new in the context of evolution. This leads to unresolved or chronic inflammatory 
activation in the body. 
Inflammation is designed to limit invasions and damage after injury, a process which has 
been essential for the survival of Homo sapiens in the absence of medication such as 
antibiotics. Recently, it has been discovered that onset to conclusion of an inflammation is a 
self-limiting and controlled process of the immune system (IS). This process of inflammation 
resolution is defined by Serhan as Resoleomics [3], a term which will be used throughout this 
article. 
Our genes and physiology, which are still almost identical to those of our hunter-gatherer 
ancestors of 100,000 years ago, preserve core regulation and recovery processes [4,5]. 
Nowadays our genes operate in an environment which is completely different to the one for 
which they were designed. 
Modern man is exposed to an environment which has changed enormously since the time of 
the industrial revolution. In recent decades there has been a tremendous acceleration in 
innovations which have changed our lives completely. As a consequence, more than 75 % of 
humans do not meet the minimum requirement of the estimated necessary daily physical 
activity [6], 72 % of modern food types is new in human evolution [7], psycho-emotional stress 
has increased and man is exposed to an overwhelming amount of information on a daily 
basis. All these factors combine to produce an environment full of modern danger signals 
which continuously activate the IIS and central stress axes. The question is whether the IIS 
and its natural inflammatory response, Resoleomics, can still function optimally in this 
modern, fast-changing environment, considering that the IIS is designed to produce short, 
intensive reactions to acute external danger [8,9]. It would seem that in the bodies of people 
who have adopted a Western lifestyle the inflammatory response is not concluded because of 
an initial excessive or subnormal onset of the response [10]. 
This article postulates how triggers from chronic altered diet and psycho-emotional stress 
negatively influence Resoleomics, thereby increasing susceptibility to the development of 
chronic, low-grade, inflammation-based diseases due to the constant activation of both the 
central stress axes and the IIS. In addition, an attempt is made to demonstrate the ways in 
which the use of anti-inflammatory medication could influence Resoleomics. 
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Resoleomics, a self-limiting process of inflammation 
Serhan and his colleagues [3] introduced the term Resoleomics to describe a self-limiting 
process of inflammation, executed and controlled by the innate immune system (IIS) and 
regulated by the sympathetic nervous system (SNS) and the hypothalamus-pituitary-adrenal 
(HPA) axis. This process controls inflammation using metabolites produced from arachidonic 
acid (AA), eicosapentaenoic acid (EPA) and docosahexenoic acid (DHA). Resoleomics operates 
locally when polymorphonuclear neutrophils (PMNs) are attracted by increased pro-
inflammatory cytokine and eicosanoids production during microbial invasion, wound 
healing or chemical injury. The function is to limit the inflammation response. The central 
control system of the inflammatory reaction is very complex. Local and central processes 
influence each other and both are responsible for an optimal resolving response (Figure 1). 
The local process can be divided into three phases [11] (Figure 2): 
Figure 1  Start and finish of a physiological inflammatory reaction in wound healing and 
situations of microbial challenge.  
Cellular damage and leakage of alarmins attract neutrophils to the damaged area (PMN’s). Sympathetic afferents activate 
the locus coeruleus (central nucleus of the sympathetic nervous system, SNS) and Noradrenaline (Norepinephrine, NE) is 
released. The released NE activates the adrenal medulla inducing the production of systemic catecholamins that supports 
the activation of the PMN. Damaged blood vessels are a source of an omega 3 rich edema (EPA and DHA). DHA and EPA 
inhibit LOX-5 directly and through conversion into resolvins and protectins. Both PGE2 and PGD2, produced by the 
breakdown of AA by COX-2 activity, will now override the strong chemotaxic effect of LTB4. The combined action of 
protectins, resolvins and lipoxins produced out of AA will put a hold on the pro-inflammatory activity of PMN’s, which is 
supported by the increased production of systemic cortisol. Cortisol further activates macrophages (M-Ph) to phagocytose 
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issue debris and quiet PMN by releasing substances such as LXA4, resolvin E1 (RvE1), prostanoid D1 (PD1), fibroblast growth 
factor (FGF), vascular endothelial growth factor (VEGF) and epithelial growth factor (EGF) at the same time. Further edema 
leakage will be stopped, whereas angiogenesis and production of connective tissue will take place, finishing the 
inflammatory reaction and starting the production of new tissue. 
 
Figure 2  Inflammation is a controlled process with an initiation, resolution and termination 
phase.  
After microbial invasion, lesion or chemical injury, the initiation phase starts with the production of pro-inflammatory 
mediators like LTB4 and PG2. These mediators increase inflammation until the Eicosanoid Switch, the end of the initiation 
phase, takes place. This occurs when the level of PGE2 plus PGD2 is equal to the LTB4 level. The resolution phase is 
entered, triggering the generation of anti-inflammatory mediators like LK, resolvins, protectins, maresins, PGD2 and PGF2a. 
When the total level of anti-inflammatory mediators exceeds the level of LTB4 the Stop Signal takes place. This is the last 
phase, the inflammation will be terminated by clearing the affected area [11]. The stress hormones produced by the 
systemic stress axes have a direct effect on the inflammation phases. A microbial invasion, lesion or injury sends off an 
alarm in the body, setting off the systemic stress system which produces NE as response and tunes the system to insulin 
and cortisol resistance [12]. The Eicosanoids Switch to resolution can only take place when NE is equal to the level of 
cortisol plus insulin and when cortisol sensitivity is recovered. The Stop Signal requires a low level of NE and normalized 
cortisol sensitivity. The termination phase is entered when the stress axes are switched off 
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1. Initiation phase 
2. Resolution phase 
3. Termination phase 
 
Initiation phase 
Pro-inflammatory eicosanoids, like leukotrienes B4 (LTB4) and prostaglandins (PGs) initiate 
the inflammatory response. PMNs generate LTB4 and PGE2 from precursor AA with the use 
of lipoxygenase-5 (LOX-5) and cyclo-oxygenase 2 (COX-2). Both eicosanoids enhance 
inflammation, LTB4 being the strongest chemotoxic compound of cytotoxic neutrophils. 
PGE2 and/or PGD2, although initially pro-inflammatory, determine the switch to the next 
phase, the resolution of the inflammation. 
 
Resolution phase 
This phase starts with the Eicosanoid Switch to resolution. When the PGE2 and/or PGD2 level 
is equal to the level of LTB4, the PMNs activate the switch from pro-inflammatory to anti-
inflammatory eicosanoids production by limiting the production of LOX-5. This switch is 
responsible for the production of anti-inflammatory lipoxins (LXs) from AA through 
activation of lipoxygenase −12 (LOX-12), lipoxygenase-15 (LOX-15) and acetylated COX-2 
[13,14]. This last mechanism has been found to be responsible for the production of more 
stable aspirin-triggered LXs (ATLs) with a longer half-value period [15]. Other resolving 
metabolites that support LXs are resolvins, (neuro)protectins and maresins produced from 
respectively EPA and DHA [11,16]. A second substantial increase of COX-2 activity will 
produce anti-inflammatory PGs (PGD2 and PGF2a) during this phase [17]. 
 
Termination phase 
This phase starts when the Stop Signal takes place. This happens when sufficient anti-
inflammatory mediators such as LXs are available to stop the pro-inflammatory process 
[13,14]. LXs are capable of inhibiting both PMN infiltration and the activity of cytotoxic cells of 
the ISS, inducing phagocytosis to clear debris by non-cytoxic macrophages and attenuating 
an accumulation of the pro-inflammatory transcription factors, ie nuclear factor-kappaB (NF-
kB) and activator protein 1 (AP-1) [18,19]. 
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Central stress axes and Resoleomics 
This section deals solely with the effect of the sympathetic, parasympathetic and the HPA axis 
on Resoleomics. The systemic stress system is closely linked to the IIS via the stress axes of 
our body. Anything that can activate the sympathetic-adrenal-medulla (SAM) and HPA axes 
will have its effect on the IIS [20] and therefore on Resoleomics. Seen in reverse, it is precisely 
the IIS that can trigger stress axes, inducing a systemic stress reaction in the body [21]. In the 
SNS, which initially activates the IIS, inhibition of the IIS is provided by the strong anti-
inflammatory neurotransmitter acetylcholine (ACh), produced by the parasympathetic 
nervous system [22]. 
 
The systemic stress reaction follows a two-wave pattern. Activation of the SAM axis is 
considered the first wave, giving rise to the excretion of brain norepinephrine (NE) by the 
Locus Coeruleus (LC). The descending pathway activates sympathetic motor neurons in the 
medulla oblongata, which stimulate the adrenal glands (through sympathetic efferent nerves). 
The adrenal gland will now excrete catecholamines, which activate and induce proliferation 
of ISS cells. NF-kB increases pro-inflammatory cytokines production, such as interleukin 1-
beta (IL1-β), interleukin 6 (IL-6) and tumor necrosis factor (TNF). Both the IIS and Th1 of the 
adaptive IS contain receptors sensitive to catecholamines. Cerebral catecholamines affect the 
activity of spleen, thymus, bone marrow and lymphoid nodes [23]. NE has been shown to 
activate the IIS at the onset of inflammation, while long-term activation of the SNS induces 
IIS inhibition [24]. 
 
The second wave of the systemic stress reaction corresponds with the activation of the HPA 
axis, with glucocorticoids (GCs) as end product. Cortisol is capable of inhibiting the IIS 
through the upward regulation of inhibiting factor kappa B (IkB), while informing the 
immunological cortex through the migration of different immune cells to the brain [25,26]. 
Cortisol, the regulator of the IIS response, can guide the inflammation into resolution phase. 
Termination is instigated when cortisol “overrules” the NE effect on NF-kB signalling through 
genetic influence and reduction of transcription of the NF-kB sensitive pro-inflammatory 
gene, resulting in the finalization of the inflammatory response (Figure 2). 
 
This “termination” effect of cortisol is normally supported by a compensatory anti-
inflammatory response through activation of the vagal anti-inflammatory loop [27]. The 
resulting production of ACh inhibits the IS through the alpha-7-nicotin-Acetylcholinergic 
Receptor (α7nAChR) [28] (Figure 1). 
 
The SNS (NE) increases the initial pro-inflammatory immune response in the initiation phase, 
whereas delayed cortisol response, induced by the HPA axis, inhibits the pro-inflammatory 
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response [29]. Integrity of the SAM axis with its NE response/ reaction is necessary for an 
adequate initial inflammatory response [30]. At the beginning of the initiation phase, there is 
resistance to both cortisol and insulin in order to allow for the activation of the IIS [12]. At the 
end of this phase, cortisol sensitivity and insulin sensitivity should be recovered to facilitate 
the Eicosanoid Switch to the resolution phase. 
 
Chronic stress exposure reduces the capacity to mount an acute stress response [31], resulting 
in an inadequate pro-inflammatory response. Chronic (psycho-emotional) stress situations 
can be responsible for the continuous production of catecholamines by the SAM axis. People 
suffering from “perpetual stress”, for example the parents of a child with cancer, showed 
chronic, increased levels of circulating pro-inflammatory cytokines [26]. This situation 
requires a high level of energy expenditure. The metabolic rate is increased to provide extra 
energy for the brain (arousal of all senses), the heart muscle and the locomotive system. The 
existing cells from the IIS are activated and will proliferate (relatively low energy expenditure), 
whereas proliferation of new immune cells (much more costly energy expenditure) will be 
blocked. Further consequences of chronic SAM activity are narrowing of the cell spectrum of 
the IIS and complete loss of activity of the Th1 section of the adaptive IS, leading to an 
insufficient capability to fight viruses, (pre)neoplastic cells and intracellularly presented 
pathogens [31]. 
 
An inflammatory response leading to solution depends on the sensitivity of glucocorticoid 
receptors (GR) and catecholamine receptors of the IIS [32]. Factors such as stress endured 
early in life, trauma and polymorphisms are possible risk factors for loss of GR and 
catecholamine sensitivity [33-35]. 
 
Suboptimal inflammatory response as a consequence of chronic stress prevents the 
Eicosanoid Switch from functioning, since the switch to the resolution phase requires 
recovered cortisol and insulin sensitivity. The initiation phase should have a maximum 
duration of 8 to 12 hrs. PMN number and activation levels should reach their maximum 
during this phase; longer duration caused by chronic stress could produce secondary damage 
to neighbouring tissues due to the strong cytotoxic effects of activated PMNs [11]. 
Supramaximal activation of PMNs could sensitize the adapted IS if contact time between self-
antigens and the IS is significantly increased [11,29]. 
 
The crosstalk between the IS and stress axes is further evidenced by the fact that acute 
production of high levels of catecholamines activate the IIS strongly [23], whereas 
eicosanoids produced from AA induce the production of local and systemic catecholamines 
[36]. Long-term activation may lead to catecholamine resistance and lack of eicosanoid 
production. This situation, combined with the aforementioned possibility of resistance to 
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insulin and cortisol, provokes a suboptimal inflammatory response and consequently the 
perpetuation and development of low-grade inflammation [26,37]. 
 
Nutritional factors and Resoleomics 
Several dietary factors influence the activity of the IIS and the function of a wide range of 
hormones, including cortisol, insulin and catecholamines. The dramatic changes in dietary 
composition since the agricultural revolution (some 10,000 years ago) and, to a greater extent, 
since the industrial revolution (some 200 years ago) have turned the intake of food into a 
common daily danger and therefore a cause of continuous systemic stress. Some of these 
changes include an increase in the omega 6/omega 3 fatty acid ratio, a high intake of 
saturated fatty acids (SFA) and refined carbohydrates, the introduction of industrially 
produced trans fatty acids, a lower intake of vitamins D and K, imbalanced intake of 
antioxidants, high intake of anti-nutrients (eg lectines, saponins) and an altered intake of 
dietary fibre [38]. 
 
The following section will discuss the impact of the changed ratio of polyunsaturated fatty 
acids (PUFAs) and the intake of food with a high glycemic load on Resoleomics. The pro-
inflammatory effects of anti-nutrients present in cereals [39], potatoes [40], legumes [41], and 
tomato have previously been extensively reviewed [7]. 
 
Role of PUFAs in inflammation 
The intake ratio of α-linoleic acid (LA) (omega 6), α-linolenic acid (ALA) (omega 3), 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in the Western diet has 
changed dramatically compared to the estimated intake ratio of hunter-gatherer diets from 
2–3:1 to 10–20:1 in the contemporary diet [42,43]. All of these PUFAs are essential for normal 
Resoleomics response, as they function as precursors for the special small mediators 
responsible for the instigation and conclusion of the inflammatory response. One of the toxic 
changes in fatty acid composition of food corresponds to the increased intake of LA since the 
production of vegetable oils in 1913. Increased LA levels affect the inflammation process in 
three ways (Figure 3): 
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Figure 3  Summary of the effects of high LA intake on Resoleomics 
1. Increase of the omega 6 / omega 3 fatty acid ratio 
2. Altered AA level 
3. Increases of inflammatory compounds, leukotoxins (LK) production 
 
Increased omega 6 / omega 3 fatty acid ratio 
The inflammatory effect of a high omega 6/ omega 3 fatty acid ratio during inflammation has 
been demonstrated in recent human studies [44,45], in vitro studies [46,47] and animal studies 
[48,49]. The higher LA levels in phospholipids in plasma and cell membranes seem to be a 
major factor responsible for incomplete Resoleomics reactions. Higher intake of omega 3 
fatty acids in the form of DHA and EPA regulate the production of pro-inflammatory 
cytokines and decrease LA levels in phospholipids in plasma and cell membranes [46,48]. The 
conversion of LA and ALA into respectively AA, DHA and EPA depend on the same enzymes 
in the desaturase and elongase cascade, with δ-6-desaturase as the rate-limiting enzyme 
(Figure 4) [50]. 
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Figure 4  Synthesis of unsaturated fatty acids in mammals by Desaturase and Elongase 
Human trials investigating the effects of omega 3 dietary supplements showed significant improvements of symptoms in 
patients suffering from diseases such as RA, inflammatory bowel disease, asthma, psoriasis, breast cancer and CVD. 
However, full remission of symptoms was not achieved [43,51]. Our conclusion is that an increased intake of omega 3 alone 
is not enough to restore Resoleomics; the intake of LA must be decreased as well. 
 
LA effect on AA level 
Higher AA levels in plasma result in more adequate inflammatory reactions, since AA is a 
precursor of pro- and anti-inflammatory substances within the self-limiting inflammatory 
process [52]. LA is the precursor for AA in the desaturase/ elongase conversion (Figure 4). 
Theoretically, LA could be the source of a sufficient level of endogenous AA. However, higher 
intake of LA does not deliver increased levels of AA in comparison to low intake [53,54]. To 
achieve the required AA level, AA should be present in the regular diet [45]. The combined 
situation of AA deficiency together with a reduced intake of omega 3 fatty acids such as DHA 
and EPA (necessary for the flip flop reaction of LOX-5 and the Eicosanoid Switch [3]), enable a 





Increased production of leukotoxin 
The third harmful effect of high LA intake is the possible production of so-called leukotoxins 
(LK). High LA levels are metabolized by CYP2C9 in the liver into biologically active oxidation 
products known as LK and leukotoxin diol (LTD). These metabolites promote oxidative stress 
responses and the activation of NFkB and AP-1, increasing the systemic release of pro-
inflammatory cytokines [55]. LK and LTD are toxic for T cells, and can kill these cells with 
pathways resembling necrosis and programmed cell death [56]. 
 
Role of high glycemic food in Inflammation 
An abundant intake of high glycemic food appears to be related to an increased susceptibility 
to the development of chronic inflammation, as has been demonstrated by several research 
groups [57-59]. The consequences of a high carbohydrate diet are complex and multiple. The 
pathways leading to disturbances of normal inflammation are: 
 
1. High glycemic food intake increases inflammation markers 
2. High glycemic food intake causes hyperglycemia and hyperinsulinemia leading to 
disturbed balances in insulin growth factor-1 (IGF-1) and androgens 
3. Chronic intake of high glycemic food causes hypoglycemia, which triggers central 
stress axes 
 
High Glycemic food increases inflammation markers 
Various clinical trials have shown that an abundant intake of high glycemic food increases 
inflammatory markers and markers of metabolic syndrome such as postprandial NFkB in 
mononuclear cells [57], high sensitive-C-Reactive Protein (hs-CRP)[58], interleukin (IL)-6, IL-
7, IL-18 [60], levels of free radicals [59], cholesterol, triglycerides [61] and even blood pressure 
[62]. Changes incurred by following a low glycemic diet include improved insulin sensitivity, 
lower blood pressure and total cholesterol, which are all key markers of the metabolic 
syndrome [58,60,61]. The high glucose-induced inflammatory response is accompanied by 
hyperinsulinemia and insulin resistance, characteristic for people suffering from obesity 
[57,59]. Increased hsCRP values, hyperinsulinemia and insulin resistance are strongly related 
to CVD risk [60]. Glycemic index (GI) and glycemic load (GL) have therefore been proposed as 
biomarkers and predictors for (chronic) inflammation [63]. 
 
Hyperglycemia and hyperinsulinemia 
Cordain demonstrated that high glycemic food is a potential risk factor for inflammation 
through disturbed signalling of mechanisms as a result of hyperglycemia and 
hyperinsulinemia [64] (Figure 5b). Long exposure to high glucose levels in blood, which leads 
to a slow recovery of the homeostasis, makes tissues vulnerable to disease [65]. High plasma 
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insulin can increase the production of IGF-1 and androgens. Both hormones are related to 
disorders such as polycystic ovarian syndrome (PCOS) [66], epithelial cell cancer (breast, 
prostate, colon) [67,68], acne [69], androgenic alopecia [70], and acanthosis nigricans [71]. 
Several pathways in this respect have been previously described in medical literature, but 
these go beyond the scope of this article. 
 
Figure 5  High glycemic food intake could cause inflammation and diseases as a result of 
hyperinsulinemia.  
The pathways in the shaded area have been extensively described by Cordain [64] (part B). Part A: The consequential 
reactive hyperglycemia is another deleterious pathway. Hyperglycemia is a danger signal, which activates the systemic 
stress system. Chronic activation will suppress the IIS, resulting in low grade inflammation and an increased vulnerability for 
excessive inflammation 
 
Hypoglycemia triggers the systemic stress system 
As previously mentioned, intake of a high glycemic diet can cause hyperglycemia and 
hyperinsulinemia. Hyperglycemia will push abundant glucose via insulin into muscle and 
adipocytes at the instigation of the inflammatory process. However, continuous intake of 
high glycemic food results in reactive hypoglycemia, ie an energy-deficient situation which 
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threatens the homeostasis of the body. As a consequence, the brain will maintain its own 
energy supply aimed at the survival of the organism (the selfish brain) [25]. To ensure 
sufficient energy supply, the brain activates its systemic stress system to induce 
gluconeogenesis (Figure 5a). Excreted catecholamines and cortisol will mobilize extra energy, 
which is allocated with priority to the brain and to the activated IS, at the expense of other 
body tissues [72]. 
 
On the basis of the above information and other referenced data, it seems plausible to state 
that aspects of the Western diet, of the modern industrialised environment and of their 
resultant lifestyles form a chronic danger to the body, triggering both the central stress axes 
and the IIS into a state of chronic activity. This state seems to be a direct cause of the 
development of low-grade inflammation and consequently of chronic inflammatory diseases 
(Figure 5a). 
 
Impact of current medication on Resoleomics 
The role of the IIS is to limit the damage of inflammation in acute situations. Anti-
inflammatory medication can be used to dampen the immune response. Nowadays, as a 
result of lifestyle changes, man is exposed to chronic inflammation and consequently to the 
chronic use of anti-inflammatory medication, much of which in fact suppresses 
Resoleomics. Current medication used to treat chronic inflammatory diseases does suppress 
the symptoms of inflammation, but complete remission of the disease is seldom realized [73]. 
Resoleomics is hindered and complete resolution of the inflammation does not take place. 
Modern chronic inflammatory diseases are treated by several groups of medication. In this 
article we focus on rheumatoid arthritis (RA) medication as an example. Four groups of anti-
inflammatory RA medication are taken into account: the prostaglandin inhibitors 
[Nonsteroidal anti-inflammatory drugs [NSAIDs: Aspirin (ASA) and COX-inhibitors], the 
Glucocorticoids (GCs), the Disease Modifying Drugs [DMARDs: Methotrexate (MTX) and 
Sulfasalazine (SSZ)] and the cytokine blockers [Biological agents: anti TNF-αlpha and IL-1 
blockers]. The mechanisms of action and possible effects on the IIS and Resoleomics are 
summarized from literature (see Table 1). Most current therapies target the IIS in an attempt to 
inhibit the production of pro-inflammatory chemical mediators (Table 1). However, an 
equally important target is the active induction of pro-resolution programs by stromal cells 
such as fibroblasts within the inflamed tissues [74]. Inhibition of MIF [75] and production of 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Positive effect of ASA and GCs on Resoleomics 
Medical intervention should stimulate the endogenous pathways of resolution and two drugs 
already known to possess these qualities are central to contemporary medicine: 
glucocorticoids (GCs) [77] and aspirin (ASA) [106,107]. It is apparent that ASA and GCs have a 
positive effect on Resoleomics, while other medications prolong the initiation phase, 
tempering and/ or blocking the resolution and termination phase of Resoleomics in various 
ways (Table 1). The positive effect of ASA on Resoleomics can be ascribed to its ability to 
produce ASA-triggered lipoxins (ATLs) through acetylation (and not through an irreversible 
inhibition) of the COX-2 enzymes [78]. These ATLs show many pro-resolving properties, 
which are essential in the resolution and termination phase of the inflammation process 
[79,108]. Long-term intake of high doses of ASA blocks PGE2 production and initiates the 
resolution phase without affecting the biosynthesis of other pro-resolving mediators [108]. 
Low and high doses of ASA increase the production of lipoxin A4 (LXA4) and 15-epi-LXA4 in 
the rat brain, suggesting that ASA could protect against neuroinflammation [109]. However, 
because of its side effects, ASA is no longer the treatment of choice for RA. In high doses, 
inhibition of the COX-1 enzyme by ASA is responsible for damage to the stomach lining. 
 
ASA and also GCs activate the ALX/FRP2 receptor, making them the ideal collaborator in the 
resolution process [77]. GCs-induced annexin-1 protein (ANXA1) [110,111] as well as ASA-
induced ATLs act on the same ALX/FPR2 receptor and dampen PMN infiltration [77,80]. 
ANXA1 also inhibits the phospholipids A2 enzyme (PLA2). Reduced PLA2 activity appears to 
reduce AA release from the cell membrane [32,112], which possibly leads to decreased levels of 
both PGs and LTs and to the delay of resolution. Besides their anti-inflammatory effects, GCs 
have a positive influence on resolution by enhancing macrophage migration and 
phagocytosis [11,113]. 
 
Adverse effects of medication on Resoleomics 
The use of anti-inflammatory medication without the capacity to induce (complete) 
resolution should be considered solution-toxic, ie hindering Resoleomics. NSAIDs are strong 
inhibitors of COX-2 and less of COX-1 enzymes [114]. Almost complete COX-2 inhibition 
decreases the PGs synthesis, and consequently leads to a higher production of LTs via LOX-5 
in PMNs [115]. PGE2 and PgD2 decrease the activity of LOX-5, decreasing neutrophil activity 
and facilitating the end of the inflammatory phase and the instigation of resolution. 
 
Immune-suppressors such as SSZ (and less powerful GCs) almost completely block NF-kB 
transcription, leading to insufficient cytokine production and suboptimal inflammation [86]. 




Perhaps the most deleterious drugs, interfering negatively with resolution, are TNF-alpha 
inhibitors such as anti TNF-alpha and MTX. MTX inhibits the proliferation of the IIS cells, 
decreasing the production and accumulation of adenosine within the IS cells [88,116]. These 
effects lead to rapid anti-inflammatory effects and symptom release. However, because of its 
side effects and incomplete resolution, this medication is qualified as solution-toxic. This 
conclusion is supported by many patients who have discontinued this treatment [73]. 
 
Another group of possible solution-toxic drugs are biological agents with an inhibiting effect 
on TNF-alpha and IL-1. Biological agents together with DMARDS (Table 1) are strong anti-
inflammatory compounds, decreasing the production of pro-inflammatory cytokines. The 
absence or insufficient activity of pro-inflammatory cytokines decreases cell communication 
and induction of COX-2 in activated neutrophils. This can lead to less production of 
resolution substances such as PgE2, PgD2 and lipoxins [54,103]. Furthermore, DMARDs and 
biological agents appear to reduce the functioning and number of IIS cells, causing 
suboptimal inflammation and possibly inflammation perpetuation [104]. 
 
Discussion 
Long-term activity of the IIS results in low-grade inflammation and chronic disease. Over the 
past years, ideas regarding the treatment of inflammation have started to change as evidence 
accumulates which shows that, although the targeting of infiltrating immune cells can control 
the inflammatory response, it does not lead to its complete resolution and a return to 
homeostasis, which is essential for healthy tissue and good health in general. 
 
Hotamisligil describes how low-grade, chronic inflammation (‘meta-inflammation’) induced 
by a nutritional and metabolic surplus, is accompanied by disturbed metabolic pathways and 
chronic metabolic disorders. He states that this inflammatory response differs from the 
classical inflammation response caused by injury [117]. However, others have shown that the 
classical response of the IIS dealing with injuries can be linked to activation of the central 
stress axes [26,28]. This article specifically discusses the relationship between the over-
activated systemic stress system and the self-limited process of inflammation, known as 
Resoleomics, executed and controlled by the innate immune system (IIS). 
 
Changes in lifestyle which are new to our evolutionary process should be considered a major 
trigger in causing chronic activation of the IS and consequently of the central stress axes and 
vice versa, thereby leading to chronic diseases such as cardiovascular diseases (CVD), 
diabetes, respiratory diseases, mental disorders, auto-immune diseases (AID) and cancers. 
This article evaluates two of the lifestyle changes which contribute to long-term activity of the 
ISS, namely, nutrition and continuous psycho-emotional stress. Other risk factors such as 
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physical inactivity [6], genetic susceptibility [118], smoking, environmental toxicity and shift 
work [119] fall beyond the scope of this article but should not be ruled out. 
 
Nutrition is an important factor in understanding the development of chronic inflammation. 
The current Western diet can disturb the resolution response in various ways (Figure 6). In the 
Ancestral human diet, foodstuffs with an increased risk of inflammation were virtually 
unknown, while nutrients able to activate the IIS are now abundant in our diet [38,120]. 
Cordain’s research has focused on relating these anti-nutrients in food (eg lectines, 
saponines) to the development of chronic inflammation and autoimmune diseases (AID) 
[7,39]. Fortunately, it seems that the human body possesses a strong capacity to recover from 
illness. If our genes are exposed to their ‘original’ environment by intake of an ancestral 
human diet, their function can recover rapidly. Research has shown that obese persons 
improve their blood markers after just 10 days following a paleolithic diet consisting of fish, 
lean meat, fruit, vegetables and nuts [121]. Similar results have been found in a study with 
aboriginals suffering from Diabetes II, who showed normalized blood markers after returning 
to their traditional lifestyle for seven weeks [122]. 
 
Figure 6  Reflection of the working mechanism demonstrating how several nutritional factors 
could induce and inhibit inflammation 
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People suffering from chronic inflammatory disease demonstrate over-activated central stress 
axes, which then lead to catecholamines, cortisol and insulin resistance. McGowan et al [123] 
show the impact of childhood abuse on the epigenetic pattern of different genes including the 
gene for GR in the hippocampus. They found a decreased level of GR and an increased 
methylation pattern of the GR gene, giving rise to a situation of lower cortisol sensibility and 
altered HPA stress responses. This could make people more vulnerable to developing diseases. 
An altered sensitivity to cortisol has been linked to diseases such as rheumatoid arthritis (RA) 
[124], post-traumatic stress syndrome [125], chronic fatigue syndrome [126], inflammatory 
diseases and AID in general [127]. 
 
The key priority in the treatment of people with chronic inflammation is to induce the 
Eicosanoid Switch to the anti-inflammatory resolution phase. Long-lasting cortisol resistance 
and insulin resistance will definitely delay or block complete resolution. The combination of 
local factors (ie DHA deficiency, low levels of protectins) disturbing the process of complete 
resolution (ie Resoleomics) and the absence of adequate NE and cortisol signalling can be 
responsible for perpetuatual inflammation by delaying the resolution phase of the 
inflammatory response (Figure 7). 
 
Figure 7  Chronic over-activation of the systemic stress system as a result of external stressors 
plays a central role in the development of chronic inflammatory diseases.  
Current intervention with anti-inflammatory medication suppresses Resoleomics and the IIS and so enhance the over-
activation of the systemic stress system 
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Current anti-inflammatory medication used in RA treatment is aimed at the suppression of 
the IIS and its inflammatory response and thus hinders Resoleomics. In addition, these 
medication interventions do not solve underlying catecholamine, cortisol and insulin 
resistance, and consequently making it impossible to achieve full recovery of the chronic 
inflammation. This suggests that chronic use of anti-inflammatory medication in fact 
impedes the body from making a full recovery. Furthermore, the ongoing low-grade 
inflammation will continuously trigger the activity of the systemic stress system [28]. 
 
Health care should focus on early detection of silent, ongoing and low-grade inflammation in 
order to avoid the development of many chronic diseases. Further research is needed to 
validate a questionnaire which addresses early symptoms of chronic low-grade inflammation, 
ie avoidance of exercise, fatigue, emotional flatness, social isolation, decreased libido, hyper or 
hyposomnia, obsessive behaviour or sensitivity to addiction [6,128]. 
 
We have made an effort to demonstrate that the science of Resoleomics can help to find new 
ways to treat people suffering from diseases based on chronic inflammation. Since over-
activated central stress axes directly delay Resoleomics, and thereby delay the resolution of 
inflammation, treatment should focus on restoring the central stress system to its default, 
healthy homeostasis. Dietary changes, psycho-emotional stress release and physical activity 






AA, Arachidonic acid; ACh, Acetylcholine; AID, Autoimmune diseases; ALA, α-linolenic acid; 
ALX/FPR2, Lipoxin A(4) receptor; ANXA 1, Annexin 1 protein; AP-1, Activator protein 1; ASA, 
Aspirin; ATLs, Stable aspirin-triggered lipoxin; COX, Cyclo-oygenase; CRP, High sensitive-C- 
Reactive Protein; CVD, Cardiovascular diseases; DHA, Docosahexaenoic acid; DMARDs, 
Disease Modifying Drugs; EPA, Eicosapentaenoic acid; GI, Glycemic index; GL, Glycemic load; 
GCs, Glucocorticoids; HPA, Hypothalamus-pituitary-adrenal; IGF-1, Insulin growth factor-1; 
IS, Immune system; IIS, Innate immune system; IL, Interleukin; LA, α-linoleic acid; LC, Locus 
Coeruleus; LOX, Lipoxygenase; LK, Leukotoxins; LTs, Leukotrienes; LTD, Leukotoxin diol; LXs, 
Lipoxins; MTX, Methotrexate; NE, Norepinephrine (ie noradrenaline); NF-kB, Nuclear factor-
KappaB; NSAIDs, Nonsteroidal anti-inflammatory drugs; PCOS, Polycystic ovarian syndrome; 
PGs/ PGE2/ PGD2/ PGF2a, Prostaglandins/ prostaglandin E2, D2, F2a; PLA2, Phospholipase A2 
enzyme; PMNs, Polymorphonuclear leukocytes; PUFAs, Polyunsaturated fatty acids; RA, 
Rheumatoid arthritis; SAM, Sympathetic-adrenal-medulla; SFA, Saturated fatty acids; SNS, 
Sympathetic nervous system; TNF, Tumour necrosis factor. 
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Chronic non-communicable diseases (NCDs) are the leading causes of work absence, 
disability and mortality worldwide. Most of these diseases are associated with low-grade 
inflammation. Here we hypothesize that stresses (defined as homeostatic disturbances) can 
induce low-grade inflammation by increasing the availability of water, sodium and energy-
rich substances to meet the increased metabolic demand induced by the stressor. One way of 
triggering low-grade inflammation is by increasing intestinal barrier permeability through 
activation of various components of the stress system. Although beneficial to meet the 
demands necessary during stress, increased intestinal barrier permeability also raises the 
possibility of the translocation of bacteria and their toxins across the intestinal lumen into the 
blood circulation. In combination with modern life-style factors, the increase in 
bacteria/bacterial toxin translocation arising from a more permeable intestinal wall causes a 
low-grade inflammatory state. We support this hypothesis with numerous studies finding 
associations with NCDs and markers of endotoxemia, suggesting that this process plays a 
pivotal and perhaps even a causal role in the development of low-grade inflammation and its 
related diseases.  
 
Introduction 
Inflammation is the response of the innate immune system triggered by stimuli like microbial 
pathogens and injury. Acute systemic inflammation such as in sepsis, trauma, burns, and 
surgery is characterized by a quick increase in plasma-levels (up to 100 fold) of pro-
inflammatory cytokines and acute phase proteins, while in low-grade inflammation there is a 
sustained but only two to three fold increase in circulation pro-inflammatory mediators (1). 
Chronic low-grade inflammation is characteristic for many non-communicable diseases 
(NCD) including diabetes type II, cardiovascular disorders, autoimmune diseases, chronic 
fatigue syndrome, depression and neurodegenerative pathologies, but until now the exact 
mechanism behind the elevated levels of inflammatory mediators found in these conditions is 
not well understood (2-5). 
 
Inflammation can be induced by the binding of pathogen-associated molecular patterns 
(PAMP) to toll-like receptors (TLR), which are expressed on different cells types including 
immune cells, adipocytes and endothelial cells. The most extensively studied PAMP is 
lipopolysaccharide (LPS) or endotoxin (the terms LPS and endotoxin will be used 
interchangeably throughout the rest of the article), a major cell wall component of Gram-
negative bacteria, which is normally present in the human circulation in very low 
concentrations. It has been hypothesized that most of this circulating LPS is derived from the 
gut, since the gut-microbiota is the biggest source of Gram-negative bacteria-derived LPS. 
However, LPS found in the circulation could also be derived from Gram-negative bacteria 
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residing in the oral cavity, respiratory and genitourinary tracts, or can be food derived (6-8). 
Under certain circumstances there can be an increase of endotoxin translocation across the 
intestinal barrier, leading to mildly increased concentrations in blood circulation. This process 
has been associated with several NCDs, like depression (9), chronic fatigue syndrome (10), 
chronic heart failure (11), type 2 diabetes (12), autism (13), non-alcoholic fatty liver disease 
(NAFLD) (14) and inflammatory bowel disease (IBD) (15), diseases that are all linked to chronic 
systemic low-grade inflammation, indicating that endotoxemia could be an important 
contributor in the development of these conditions. 
 
Here we hypothesize that stress-induction leads to a more permeable intestinal wall intended 
to facilitate an increase in the availability of water, sodium and energy-rich substances 
necessary to meet the increased metabolic demand induced by the stressor. Modern life-style 
factors, such as long-term psychosocial stress and components of our “Western” diet 
constantly challenge the stress-axis and further compromise intestinal barrier function, 
resulting in endotoxemia, low grade inflammation and its related diseases. We support our 
hypothesis by describing literature surrounding stress- and immune system activation 
processes and their relation to gut barrier function and explain how lifestyle choices impact all 
these systems. In addition we present a vast amount of literature describing associations with 
NCDs and markers of endotoxemia. Overall we conclude that stress-induced disrupted barrier 
function in parallel with elevated circulating endotoxin levels may underlie disease onset and 
progression and should be considered much more than just a risk factor for chronic disease; it 
could be a cause. 
 
1. Bacterial toxins activate the immune system via TLR 
LPS, the major cell wall component of Gram-negative bacteria, is characterized by its capacity 
to induce inflammation, fever, shock and death (1). Additionally in recent years, other cell wall 
components of Gram-negative and -positive bacteria, have been recognized to have 
endotoxic properties (16), but these will not be further addressed in the rest of the paper. 
Endotoxins are released from bacteria during infection or as a consequence of bacterial lysis. 
Although both whole bacteria and bacterial toxins can translocate transcellular or paracellular 
into the lymph, blood and mesenteric lymph nodes, it is still not precisely clear if the presence 
of endotoxin in the blood circulation (endotoxemia) also presents whole bacteria translocation 
across the intestinal wall (17).  
 
Inflammation can be induced by the binding of LPS to TLR4. The lipid-A moiety of LPS 
interacts with the LPS-sensing machinery composed of TLR4, myeloid differential protein 2, 
CD14 and LPS-binding protein (LBP). LBP transports and delivers circulating aggregates of LPS 
to lipoproteins, resulting in hepatic clearance, or delivers LPS to CD14 (the membrane bound 
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or secreted, soluble form of this molecule), leading to TLR4 activation. TLR4 activation 
activates two transcription factors, activator protein (AP)-1 and nuclear factor κB (NF-κB) (18, 
19), and stimulates the production of pro-inflammatory mediators such as prostaglandin 2 
(PgE2) (20), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, Interferon (IFN)-γ and the 
acute phase protein, C-reactive protein (CRP) (19). Simultaneously, an uncontrolled pro-
inflammatory reaction is prevented by the induction of TLR4, NF-κB and AP-1 signaling 
inhibitors, which are probably involved in creating endotoxin tolerance (21). LPS tolerance is 
defined as a reduced responsiveness to a LPS challenge following a first encounter of 
endotoxin (22). It has been suggested that the dose of LPS exposure is important for 
determining the switch between LPS tolerance and priming. For example, in macrophages, 
high LPS concentrations induced a robust pro-inflammatory response in parallel with the 
activation of inhibitory feedback mechanisms. Lower concentrations of LPS, like those 
observed in NCDs, removed transcriptional suppressors on the promotors of pro-
inflammatory genes and induced a mild but persistent expression of pro-inflammatory 
mediators (21, 23). 
 
2. Intestinal barrier function 
2.1. The paracellular pathway is important for water, mineral and nutrient 
uptake 
The intestinal barrier allows for the regulated uptake of water, minerals and nutrients and 
protects the gut lumen from damage due to harmful substances. Components can cross the 
epithelial barrier by active transport and endocytosis (transcellular) or via the paracellular 
route. Because hydrophilic solutes are limited to cross lipid membranes of epithelial cells, the 
paracellular route is an important and major route for the transport of water, solutes and 
minerals across the intestinal barrier (24, 25). Active glucose, sodium and water uptake is 
mediated by the activity of sodium-dependent glucose co-transporters (SGLT) (26). The 
transcellular absorption of glucose and sodium and the resulting basolateral disposition of 
glucose and sodium by these transporters opens up the paracellular pathway structure and 
allowing the passive flow of water and small nutrients by creating an osmotic gradient (27).  
 
Intestinal permeability is a measure of the barrier function of the gut and relates to the 
paracellular space surrounding the brush border surface of the enterocytes and the junctional 
complexes (28). The junctional complex, containing tight junctions, adherens junctions and 
desmosomes is an important regulator of the paracellular pathway and allows the passage of 
water, solutes and ions, but under normal conditions provides a barrier to larger molecules 
(28, 29). The claudin family of junctional transmembrane proteins have a substantial effect on 
paracellular permeability. While one group of sealing claudins makes the paracellular barrier 
less permeable, the other group of claudins is known to increase paracellular permeability by 
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the formation of pores that increase permeability for small solutes (30, 31). The expression of 
claudin proteins varies between tissues, explaining the variances in permeability of tight 
junctions among tissues (27). The paracellular pathway can be divided into the pore and non-
pore pathway. The pore pathway is mainly controlled by the expression of claudins, while the 
non-pore pathway is more sensitive to cytoskeletal disruptions (30). Cytoskeletal 
rearrangements can be induced by phosphorylation of the regulatory myosin light chain 
(MLC), induced by MLC-kinase (MLCK). Phosphorylation of the MLC facilitates myosin 
binding to actin and therefore aids in cytoskeletal contractility. MLCK can be activated by 
cytokines such as TNF-α, causing increases in tight junction permeability by actomyosin 
contraction and reorganization of the tight junction (32, 33). In addition, SGLT1 activation and 
associated increases in tight junction permeability are also paralleled with phosphorylation of 
MLC, indicating that MLCK is an important mediator in tight junction and paracellular 
permeability regulation (25, 34) (Figure 1). 
 
Increased intestinal permeability has been associated with autoimmune diseases, such as type 
1 diabetes (35), rheumatoid arthritis, multiple sclerosis (36), and diseases related to chronic 
inflammation-like IBD (36, 37), asthma (38), chronic fatigue syndrome and depression (10, 39). 
It has been hypothesized that chronic intestinal hyper-permeability results in a pro-
inflammatory phenotype induced by the enhanced paracellular translocation of microbial 
(and dietary) antigens across the gut barrier (40).  
 
3. Intestinal barrier function 
 
3.1. Stress increases permeability of the intestinal barrier  
Stressful stimuli activate the sympathetic nervous system (SNS) and hypothalamic-pituitary-
adrenal (HPA)-axis. Activation of both systems increases the availability of water, minerals and 
energy-rich substances in order to meet with the body’s metabolic demand (41, 42). The SNS 
responds instantly to physical and psychological stress by reallocating energy into different 
organs by neuronal regulation of heart rate, blood flow, release of catecholamines (adrenalin 
and noradrenalin) from the adrenal medulla (43) and stimulation of the renin-angiotensin-
aldosterone system (44), involved in retention of water and sodium from the kidneys. In 
addition to the kidneys, water and sodium reabsorption can also be achieved at the level of the 
intestine. The intestinal wall is innervated by adrenergic sympathetic nerve fibers that upon 
stimulation increase water and sodium absorption (45, 46), which is paralleled by increases in 
intestinal permeability. The SNS-induced increase in permeability is likely mediated by β2-
adrenergic receptors expressed on epithelial cells (47). Activation of the β2-adrenergic-
receptors stimulated SGLT1-mediated glucose absorption from the gut (48, 49) and the 
resulting basolateral disposition of glucose and sodium by these transporters opens up the 
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paracellular pathway (27) (Figure 1). Not surprisingly, blockage of the SNS by means of thoracic 
epidural anesthesia resulted in the blockage of the endotoxin-induced increase in intestinal 
permeability in rats (50). 
 
Activation of the HPA-axis leads to the release of glucocorticoids that potentiate some of the 
actions of catecholamines. Essential to this response are the neurons in the paraventricular 
nucleus of the hypothalamus expressing corticotropin-releasing hormone (CRH) and other 
co-secretagogues, such as arginine vasopressin and oxytocin, both involved in the regulation 
of water homeostasis. Arginine vasopressin and CRH trigger the immediate release of 
adrenocorticotropic hormone (ACTH) from the anterior pituitary, which in turn induces the 
release of glucocorticoids and to some extend mineralocorticoids from the adrenal cortex, 
stimulating gluconeogenesis and increasing sodium and water retention respectively (51, 52). 
Intestinal permeability is regulated by several components of the HPA-axis. 
 
In epithelial HT-29 monolayers, exposure to CRH resulted in an increased response to LPS as 
reflected by a decrease in transepithelial resistance and a significant increase in the 
expression of the pore forming protein, claudin 2 (27). Interestingly enough, these effects were 
mediated by an increase in TLR4 expression, an observation that could be repeated in mice 
treated with the water-avoid stressor (53). TLR4 activation resulted in the activation of the 
transcription factor NF-κB, which has specific binding sites in the claudin 2 gene promoter 
(54), indicating that in epithelial cells CRH affects both intestinal permeability and 
inflammatory pathways. 
 
In rats, exposure to restricted stress or swimming stress increased intestinal permeability 
throughout the whole intestinal tract as measured by the fractional secretion of the urinary 
recovery of sucrose (reflecting gastric permeability), the lactulose-mannitol ratio (as a marker 
for small intestinal permeability) and sucralose (reflecting both small intestinal and colonic 
permeability) (55). Other experimental animal stress models such as thermal injury or early 
maternal deprivation induced the development of gastric ulcers, altered gastrointestinal 
motility and ion secretion, and increased intestinal permeability (reviewed by Caso et al. 2008 
(56)). SGLT1 expression was markedly increased in the rat jejunum and ileum after 8 weeks of 
restraint stress. These findings were paralleled with an increase in intestinal lymphocytic 
infiltration and adrenal gland weight gain (26). The up-regulation of the SGLT1 is probably 
necessary to meet with the increased water, sodium and nutrient demand, induced by 
chronic stress (42). 
 
The effect of acute stress on intestinal permeability was also investigated in humans (57). In 
healthy volunteers subjected to a public speech test, high cortisol-responders displayed 
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increased intestinal permeability as measured by the lactulose-mannitol ratio. Exogenous 
CRH administration also increased intestinal permeability, yet the CRH-induced hyper-
permeability could be suppressed by the mast cell stabilizer disodium cromoglycate. Mast cell 
stabilization before the public speech test also did not alter intestinal permeability, however, it 
should be noted that in this experiment a control group was not included. Nevertheless, these 
results identify CRH as an important factor in the stress-induced alterations of the intestinal 
barrier function. These alterations seemed to be mediated by intestinal mast cells that upon 
activation secrete pro-inflammatory mediators like IFN-γ and TNF-α. A variety of pro-
inflammatory cytokines increases epithelial and endothelial paracellular permeability by 
modulating the structure of the tight junction and by inducing cytoskeletal disruptions via 
activation of MLCK (32, 34, 58) (Figure 1). For example, IFN-γ increased epithelial permeability 
of T84 monolayers to large molecules (10 kDa). Interestingly, the IFN-γ-induced increase in 
permeability also up-regulated the passage of FITC-labeled-endotoxin by ten-fold (59). 
 
4. Neuroendocrine- immune interactions  
The complex neuroendocrine-immune interactions are evidenced by the fact that emotional 
stressors influence the immune response and that pure immunological stimuli impact on 
cognitive performance (60). Inflammatory mediators activate the HPA-axis with the purpose 
to provoke disease behavior and redirect energy-rich nutrients towards the immune system 
(61). Cytokines have been shown to increase nutrient availability to meet with the 
inflammation-dependent increased metabolic demand. For example, the cytokine Il-1α 
increased whole body glucose metabolism on a central level (62) and cytokines like Il-6, TNF-
α, Il-1 and IFN independently evoke a HPA-axis response (63-65). Immune mediators can 
communicate with the brain via several pathways. By stimulating afferent sensory nerve 
fibers, entering the brain via the circumventricular organs or by binding to cerebral blood 
vessel endothelium immune mediators effectively redirect energy-rich substrates towards the 
immune system (41, 42). 
 
Besides inflammatory cytokines, prostaglandins synthesized via the cyclooxygenase system 
play a central role in inflammation and HPA-axis activation. Zimomra et al. (65) demonstrated 
that in rats the initial activation of the HPA-axis by LPS is mediated by prostaglandins, like 
PgE2, while inflammatory cytokines maintain corticosterone levels at later time-points. In this 
study it was suggested that prostaglandins stimulated corticosterone release in a direct 
manner, since the peak in circulating corticosterone levels was observed long before the peak 
in circulating ACTH. This idea was confirmed by a study in rodents, showing that PgE2 
directly stimulated the release of glucocorticoids from the adrenal gland (66). In human 
adrenal cells expressing TLR2 and TLR4, LPS stimulation resulted in the release of cortisol. 




As indicated, TLR4 activation stimulates the release of PgE2 by immune cells, adipocytes, 
endothelial, epithelial and probably also adrenal cells (68), inducing the peripheral release of 
glucocorticoids from the adrenal gland (66). PgE2 also activates glucocorticoid production 
through activation of the HPA-axis at the level of the hypothalamus and the pituitary (69). 
Macrophages, homing in blood vessels in the cranium, are directly activated by danger signals 
such as LPS. Activation of these special macrophages induces the production of PgE2 which 
directly stimulates the paraventricular nucleus of the hypothalamus, leading to higher 
production of glucocorticoids which should probably protect against possible inflammation 
of the brain (69). 
 
5. Acute stress increases pro-inflammatory pathways by 
increasing intestinal permeability 
Acute stress modulates the immune response and changes immune cell distribution. These 
neuroendocrine effects on the immune system are mediated by stress-hormones released 
from the adrenal gland, by direct innervation of sympathetic nerve fibers into lymphoid 
organs and by stress hormone receptors expressed on immune cells, like glucocorticoid 
receptors (GR) and α- and β-adrenergic receptors (70-72). It has been suggested that by 
mobilizing immune cells, the stress response, also known as the “fight-flight reaction”, 
prepares the immune system for oncoming challenges (70). 
 
In addition, acute stress increases circulating pro-inflammatory mediators (73-75). In subjects 
exposed to acute stress, NF-κB was up-regulated in peripheral blood mononuclear cells in 
parallel with elevated levels of circulating catecholamines and glucocorticoids (76). Until now 
it is not completely understood what causes this pro-inflammatory response. Glucocorticoids 
mostly have an inhibitory effect on inflammatory pathways and catecholamines a rather 
modulating than activating influence on the immune system (71, 72, 77), however, it has been 
shown that activation of the β-adrenergic receptor by noradrenalin (but not adrenalin) 
increased NF-κB binding to DNA in monocytes in vitro (76). A recent study in rodents showed 
that acute stress-induced neuro-inflammation could be prevented by a pre-stress treatment 
with antibiotics or an inhibitor of MLCK. In addition, these treatments prevented stress-
induced hyper-permeability and endotoxemia, indicating that it is not the stress-factor itself 
producing a pro-inflammatory response of the immune system, but the fact that stress 
increases barrier permeability and the translocation of endotoxin into the circulation. Pre-
stress probiotic treatment with Lactobacillus farciminis had similar effects, which could be 
explained by its ability to enhance intestinal barrier function (78). In agreement with these 
results, it could be hypothesized that the (short lasting) pro-inflammatory activity in humans 
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observed during acute stress is initiated by a stress-induced increase in intestinal 
permeability, mediated by the SNS and components of the HPA-axis, and resulting in higher 
levels of translocating endotoxin interacting with TLR on immune cells, adipocytes and 
epithelial cells. A schematic overview of the complex neuroendocrine-immune interactions 
and their relation to gut barrier function are displayed in Figure 2. 
 
6. Chronic stress dysregulates the HPA-axis and changes immune 
function 
Chronic psychological stress is known to dysregulate the immune system. These alterations 
are accompanied by low-grade inflammation, delayed wound healing and increased 
susceptibility to infectious diseases (79). Chronic stress leads to hypercortisolemia (77), long 
term permeability of barriers, endotoxemia and low-grade inflammation (our hypothesis and 
theory). Normally, the release of glucocorticoids puts a limit on the maximum activity of the 
immune system, however, chronic HPA-axis stimulation can result in glucocorticoid 
resistance at the level of the immune system, making it insensitive to its inhibitory and 
modulatory actions (2). This process is observed in several conditions (including conditions 
related to psychosocial stress), whereby immune cells from patients are less responsive to the 
inhibitory actions of glucocorticoids on cytokine release and cell proliferation after 
stimulation in vitro (80-83). In addition, chronic stress induces a shift in the production of 
type 1 cytokines towards type 2 cytokine production. It can be deducted that by this 
mechanism, the part of the immune system involved in the clearance of extracellular bacteria 
and bacterial toxins (the type 2 response) is prevented from being suppressed, protection 
against ongoing microbial infiltration (endotoxemia) is guaranteed, while the type 1 response, 
involved in clearance of intracellular pathogens (like viruses) is inhibited (71, 84). 
 
7. Life style-related factors induce endotoxemia  
The fact that stress increases barrier permeability and thereby enhances the availability of 
water, sodium and nutrients, makes sense from an evolutionary perspective. However, the 
question arises if the accompanied translocation of bacteria and their toxins should also be 
considered beneficial for the host. We speculate that when the composition of the microbiota 
is physiological, and barrier opening is short-lasting, acute stress will not produce low-grade 
inflammation. However, modern people suffer from new multi-factorial stressors, such as 
chronic psychosocial stress and the consumption of a “Western diet”, which constantly 
challenges the stress-axis, alters microbiota composition and thereby compromises intestinal 
barrier function. This next section discusses how modern lifestyle factors impact the gut-




7.1. Gut microbiota modulate stress-axis and influence gut barrier function 
Large differences in the composition of the gut-microbiota and an overall reduction in 
microbial diversity are observed in Western populations when compared to traditional 
Hunter-gatherers or people from rural Africa (85, 86). These environment and diet-induced 
changes in gut microbiota have been connected to an increased susceptibility to chronic 
diseases, like IBD, obesity, type 1 and type 2 diabetes (87). The gut microbiota influences 
inflammatory (88) and metabolic processes (89) and has been shown to influence the 
development of the HPA-axis and immune system (90, 91). For example, exposure to LPS 
during developmental periods can exaggerate the HPA-axis and immune response to stress 
(92, 93), but also the absence of bacteria can induce these effects. Animals raised in germ-free 
environments showed an exaggerated HPA-axis response, which was normalized by 
colonization with fecal matter from specifically germ free animals or by the administration of 
the Gram-positive Bifidobacterium infantis (94). Vice versa, exposure to social stress changed 
the composition of the gut microbiota in mice (95, 96) and prenatal stress altered the 
microbiome in rhesus monkeys by reducing the overall numbers of the Gram-positive 
Bifidobacteria and Lactobacilli (97), indicating that chronic stress affected the composition of 
the gut microbiome. Stress influences gut motility, secretions, and mucin production, thereby 
altering the habitat of resident bacteria, promoting changes in the composition of the gut 
microbiome (98) and allowing the growth of pathogenic bacteria (99). 
 
Increasing evidence supports an important role for microbiota on the homeostasis of the 
intestinal barrier. Certain strains of the Gram-positive Lactobacilli decreased intestinal 
permeability in several animal and human disease models (78, 100). Bifidobacterium infantis 
reduced intestinal permeability (as assessed by 70-kDa fluorescein isothiocyanate–dextran 
transmucosal flux) and ameliorated symptoms in a neonatal necrotizing enterocolitis mouse 
model (101). Further evidence indicating the influence of the gut-microbiota on intestinal 
permeability was presented in detoxifying alcoholic-dependent subjects: Lower levels of 
Ruminococcaceae and higher abundance of Lachnospiraceae (Dorea) and Blautia were 
associated with increased intestinal permeability (102). In addition, higher levels of certain 
pathogenic bacteria can increase intestinal permeability by disrupting the epithelial barrier 
and triggering cell death and inflammation. These bacteria have the ability to bind and/or 
translocate through endothelial and microfold cells and have been shown to secrete toxins or 
other effector molecules via specialized secretion systems. Although the exact mechanisms 
are not well described, most pathogenic gut bacteria including Escherichia coli, Helicobacter 
pylori, Staphylococcus aureus, Cholera Pseudomanas fluorescens, Pseudomanas eruginosa, 
Yersinia enterocolitica, Campylobacter jejuni and Salmonella typhimurium alter paracellular 
permeability by disassembling tight junctions and generating cytoskeleton changes by 
increasing inflammation (reviewed by Barreau et al. (103)). As an example, a strain of 
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Escherichia coli, normally present in the human gut, induced focal leaks in colonic epithelial 
monolayers and in rat distal colon by using α-hemolysin, allowing for their paracellular 
translocation across the epithelial layer (104). 
 
7.2. High-caloric and high-fat diets induce inflammation and increase 
circulating endotoxin levels 
Compared to ealthy individuals, patients suffering from obesity have higher circulating 
endotoxin levels together with greater levels of circulating pro-inflammatory cytokines and 
insulin resistance (105). Food intake can produce postprandial immune activation and elevate 
endotoxin levels when a meal is high in calories (106) or has a high fat content (6, 107-109). 
 
Rodents fed a 4-week high-fat diet (72% fat) showed a constant elevation in circulating 
endotoxin levels, while in control animals endotoxin levels only increased during feeding 
hours. Furthermore, a high-fat diet produced fasting glycaemia, insulin resistance, general 
weight gain and weight gain of the liver and visceral and subcutaneous adipose tissue. In 
addition, adipose tissue F4/80-positive cells (indicating the infiltration of macrophages), 
markers of inflammation and liver triglyceride content were increased. Interestingly, almost 
similar effects were observed in mice subcutaneously infused with LPS (resulting in similar 
circulating LPS levels as observed in the high-fat fed mice). These effects were mediated by 
TLR4, since mice lacking CD14, which is important for the recognition of LPS to this receptor, 
showed a delayed response to a high-fat diet or LPS injections (107). 
 
In healthy humans a 910 calories high-fat and high carbohydrate meal resulted in increased 
circulating endotoxin levels and elevated levels of LBP in parallel with higher inflammatory 
markers and increased protein expression of TLR2 and TLR4 in isolated leukocytes. A meal 
high in fruits and fibre did not induce these effects (108). Plasma endotoxin levels, pro-
inflammatory markers and leukocyte TLR4 expression increased after the intake of cream (300 
calories), while the intake of 300 calories of glucose resulted only in a pro-inflammatory 
response and the intake of orange juice and water showed none of these effects (110). In 
healthy individuals, plasma endotoxin levels increased about 50% after the intake of a high-fat 
meal (900 calories) (6) and 4 weeks consumption of a Western-style diet raised plasma 
endotoxin activity levels by 71% (111). 
 
How exactly the intake of a high-caloric meal increases circulating endotoxin levels is still 
unclear but has been explained by several mechanisms (reviewed by Kelly et al., 2012 (112). 
One of these suggested mechanisms is that the introduction of a high-fat diet modulates the 
expression of genes involved in the barrier function in epithelial cells, thereby directly 
compromising the integrity of the tight junction (113). Another explanation could be that a 
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high-caloric/high-fat meal induces high levels of insulin and leptin, hormones that directly 
activate the SNS (114, 115). Moreover insulin enhances SGLT1 mediated glucose absorption 
(116). Activation of the SGLT1 and the SNS leads to increased permeability of the gut barrier, 
which may induce the observed post-prandial endotoxemia (our hypothesis and theory). 
 
7.3. Gliadin compromises the integrity of tight junctions 
The intake of wheat and other cereal grains has been implicated in the development of 
inflammation-related diseases, by inducing inflammation and increasing intestinal 
permeability (40). Gliadin, a component of gluten, has been demonstrated to increase 
permeability in human Caco-2 intestinal epithelial cells by reorganizing actin filaments and 
altering expression of junctional complex proteins (117). Several studies by the group of 
Fasano et al. show that the binding of gliadin to the chemokine receptor CXCR3 on epithelial 
IEC-6 and Caco2 cells releases zonulin, a protein that directly compromises the integrity of 
the junctional complex (118, 119). 
 
7.4. Alcohol consumption increases intestinal permeability 
Alcohol consumption is an important risk factor for disease and is one of the major causes of 
chronic liver disease. Increased intestinal permeability has been observed during chronic 
alcohol consumption. In an animal model of chronic alcoholic liver disease, alcohol feeding 
for 8 weeks increased intestinal permeability (120). In humans, alcohol dependence induced 
changes in the gut microbiota composition that were associated with increased intestinal 
permeability (102). Furthermore, increased intestinal permeability and higher circulating 
endotoxin levels were observed in patients with chronic alcohol abuse (121-123). 
 
7.5. Exercise induced heat-stress increases intestinal permeability 
Exercise increases body temperature, reduces intestinal blood flow (reallocated to the muscles 
and cardiac system) and increases intestinal permeability by activating the SNS and HPA-axis. 
Already in 1992, Oktedalen et al. (124) showed that marathon runners displayed a significant 
increase in intestinal permeability. In addition, studies have indicated that strenuous exercise 
induced higher circulating endotoxin levels and activated the immune system (125-128). 
Further evidence of exercise- and heat-induced increased intestinal permeability, leading to 





8 Endotoxemia is associated with diseases related to chronic 
inflammation 
Multiple human studies have emerged that find associations with NCDs and markers of 
endotoxemia. Even aging, associated with higher sympathetic nerve activity (130) and higher 
circulating inflammatory mediators like Il-6, has been linked to higher plasma concentration 
of LPS and LBP (131). In further support of our theory, in this section an overview is given of 
human studies finding changes in levels of endotoxin or endotoxin-related markers in NCDs 
(Table 1). 
 
8.1. Metabolic syndrome 
Metabolic syndrome is accompanied by an increased risk for NAFLD, obesity, type 2 diabetes 
and cardiovascular diseases. All of these conditions are related to and even predicted by an 
increased sympathetic activity (132) and a dysregulated HPA-axis (133). Higher circulating 
endotoxin and LBP levels are associated with risk factors of the metabolic syndrome, like 
insulin resistance, obesity, dyslipidemia and chronic inflammation (134-137). Patients 
suffering from NAFLD exhibited significantly higher serum endotoxin levels in contrast to 
healthy controls (14). Farhardi et al. (138) indicated that elevated plasma endotoxin levels in 
these patients were related to an impaired intestinal barrier function, because, only in the 
patient group was the intake of a permeability stressor (aspirin) shown to increase the 0–24 h 
urinary excretion of sucralose (a marker of whole-gut permeability). Furthermore, augmented 
plasma LBP levels in concert with increased plasma levels of TNF-α were observed in obese 
NAFLD patients compared to healthy controls (139). 
 
Elevated circulating levels of endotoxin and LBP were detected in type 2 diabetics (12, 135, 
140-142). Compared to healthy controls, obese individuals and type 2 diabetics showed higher 
endotoxin levels after the intake of a high-fat meal. Increased endotoxin levels were observed 
in all challenged individuals, yet higher endotoxin levels were seen in individuals suffering 
from metabolic illnesses, suggesting an increased intestinal permeability in these patients 
(143). This was further indicated by a recent study showing that increased serum levels of 
endotoxin, Il-6 and TNF-α are found in type 2 diabetic patients compared to healthy 
individuals. The level of endotoxin was positively related to zonulin, a marker for intestinal 
permeability (12). 
 
A large cohort of patients with coronary artery disease identified increased serum LBP levels 
to be associated with total and cardiovascular mortality (144). Moreover, circulating LBP levels 
were associated with carotid intima media thickness (a marker of atherosclerosis), obesity, 




Patients suffering from chronic heart failure with aggravated renal function showed increased 
circulating endotoxin levels and an impairment of the intestinal barrier (11). Wiedermann et al. 
(146), showed that subjects with the highest levels of circulating endotoxin (90th percentile) 
had a 3-fold increased risk of incident atherosclerosis. Higher serum endotoxin and pro-
inflammatory cytokine concentrations were seen in patients with edematous chronic heart 
disease compared to stable patients and healthy controls. Intriguingly, after short-term 
diuretic treatment, circulating endotoxin concentrations decreased in edematous patients 
(147). Diuretic treatment (like angiotensin-converting enzyme (ACE) inhibitors) ameliorated 
intestinal inflammation, perhaps by impacting on intestinal permeability through interference 
with the renin-angiotensin-aldosterone system. Several components of this system (renin, 
ACE and angiotensin II) have been shown to stimulate pro-inflammatory pathways (44, 148). 
 
8.2. IBD 
Ulcerative colitis and Crohn’s disease are intestinal inflammatory disorders, also known as 
IBD, which have been causally linked to chronic psychological stress (149), altered immune 
function, changes in the gut microbiota, increased intestinal permeability and endotoxemia 
(150). For example, increased plasma endotoxin and LBP levels were measured in both patient 
groups, but were more pronounced in patients with active disease compared to inactive 
disease and were associated with disease severity (151). In addition, detectable plasma 
endotoxin levels and higher plasma levels of LBP were more frequently observed in IBD 
patients compared to controls (15, 152) and were correlated with disease severity and 
circulating TNF-α levels (153). 
 
8.3. Psychiatric diseases 
Over the last decade, the role of the gut-brain axis has emerged as an important mediator in 
the development of psychiatric and mood disorders (154). Moreover, higher endotoxin levels 
and intestinal barrier dysfunction are observed in several of these conditions. For example, 
Parkinson’s patients exhibited increased total intestinal permeability and a more intense 
staining for Escherichia coli LPS and oxidative stress markers in intestinal sigmoid mucosa 
samples. However, in these patients endotoxin levels resembled control samples and serum 
LBP concentrations were lower compared to healthy individuals (155). Higher serum 
endotoxin levels are associated with severe autism, sporadic amyotrophic lateral sclerosis and 
Alzheimer’s disease (13, 156). Furthermore, increased IgA and IgM responses against LPS of 
commensal bacteria were seen in chronic fatigue syndrome (10) and depression (9). 
Intriguingly, chronic oral infection of periodontitis was associated with Alzheimer’s disease 
where higher antibody levels against oral pathogens were observed years before the onset of 
symptoms in people suffering from Alzheimer’s disease (157), suggesting there was an 
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Chronic low-grade inflammation is an eminent feature of NCDs. In addition, many studies 
report increased circulating endotoxin levels and increased gut permeability in patients 
suffering from these conditions. As reviewed in this paper, stress-induced increases in 
intestinal permeability, in combination with modern life-style factors, raise the possibility of 
translocation of bacteria and/or their toxins across the more permeable gut barrier. The 
resulting, long lasting, endotoxemia should be considered much more than just a risk factor 
for chronic disease; it could be a cause. Notwithstanding the fact that the exact origin and 
sequence of events involved in development of NCDs remain to be unsolved, evidence 
indicates that a disrupted barrier function in parallel with elevated circulating endotoxin levels 
may underlie disease onset and progression. For this reason, applying therapies aimed at 
restoring intestinal barrier function, lifestyle changes and stress management should be 
considered as an important strategy in preventing and attenuating the pro-inflammatory state 
observed in NCDs. 
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Figure 1. MLC phosphorylation increases intestinal permeability.  
Activation of the SNS stimulates intestinal permeability by increasing the activity of SGLT1 on epithelial cells. Activation of 
SGLT1 is paralleled by MLC phosphorylation by MLCK, inducing actomyosin contraction and reorganization of the tight 
junction. The resulting increase in paracellular permeability raises the possibility of translocation of bacteria and/or their 
toxins across the more permeable gut barrier. Pro-inflammatory cytokines produced by activated immune cells residing in 






Figure 2. The complex neuroendocrine-immune interactions and their relation to gut barrier 
function.  
Stressors, including inflammatory mediators, activate the SNS and HPA-axis. Activation of the HPA-axis stimulates the 
neurons in the paraventricular nucleus of the hypothalamus to secrete CRH and AVP that trigger the release of ACTH from 
the anterior pituitary, resulting in the secretion of corticosteroids from the adrenal cortex. CRH has been shown to affect 
intestinal permeability. SNS activation results in the release of catecholamines from the adrenal medulla. The intestinal wall 
is innervated by adrenergic sympathetic nerve fibers that upon stimulation increase water, sodium and glucose absorption, 
paralleled by increased intestinal permeability. The resulting increase in translocation of endotoxin across the intestinal 
barrier can stimulate immune cells in the underlying lamina propria to secrete pro-inflammatory cytokines and 
prostaglandins like PgE2. Inflammatory mediators communicate with the brain by stimulating afferent sensory nerve fibers, 
by entering the brain via the circumventricular organs or by binding to cerebral blood vessel endothelium. Continuous 
stress-induced impairment of the intestinal barrier creates a vicious circle whereby inflammatory cytokines will persistently 
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Wheat is one of the most consumed cereal grains worldwide and makes up a substantial part 
of the human diet. Although government supported dietary guidelines in Europe and the 
U.S.A advise individuals to eat adequate amounts of (whole) grain products per day, cereal 
grains contain “anti-nutrients”, such as wheat gluten and wheat lectin, that in humans can 
elicit dysfunction and disease. In this review we discuss evidence from in vitro, in vivo and 
human intervention studies that describe how the consumption of wheat, but also other 
cereal grains, can contribute to the manifestation of chronic inflammation and auto-immune 
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Inflammation is the response of the innate immune system triggered by noxious stimuli, 
microbial pathogens and injury. When a trigger remains or when immune cells are 
continuously activated an inflammatory response may become self-sustainable and chronic. 
Chronic inflammation has been associated with many medical and psychiatric disorders, 
including cardiovascular disease, metabolic syndrome, cancer, auto-immune diseases, 
schizophrenia and depression [1,2,3]. Furthermore, it is usually associated with elevated levels 
of pro-inflammatory cytokines and acute phase proteins, such as interferons (IFNs), 
interleukin (Il)-1, Il-6, tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP). While 
clear peripheral sources for this chronic inflammation are apparent in some conditions (i.e. fat 
production of cytokines in the metabolic syndrome), in other disorders, such as major 
depression, the inflammatory source is not completely understood. Genetic vulnerability, 
psychological stress and poor dietary patterns have all been repeatedly implicated as being of 
significant importance in the development of an inflammatory phenotype [3,4,5]. Dietary 
factors associated with inflammation include a shift towards a higher n-6:n-3 fatty acid 
ratio [5] and a high intake of simple sugars [6]. Other substances in our daily food, like those 
found in wheat and other cereal grains, are also capable of activating pro-inflammatory 
pathways. 
 
2. Wheat grain, gluten and disease 
2.1. Wheat allergy and intolerance 
The ingestion of wheat products has been reported to be responsible for IgE-mediated allergic 
reactions. Wheat-dependent exercise-induced anaphylaxis is a syndrome in which the 
ingestion of a product containing wheat followed by physical exercise can result in an 
anaphylactic response. Several proteins present in wheat, most notably gluten proteins have 
been shown to react with IgE in patients [7]. Other allergic responses that appear to be related 
to a range of wheat proteins include Bakers asthma, rhinitis and contact urticaria [7,8]. 
 
More common than wheat allergies are conditions involving wheat intolerance, including 
coeliac disease (CD), which is estimated to affect 1% of the population of Western Europe, and 
dermatitis herpetiformis, which has an incidence between about 2-fold and 5-fold lower than 
CD [9]. The close association between type 1 diabetes and CD [10] and the observation that 
auto-immune diseases seem to be more prevalent in coeliac patients and their relatives [11] 




2.2. Wheat grain and gluten  
Gluten is the main structural protein complex of wheat consisting of glutenins and gliadins. 
When wheat flour is mixed with water to form dough, the gluten proteins form a continuous 
network which provides the cohesiveness and viscoelasticity that allows dough to be 
processed into bread, noodles and other foods. The protein contents of wheat varies between 
7-22% with gluten constituting about 80% of the total protein of the seed [9]. Glutenins are the 
fraction of wheat proteins that are soluble in dilute acids and are polymers of individual 
proteins. Prolamins are the alcohol soluble proteins of cereal grains and are specifically 
named gliadins in wheat. Gliadins are monomeric proteins and are classified into three 
groups: these are α/β-gliadins, γ-gliadins and ω-gliadins [7]. 
 
2.3. Gluten, gliadin and CD 
Gliadin epitopes from wheat gluten and related prolamins from other gluten-containing 
cereal grains, including rye and barley, can trigger CD in genetically susceptible people. The 
symptoms of this disease are mucosal inflammation, small intestine villous atrophy, increased 
intestinal permeability and malabsorption of macro- and micronutrients. CD, a chronic 
inflammatory disorder mediated by T-cells, is preceded by changes in intestinal permeability 
and pro-inflammatory activity of the innate immune system. Gliadin immunomodulatory 
peptides can be recognized by specific T-cells, a process that can be enhanced by the 
deamidation of gliadin epitopes by tissue transglutaminases that convert particular glutamine 
residues into glutamic acid resulting in a higher affinity for HLA-DQ2 or DQ8 expressed on 
antigen presenting cells (APC) [10]. Serum antibodies, among which are antibodies against 
tissue transglutaminases, are also found in CD. The HLA-DQ2 or HLA-DQ8 is expressed in 
99.4% of the patients suffering from CD [10], but interestingly enough there is a group HLA-
DQ2/DQ8 negative patients suffering from gastrointestinal symptoms that respond well to a 
gluten-free diet. This group of “gluten-sensitive” patients does not have the CD serology and 
histopathology, but does present the same symptoms and shows improvements when 
following a gluten-free diet [12,13]. 
 
2.4. Gliadin and immunity 
There are at least 50 gliadin epitopes that exert immunomodulatory, cytotoxic and gut 
permeating activities that can be partially traced back to different domains of α-gliadin. Where 
some immunomodulatory gliadin peptides activate specific T-cells, others are able to induce a 
pro-inflammatory innate immune response [10]. Stimulation of immune cells by gliadin is not 
only restricted to CD patients; the incubation of peripheral blood mononuclear cells (PBMC) 
from healthy HLA-DQ2 positive controls and CD patients with gliadin peptides stimulated the 
production of IL-23, IL-1β and TNF-α in all donors tested. Still the production of cytokines was 
significantly higher in PBMC derived from CD patients [14]. Similar results were obtained by 
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Lammers et al. [15] showing that gliadin induced an inflammatory immune response in both 
CD patients and healthy controls, yet IL-6, Il-13 and IFN-γ were expressed at significantly 
higher levels in CD patients. IL-8 production was only expressed in a subset of healthy and CD 
individuals after stimulation with a specific gliadin peptide and appeared to dependent on the 
CXCR3 chemokine receptor only in CD patients. Sapone et al. [16] showed that in a subset of 
CD patients, but not in gluten-sensitive patients (with 36% of the studied individuals in this 
group being HLA-DQ2/DQ8 positive), there is an increased IL-17 mRNA expression in the 
small-intestinal mucosa compared to healthy controls. The same group showed that in a 
subset of gluten sensitive patients (with 50% of the studied individuals being HLA-DQ2/DQ8 
positive) there is a prevailing stimulation of cells of the innate immune system, while in CD 
both the innate and adaptive immune system are involved [13]. 
 
2.5. Gliadin and intestinal permeability 
In order for gliadin to interact with cells of the immune system it has to overcome the 
intestinal barrier. Gliadin peptides cross the epithelial layer by transcytosis or paracellular 
transport. Paracellular transport occurs when intestinal permeability is increased, a feature 
that is characteristic for CD [17]. It is indicated by several studies that increased intestinal 
permeability precedes the onset of CD and is not just a consequence of chronic intestinal 
inflammation [18,19]. Gliadin has been demonstrated to increase permeability in human 
Caco-2 intestinal epithelial cells by reorganizing actin filaments and alter expression of 
junctional complex proteins  [20]. Several studies by the group of Fasano et al. show that the 
binding of gliadin to the chemokine receptor CXCR3 on epithelial IEC-6 and Caco2 cells 
releases zonulin, a protein that directly compromises the integrity of the junctional 
complex [21,22]. Although zonulin levels were more up-regulated in CD patients, zonulin was 
activated by gliadin in all intestinal biopsies from both CD and non-CD patients [21,22], 
suggesting that gliadin can increase intestinal permeability also in non-CD patients, yet 
increased intestinal permeability was not observed in a group of gluten-sensitive patients [13]. 
 
3. Increased intestinal permeability 
3.1. Increased intestinal permeability is associated with disease 
Chronically increased intestinal permeability (or leaky gut syndrome) allows for the increased 
translocation of both microbial and dietary antigens to the periphery which can then interact 
with cells of the immune system. Shared amino acid motifs among exogenous peptides (HLA-
derived peptides and self tissue) may produce cross reactivity through immunological 
mimicry, thereby disturbing immune tolerance in genetically susceptible individuals [23]. Not 
surprisingly, increased intestinal permeability has been associated with auto-immune 
diseases, such as type 1 diabetes [24], rheumatoid arthritis, multiple sclerosis [18], but also with 
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diseases related to chronic inflammation like inflammatory bowel disease [18,25], asthma [26], 
chronic fatigue syndrome and depression. The latter two conditions see patients with 
significantly greater values of serum IgA and IgM to LPS of gram-negative enterobacteria 
compared to controls, implying intestinal permeability is increased in these 
patients [27,28,29]. 
 
3.2. Intestinal barrier function and inflammation  
The intestinal barrier allows the uptake of nutrients and protects from damage of harmful 
substances from the gut lumen. Macromolecules that can be immunogenic like proteins, large 
peptides but also bacteria and lectins can be endocytosed or phagocytosed by enterocytes 
forming the epithelial layer of the gut. Absorbed proteins generally will be entering the 
lysosomal route and will be degraded to small peptides. Normally, only small amounts of 
antigen pass the barrier by transcytosis and interact with the innate and adaptive immune 
system situated in the lamina propria. Highly specialized epithelial microfold (M) cells 
function as active transporters of dietary and microbial antigens from the gut lumen to the 
immune system where either a pro-inflammatory or tolerogenic immune response can be 
generated. The paracellular route is regulated by the junctional complex that allows the 
passage of water, solutes and ions, but under normal conditions provides a barrier to larger 
peptides and protein-sized molecules. When the barrier function is disrupted there is an 
increased passage of dietary and microbial antigens interacting with cells of the immune 
system [25,30] (Figure 1).  
 
3.3. The role of zonulin signaling on intestinal permeability 
Intestinal permeability is a measure of the barrier function of the gut which relates to the 
paracellular space surrounding the brush border surface of the enterocytes and the junctional 
complexes consisting of tight junctions, adherent junctions, desmosomes and gap 
junctions [31]. The junctional complexes are regulated in response to physiological and 
immunological stimuli, like stress, cytokines, dietary antigens and microbial products [31]. As 
mentioned before, zonulin, a protein identified as prehaptoglobulin-2 (the precursor of 
haptoglobin-2) is also a regulator of intestinal permeability. Haptoglobin-2, together with 
haptoglobin-1, is one of the two gene variants of the multifunctional protein haptoglobin and 
is associated with an increased risk for CD (homozygotes and heterozygotes) and severe 
malabsorption (homozygotes) [32,33]. The haptoglobulin-2/zonulin allele has a frequency of 
about 0.6 in Europe and the U.S.A, but varies throughout the world depending on racial 





Figure 1. Increased intestinal permeability allows for the passage of microbial and dietary 
antigens across the epithelial layer into the lamina propria where these antigens can be taken up 
by APC and presented to T-cells. JC, junctional complex. 
 
3.4. High zonulin levels are observed in auto-immune and inflammatory 
diseases 
Zonulin signalling is proposed to cause rearrangements of actin filaments and induces the 
displacement of proteins from the junctional complex, thereby increasing 
permeability [18,32,35]. Gliadin peptides initiate intestinal permeability through the release of 
zonulin, thereby enabling paracellular translocation of gliadin and other dietary and microbial 
antigens, which by interacting with the immune system give rise to inflammation. In this 
manner a vicious cycle is created in which, as a consequence of the persistent presence of 
pro-inflammatory mediators, intestinal permeability will increase even further. High zonulin 
levels (together with increased intestinal permeability) have been observed in auto-immune 
and inflammatory diseases like CD, multiple sclerosis, asthma and inflammatory bowel 
disease and the haptoglobin polymorphism is associated with rheumatoid arthritis, 
ankylosing spondylitis, schizophrenia and certain types of cancer [32]. 
The zonulin inhibitor Larozotide acetate was tested in an inpatient, double-blind randomized 
placebo controlled trial. The group of CD patients in the placebo group that were exposed to 
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gluten showed a 70% increase in intestinal permeability, while no changes were seen in the 
group exposed to Larazotide acetate. Also gastrointestinal symptoms were significant more 
frequent in the placebo group [32]. These results suggest that in CD patients, when intestinal 
barrier function is restored, autoimmunity will disappear while the trigger (gluten) is still there. 
Besides gliadin from wheat gluten, the lectin wheat germ agglutinin (WGA) has also been 
shown to stimulate cells of the immune system and increase intestinal permeability, as we will 
now further discuss.  
 
4.  WGA 
4.1. Dietary WGA 
Lectins are present in a variety of plants, especially in seeds, where they serve as defense 
mechanisms against other plants and fungi. Because of their ability to bind to virtually all cell 
types and cause damage to several organs, lectins are widely recognized as anti-nutrients 
within food [36]. Most lectins are resistant to heat and the effects of digestive enzymes and are 
able to bind to several tissues and organs in vitro and in vivo (reviewed by Freed 1991 [37]). The 
administration of the lectin WGA to experimental animals caused hyperplastic and 
hypertrophic growth of the small intestine, hypertrophic growth of the pancreas and thymus 
atrophy [36]. Lectin activity has been demonstrated in wheat, rye, barley, oats, corn and rice, 
however the best studied of the cereal grain lectins is WGA [38].  
 
The highest WGA concentrations are found in wheat germ (up to 0.5 g/kg [39]). Although 
unprocessed wheat germ, like muesli, contains far higher amounts of active WGA than do 
processed wheat germ products, WGA activity is still apparent in several processed breakfast 
cereals as assessed by hemagglutination and bacterial agglutination assays [40,41]. A summary 
of the amount of active WGA in commonly consumed wheat derived products is listed in 
Table 1.  
 
4.2. WGA binds to cell surface glycoconjugates  
WGA binds to N-glycolylneuraminic acid (Neu5Ac), the sialic acid predominantly found in 
humans [42], allowing it to adhere to cell surfaces like the epithelial layer of the gut. The 
surface of many prokaryotic and eukaryotic cells are covered with a dense coating of 
glycoconjugates, also named glycocalyx. Sialic acids are a wide family of nine-carbon sugars 
that are typically found at the terminal positions of many surface exposed glycoconjugates 
and function for self recognition in the vertebrate immune system, but they can also be used 
as binding target for pathogenic extrinsic receptors and molecular toxins [43,44,45]. WGA 
binding to Neu5Ac of the glycocalyx of human cells (and pathogens expressing Neu5Ac) 
allows for cell entry and could disturb immune tolerance by evoking a pro-inflammatory 




4.3. WGA and immunity 
WGA induces inflammatory responses by immune cells. For example, WGA has been shown 
to trigger histamine secretion and granule extrusion from non-stimulated rat peritoneal mast 
cells [46], induce NADP-oxidase activity in human neutrophils [47] and stimulate the release 
of the cytokines IL-4 and IL-13 from human basophils [48]. In human PBMC, WGA induced 
the production of IL-2, while simultaneously inhibiting the proliferation of activated 
lymphocytes [49]. WGA stimulated the secretion of IL-12, in a T and B-cell independent 
manner in murine spleen cells. IL-12, in turn, activated the secretion of IFN-γ by T or natural 
killer cells [50]. In murine peritoneal macrophages WGA induced the production of the pro-
inflammatory cytokines TNF-α, IL-1β, IL-12 and IFN-γ [51]. Similar results have been observed 
in isolated human PBMC, given that nanomolar concentrations of WGA stimulated the release 
of several pro-inflammatory cytokines. In the same study a significant increase in the 
intracellular accumulation of IL-1β was measured in monocytes after WGA exposure [52]. 
These results indicate that when delivered in vitro WGA is capable of directly stimulating 
monocytes and macrophages, cells that have the ability to initiate and maintain inflammatory 
responses. Monocytic cells have been shown to engulf WGA via receptor-mediated 
endocytosis or by binding to non-receptor glycoproteins [53]. 
 
Human data showing the influence of WGA intake on inflammatory markers are lacking, 
however, antibodies to WGA have been detected in the serum of healthy individuals [54]. 
Significantly higher antibody levels to WGA were measured in patients with CD compared to 
patients with other intestinal disorders. These antibodies did not cross-react with gluten 




Table 1. Amount of active WGA in wheat derived products 
Wheat derived products WGA µg/g (±SD)  Reference source 
Wheat germ 300 (±35) Vincenzi et al., 2000  [56] 
Wheat germ 100 - 500  Peumans and Van Damme, 1996 
 [39] 
Semolinaa 4.0 (±1.0) – 10.7 (±1.5)  Matucci et al., 2004  [57] 
Floura  4.3 (±0.7) – 4.4 (±1.0)   
Wholemeal flour a 29.5 (±2.5) – 50 (±5.5)   
Pastaa  ≤ 0.4 (±0.2) – 3.2 
(±0,2) 
 
Pasta  cookeda ≤ 0.3 (±0.2)  
Wholemeal pasta (enriched 
with wheat germ) 
40 (±2.7)    
Wholemeal pasta (enriched 
with wheat germ) cooked 
Not detectable  
Wholemeal pastaa  0 – 5.7 (±0.2)  
Wholemeal pasta cookeda Not detectable  
Breakfast cerealsa  13 - 53  Ortega-Barria et al., 1994  [41] 
a  Values are obtained from more than one product and from different manufacturers. 
 
4.4. WGA and intestinal permeability 
After ingestion, WGA is capable of crossing the intestinal barrier. In animal models, WGA has 
been shown to reach the basolateral membrane and walls of the small blood vessels in the 
subepithelium of the small intestine [36]. WGA can be phagocytosed by binding to membrane 
non-receptor glycoproteins, a process that has been observed in Caco-2 cells [58]. WGA can 
also be endocytosed by antigen sampling M-cells [59,60] or by enterocytes via binding to 
epidermal growth factor receptors [61]. Another possible route for lectin entry into the 
periphery is by paracellular transport, a process that can be further aggravated by the binding 
of gliadin to the chemokine receptor CXR3 on enterocytes. 
 
WGA itself has been found to affect enterocyte permeability. Investigations by Dalla Pellegrina 
et al. [52] showed in vitro that exposure to micromolar concentrations of WGA impairs the 
integrity of the intestinal epithelial layer, allowing passage of small molecules, like lectins. At 
the basolateral side of the epithelium, WGA concentrations in the nanomolar range induced 
the secretion of pro-inflammatory cytokines by immune cells [52]. This may further affect the 
integrity of the epithelial layer, heightening the potential for a positive feedback loop between 
WGA, epithelial cells and immune cells. When combined, these mechanisms are likely able to 
significantly increase the percentage of consumed WGA that can cross the epithelial layer 
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compared to the low percentage of WGA crossing by means of transcytosis (0.1%) alone [52]. 
This suggests that together with gliadin, WGA can increase intestinal permeability, resulting 
in an increase of translocating microbial and dietary antigens interacting with cells of the 
immune system. 
 
5.  Animal data on cereal grain intake 
There are two rodent models of spontaneous type 1 diabetes: the non-obese-diabetic (NOD) 
mouse and the diabetes-prone BioBreeding (BBdp) rat. In these animals a cereal-based diet 
containing wheat induced the development of type 1 diabetes, while animals fed a 
hypoallergenic diet (gluten free) or a hypoallergenic diet supplemented with casein showed a 
decreased incidence and a delayed onset of this disease. BBdp rats fed a cereal-based diet 
showed increased intestinal permeability and a significant increase in the percentage of IFN-γ 
producing Th1 lymphocytes in the mesenteric lymph nodes in the gut [30]. Compared to 
animals fed a hypoallergenic diet, NOD mice fed a wheat-based diet expressed higher mRNA 
levels of the pro-inflammatory cytokines IFN-γ and TNF-α and the inflammatory marker 
inducible NO synthase in the small intestine. While these diet-induced changes in gut-wall 
inflammatory activity did not translate to increased cytokine mRNA in Peyers patches, 
structures that contribute to immune regulation to exogenous antigens, it is possible that the 
gut-signal may promote systemic inflammation via other mechanisms, such as activating 
intraepithelial lymphocytes and mesenteric lymph node cells [62]. These in vivo results show 
that in two rodent models of spontaneous type 1 diabetes a cereal containing diet induces the 
(early) onset of disease and increases markers of inflammation. In addition, Chignola et al. [63] 
have shown in rats that a WGA-depleted diet was associated with reduced responsiveness of 
lymphocytes from primary and secondary lymphoid organs after in vitro stimulation and 
attenuated spontaneous proliferation when compared to lymphocytes from rats fed a WGA-
containing diet, indicating the stimulatory effect of WGA on cells of the immune system.  
 
6.  Human studies on cereal grain intake and inflammation 
6.1. Human epidemiological data on cereal grain intake and inflammation 
Observational prospective and cross-sectional studies show that the intake of whole grain 
products is associated with reduced risks for developing type 2 diabetes, cardiovascular 
diseases, obesity and some types of cancer [64]. Inflammation is associated with these 
conditions and some studies have shown that associations between the intake of whole grains 
and decreased inflammatory markers (CRP, Il-6) are found [65]. Intervention studies, however, 
do not demonstrate a clear effect of the intake of whole grains on 
inflammation [66,67,68,69,70,71] and it could therefore be that other components in the diet 




It has been shown that the intake of whole grains is associated with healthier dietary factors 
and a healthier lifestyle in general. In a Scandinavian cross sectional study, the intake of whole 
grains was directly associated with the length of education, the intake of vegetables, fruits, 
dairy products, fish, shellfish, coffee, tea and margarine and inversely associated with 
smoking, BMI and the intake of red meat, white bread, alcohol, cakes and biscuits [72]. Good 
quality epidemiological studies attempt to control for these confounding factors, but with the 
consequence that associations are attenuated or become insignificant. 
 
6.2. Human intervention trials on cereal grain intake and inflammation 
To really estimate the causal relationship of cereal grain intake and inflammation, 
intervention trials provide us with better evidence. Wolever et al. [71] showed that a diet with a 
low glycemic index (containing whole grains) compared to high (containing refined grain 
products), resulted in sustained reductions in postprandial glucose and CRP levels on the 
long-term in patients with type 2 diabetes treated with diet alone. A refined grain is a whole 
grain that has been stripped of its outer shell (fiber) and its germ, leaving only the endosperm, 
resulting in lower levels of macro- and micronutrients and a higher dietary glycemic index for 
refined grains compared to whole grains. Refined wheat products contain less WGA, but still 
contain a substantial amount of gluten. It should be noted that whole grains contain 
phytochemicals, like polyphenols, that can exert anti-inflammatory effects which could 
possibly offset any potentially pro-inflammatory effects of gluten and lectins [73]. 
 
 The substitution of whole grain (mainly based on milled wheat) for refined grains products in 
the daily diet of healthy moderately overweight adults for 6 weeks did not affect insulin 
sensitivity or markers of lipid peroxidation and inflammation [66]. Consistent with these 
finding are the results of Brownlee et al. [67], who showed that infrequent whole-grain 
consumers, when increasing whole grain consumption (including whole wheat products), 
responded with no improvements of the studied biomarkers of cardiovascular health, 
including insulin sensitivity, plasma lipid profile and markers of inflammation. The 
substitution of refined cereal grains and white bread with 3 portions of whole wheat food or 1 
portions of whole wheat food combined with 2 servings of oats significantly decreased the 
systolic blood pressure and pulse pressure in middle-aged, healthy, overweight men and 
women, yet none of the interventions significantly affected systemic markers of 
inflammation [70]. In obese adults suffering from metabolic syndrome there were 
significantly greater decreases in CRP and the percentage of body fat in the abdominal region 
in participants consuming whole grains compared to those consuming refined grains. It must 
be noted that both diets were hypocaloric (reduced by 500 kcal/d) [69]. Most of the 
intervention studies mentioned above attempted to increase whole-grain intake and were 
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using refined grain diets as controls, thereby making it very difficult to draw any conclusions 
on the independent role of cereal grains in disease and inflammation. 
 
6.3. Health effects of the paleolithic diet 
There are few studies that investigate the influence of a paleolithic type diet comprising lean 
meat, fruits, vegetables and nuts, and excluding food types, such as dairy, legumes and cereal 
grains, on health. In domestic pigs the paleolithic diet conferred higher insulin sensitivity, 
lower CRP and lower blood pressure when compared to a cereal based diet [74]. In healthy 
sedentary humans the short-term consumption of a paleolithic type diet improved blood 
pressure and glucose tolerance, decreased insulin secretion, increased insulin sensitivity and 
improved lipid profiles [75]. Glucose tolerance also improved in patients suffering from a 
combination of ischemic heart disease and either glucose intolerance or type 2 diabetes that 
were advised to follow a paleolithic diet. Control subjects who were advised to follow a 
Mediterranean-like diet based on whole grains, low-fat dairy products, fish, fruits and 
vegetables did not significantly improve their glucose tolerance despite decreases in weight 
and waist circumference [76]. Similar positive results on glycemic control were obtained in 
diabetic patients when the paleolithic diet was compared with the diabetes diet. Participants 
were on each diet for 3 months where the paleolithic diet resulted in a lower BMI, weight and 
waist circumference, higher mean HDL, lower mean levels of hemoglobin A1c, triacylglycerol 
and diastolic blood pressure, yet levels of CRP were not significantly different [77]. Although 
the paleolithic diet studies are small, these results suggest that, together with other dietary 
changes, the withdrawal of cereal grains from the diet has a positive effect on health. 
Nevertheless, because these studies are confounded by the presence or absence of other 
dietary substances and by differences in energy and macronutrient intake, factors that could 
all affect markers of inflammation, it is difficult to make a concise statement on the impact of 
cereal grains on these health outcomes. 
 
6.4. Rechallenge trial of effects of dietary gluten 
One human intervention study specifically focused on the effects of dietary gluten on 
inflammation. Biesiekierski et al. [12] undertook a double-blind randomized, placebo-
controlled rechallenge trial to investigate the influence of gluten in individuals with irritable 
bowel syndrome but without clinical features of CD, who reached satisfactory levels of 
symptom control with a gluten-free diet. After screening the participants, about 50% of the 
individuals in both the gluten and placebo group were HLA-DQ2 and/or HLA-DQ8 positive. 
Participants received either gluten or placebo together with a gluten-free diet for 6 weeks. 
End-points in the study were symptom assessments and biomarkers of inflammation and 
intestinal permeability. The patients receiving gluten reported significantly more symptoms 
compared to the placebo group. The most striking outcome of this study was that for all the 
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endpoints measured there were no differences in individuals with or without HLA-DQ2/DQ8, 
indicating that the intake of gluten can cause symptoms also in individuals without this 
specific HLA-profile. No differences in biomarkers for inflammation and intestinal 
permeability were found between both groups, however, inflammatory mediators have been 
implicated in the development of symptoms in patients with irritable bowel syndrome [78]. It 
could therefore be that the markers used to measure inflammation and intestinal permeability 
were not sensitive enough to detect subtle changes on the tissue level. 
 
7. Conclusion 
In the present review we describe how the daily consumption of wheat products and other 
related cereal grains could contribute to the manifestation of chronic inflammation and auto-
immune diseases. Both in vitro and in vivo studies demonstrate that gliadin and WGA can 
both increase intestinal permeability and activate the immune system. The effects of gliadin 
on intestinal permeability and the immune system have also been confirmed in humans. 
Other cereal grains containing related prolamins and lectins have not been so extensively 
studied and therefore more research investigating their impact on intestinal permeability and 
inflammation is required. It would be interesting to further elucidate the role of other 
prolamins on zonulin release and intestinal permeability.  
 
In CD and gluten-sensitive individuals adverse reactions to the intake of wheat, rye and barley 
are  clinically apparent, however, it is important to gain better insights on the effects of the 
consumption of these cereal grains in other groups of patients and in healthy individuals. It 
would be of high interest to investigate the effects of the withdrawal of cereal grain products 
from the diet on inflammatory markers and intestinal permeability in healthy subjects and 
patients suffering from inflammation-related diseases and measure the same parameters in a 
rechallenge trial. Ideally, in such an intervention study, the diet must be completely controlled 
and combined with the appropriate substitution of foods in the cereal grain-deprived diet so 
that small dietary variations and alterations in energy intake can be avoided and cannot 
potentially influence inflammatory markers. 
  
 Until now, human epidemiological and intervention studies investigating the health-effects 
of whole grain intake were confounded by other dietary and lifestyle factors and therefore well 
designed intervention studies investigating the effects of cereal grains and their individual 
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Various positively selected adaptations to new nutrients have been identified. Lactase 
persistence is among the best known, conferring the ability for drinking milk at post weaning 
age. An augmented number of amylase gene (AMY1) copies, giving rise to higher salivary 
amylase activity, has been implicated in the consumption of starch-rich foods. Higher AMY1 
copy numbers have been demonstrated in populations with recent histories of starchy-rich 
diets. It is however questionable whether the resulting polymorphisms have exerted positive 
selection only by providing easily available sources of macro and miconutrients. Humans 
have explored new environments more than any other animal. Novel environments challenge 
the host, but especially its immune system with new climatic conditions, food and especially 
pathogens. With the advent of the agricultural revolution and the concurrent domestication of 
cattle came new pathogens. We contend that specific new food ingredients (e.g. gluten) and 
novel pathogens drove selection for lactase persistence and higher AMY gene copy numbers. 
Both adaptations provide ample glucose for activating the sodium glucose-dependent co-
transporter 1 (SGLT1), which is the principal glucose, sodium and water transporter in the 
gastro-intestinal tract. Their rapid uptake confers protection against potentially lethal 
dehydration, hyponatraemia and ultimately multiple organ failure. Oral rehydration therapy 
aims at SGLT1 activity and is the current treatment of choice for chronic diarrhoea and 
vomiting. We hypothesize that lifelong lactase activity and rapid starch digestion should be 




Adaption to new environmental challenges aims at phenotypic adjustments either by 
epigenetic (rapid, but labile) and genetic (slow, but robust) changes through processes such as 
epimutation and de novo mutation, the latter e.g. by variation of gene copy number (GCN) (1, 
2). Many environmental factors have shaped the human genome, including climate, diet and 
microbial load (3). Although the first two certainly excreted selective pressure on humans, the 
main selective pressure seems to derive from pathogens because of their high lethality (4). 
Fumagalli et al. (4) identified a surprisingly high number of more than one hundred genes 
carrying signatures of a pathogenic environment and presenting as an increase in allele 
frequency (GCN). Conversely, for dietary regimes and climatic conditions, no gene shows a 
similar correlation between an environmental factor and GCN (4). Other authors have shown 
that climate and diet do act as selective pressure factors in humans (5, 6), but the majority of 
the literature indicates that it are pathogens and the pathogenic load that should be 
considered as the principal environmental factors causing selective pressure in humans (7,8).  
 
Two recent changes in the human diet i.e. the inclusion of dairy products and the increased 
intake of starch, have been related with genetic adaptations, i.e. lactase (also known as lactase-
phlorizin hydrolase; LPH) persistence (9) and salivary amylase (AMY1) GCN (10), respectively. 
Both adaptations are ascribed to toxicosis as the possible causes of the observed high positive 
selection pressure of these alleles, but there have to our knowledge as yet been no suggestions 
that they might confer protection against an increased pathogenic load since the rise of 
agriculture. Pathogens such as Mycobacterium tuberculosis, Rotavirus, E. coli, Mycoplasma 
pneumoniae and fungi producing highly toxic mycotoxins, together with gluten as a novel 
food ingredient, may cause devastating effects in humans through pathways ending up in 
dehydration, hyponatraemia and lack of energy, ending up in multiple organ failure (MOF). 
We suggest (our hypotheses) that improved lactose and starch digestion through lactase 
persistence and augmented AMY1-GCN provided a survival advantage by facilitating the 
activity of the immune system and the most important glucose, water and sodium transporter 
in the gut and thereby conferred protection against infections and infection-driven 




1. Lactase persistence, existing hypotheses 
1.1. The UVB-vitamin D-calcium-rickets hypothesis 
Swallow et al. (9) related the higher and longer intake of milk and milk products to lactase 
persistence after infant age through the emergence of polymorphisms in the regulation of the 
lactase gene (11, 12). The hypothesis was subsequently supported by others (13). Several 
explanations have been given for the positive selection of these polymorphisms leading to 
lifelong lactase persistence. One of them highlights the advantage of the improved calcium 
intake if lactose could be digested (14). The low UV-B levels at high latitudes are associated 
with an increased risk of developing rickets and osteomalacia due to the lack of cutaneous 
vitamin D production during the long winter period. In the gut, the vitamin D hormone, 1,25-
dihydroxyvitamin D, stimulates the expression of proteins involved in the absorption of 
calcium, which is itself an essential mineral required for bone health, signal transduction and 
others. Milk born calcium may also help to prevent rickets by impairing the breakdown of 
vitamin D in the liver (15).  
 
Rickets narrow the female birth channel and thereby increases the chance of mortality of both 
mother and child during labour (16). The only successful preventive measure is by caesarean 
section, which has been part of human anthropology probably since millennia (17) and seems 
to have saved thousands of people also in recent times (16). However, Itan and Swallow (11), 
using a flexible demic computer simulation model to explore the spread of lactase persistence, 
challenged the vitamin D-rickets model by showing the absence of a relationship between 
lactase persistence and the requirement of more vitamin D in people living at Northern 
latitudes.  
 
The vitamin D-calcium-rickets hypothesis based on the low ultraviolet-B (UVB) radiation at 
high latitudes does not hold in the light of the very low prevalence of lactase persistence 
among other individuals living in northern regions such as those living in Siberia or the 
Amerindians living in the north of America (18, 12). Lactase persistence reaches the highest 
prevalence in countries around the Baltic- and North Sea (19, 17), which coincides with 
extreme dermal depigmentation, unique for this part of the world population (20). It is widely 
accepted that depigmentation is a consequence of living at high latitude and lack of vitamin D 
producing UVB radiation. UVB radiation (280-340 nm) is necessary for the conversion of pre-
vitamin D3 into vitamin D, which prevents the development of rickets. Pale skin obviously 
captures more sunlight because of the reduced absorption by melanocytes (21).  
 
Although there is a trend for lighter skin colour with increasing latitude, no other population 
exhibits the extreme dermal depigmentation encountered in Europeans living in the circum 
Baltic/North Sea region, even not populations living at higher latitudes, which suggests an 
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additional geographic selection pressure. It is possible that populations in the North of Europe 
experienced another threat to their calcium homeostasis due to the spread of agriculture in 
general, and in particular because of the consumption of wheat and barley.  
 
1.2. The influence of cereals 
Cordain et al. (20) stated that ‘Whole cereals are rachitogenic because their high fibre content 
impairs the entero-hepatic circulation of vitamin D, leading to increased faecal elimination of 
25-hydroxyvitamin D3, thereby progressively lowering plasma 25-hydroxyvitamin D3 
concentrations in humans’. Moreover, whole grains are poor sources of calcium, and their 
high phytate content reduces calcium bioavailability and thereby additionally contributes to 
their rachitogenicity. The region around the Baltic/North Seas is one of the few high-latitude 
regions in the world where cereal grains can be successfully grown without intensive modern 
agricultural procedures. Usually, at high latitudes, extreme temperatures render the growing 
season too fleeting for cereal crops to effectively compete with animal foods as a staple. 
Because the warm Gulf Stream flows into the North and Baltic Seas and because of the 
nearness to a maritime heat sink, temperatures in the surrounding landscapes were 
sufficiently high to allow Neolithic farmers to successfully grow cereals as staples, primarily 
wheat and barley (20).  
 
1.3. Our hypotheses: Lactase and the immune system 
To our knowledge, there has been no suggestion of a relation between lactase persistence and 
the immune system in which lactase confers protection against potentially lethal pathogens. 
Apart from the digestion of lactose, lactase is important for the intestinal absorption of 
quercetin. By the hydrolysis of the naturally occurring quercetin-glucosides, quercetin 
absorption may increase drastically in the presence of lactase (22). Quercetin is one of the 
most abundant flavonols in edible plants (USDA database 2011) and is considered vital to 
maintain immune function (23). Epidemiological studies indicate that higher compared to 
lower quercetin intake is associated with reduced risk for ischemic heart disease, type 2 
diabetes mellitus, asthma, and various types of cancer including lung cancer, colorectal 
cancer, prostate cancer (24) and has widespread antimicrobial effects against viruses, bacteria 
and fungi (25). 
 
As stated in the introduction, pathogens have exerted strong selective pressure in human 
evolution (4). One of the most lethal infectious diseases in humans is and has been 
pneumonia (26). Every year 65,000 people in the USA die because of influenza and 
pneumonia (27). Pneumococcal load has been a strong selective pressure factor shaping the 
human immune system and genome (28). Another microbe producing pneumonia atypical in 
humans and pneumonia in cattle is Mycoplasma mycoides (29). Mycoplasma pneumoniae in 
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cattle and probably humans became important with the rise of domestication of cattle, 
including cows and goats, some 10,000 years ago (30). Domestication of cattle was the starting 
point of introducing milk and milk products into the human diet and also the time point when 
the polymorphism for lactase persistence typical for Europeans arose (12). Even now farmers 
seem to be at surprisingly high risk (10 to 50 times more than expected) for the development 
of pneumonitis (31).  
 
Quercetin has effective antibiotic effects against bacteria producing pneumonia but only at 
high doses (32). These might be provided by lactase (32) suggesting benefits in immune 
function by lifelong lactase-facilitated quercetin absorption. We suggest that positive 
selection of lactase persistence is related with increased protection against potentially lethal 
pneumonia-causing pathogens. 
 
1.4. Conclusions so far 
Taken together, lactase persistence is a very recent polymorphism and its positive selective 
pressure has been extremely strong (33). It is hard to conceive that such a high selective 
pressure was caused by diseases with low lethality such as osteomalacia, and osteoporosis, or 
because of the adaptation to a novel food with nevertheless high caloric and micronutrient 
contents. On the other hand, rickets and pathogenic load are strong selective pressure factors. 
Pathogenic load has been the leading roller coaster of human evolution and it is therefore 
conceivable that subjects with lactase persistence are better protected against the mentioned 
pathogens. This hypothesis is easily testable by measuring the difference in infection 





2. Salivary AMY1 gene copy number 
2.1. AMY1 copy number and starch consumption 
In 2007 Perry et al. (10) published a seminal paper relating the number of amylase (AMY1) gene 
copies to the amount of dietary starch. They found that the number of the salivary amylase 
gene copies correlates positively with salivary amylase protein levels and that individuals from 
populations with high-starch diets have, on the average, more AMY1 gene copies than those 
with traditionally low-starch diets. Since the publication of Perry et al., several hypotheses 
have been proposed to explain positive selection of augmented AMY1-GCN. More AMY1 
copies and amylase protein could ‘buffer against the fitness-reducing effects of intestinal 
disease and toxicosis’ (10), although they did not specify what environmental factor(s) would 
cause intestinal disease.  
 
2.2. Existing hypotheses 
One hypothesis relates salivary amylase activity to satiety (34). This effect could buffer against 
overeating, although higher amylase levels during stressful situations may produce the 
opposite. For instance, emotional overeating in response to psychosocial stress is a 
behavioural trait related to childhood obesity and psychosocial stress factors increase salivary 
amylase production (35). Our society is characterized by food abundance, overeating 
increases the risk of obesity, and obesity is a risk factor for diabetes mellitus type 2, 
cardiovascular diseases (CVD) and others (36). A buffering effect against overeating could 
therefore decrease the incidence of CVD and related disorders. CVD and related disorders 
affect a wide range of people, CVD are still the major causes of mortality worldwide (37) and 
mortality is an important driving force in evolution by exerting selective pressure (38). It could 
therefore theoretically be possible that augmented AMY1-GCN developed through selective 
pressure of early mortality caused by increased obesity and CVD.  
 
The above hypothesis, however, does not hold in the light of the estimated time of augmented 
AMY1-GCN occurrence and also not when considering that the capacity of overeating 
probably saved people from starvation at times when food was not available (39). The 
estimated time of appearance of augmented AMY1-GCN is around 200,000 years ago, 
although this estimate needs confirmation by the generation of AMY1 sequences from 
multiple humans (10). Obesity and CVD are widely considered modern diseases that arose 
very recently (40), while CVD mortality is highest among elderly people (41). At the time of the 
occurrence of the increase of AMY1-GCN, humans hardly reached an average age of 35 years, 
while even 200 years ago the average lifespan was only 30-40 years (42). It is therefore 
questionable whether obesity, CVD and mortality caused by overeating would have exerted 
the necessary high selective pressure on ancient populations in which the positive selection 




A second hypothesis relates higher AMY1-GCN and increased amylase protein in saliva with 
certain sensory properties of starchy foods (43). Taste and viscosity could perhaps be detected 
earlier in individuals with higher AMY1-GCN, although the benefit of this trait is unclear (35, 
43), making this hypothesis weak while  lacking sufficient scientific strength to suggest 
positive selection.  
 
Recently it has been shown by Mandel et al. (44) that, following the intake of starch-rich foods, 
individuals with high endogenous salivary amylase activity regulate glucose homeostasis 
better than individuals with lower salivary amylase activity (44). They state that efficient starch 
digestion could have had “immense benefits” and relate this benefit with protection against 
toxicosis and lower gastrointestinal malaise. This is exactly in line with our hypothesis which 
states that through more efficient starch digestion people were and are protected against 
multiple organ failure, dehydration and hyponatremia by upregulating the activity of SGLT1 
(see our hypotheses) 
 
It seems clear that no conceivable mono-hypothesis has as yet been generated for the 
augmentation of AMY1-GCN in human populations with high starch intakes. Adaptation to 
changes in food intake without evolutionary advantages, such as mortality before or during 
reproductive age or significantly reduced fitness, is unlikely to provide a sufficiently strong 
platform to explain accelerated positive selection. Before stressing our hypothesis, two other 
factors speak against the hypothesis that certain human populations have adapted to a 
nutrient, merely because it was incorporated in the diet.  
 
2.3. AMY1 expression relates to stress and pancreatic amylase activity is huge 
If humans adapted to starch rich food through increased expression of the amylase protein 
(related with higher AMY1-GCN), then why would amylase protein production be highest 
when salivary glands are (co)activated by the sympathetic nervous system (45)? It is widely 
recognized that the sympathetic nervous is the first wave of the acute stress responses. This 
would imply that starch intake produces stress, while stress is a reaction to danger (46). The 
logical consequence is that starch-rich food is dangerous: something living on starch-rich 
food is dangerous, or something within starch-rich food protects the starch-producing plant 
against something dangerous and the resulting compounds might be toxic to humans. The 
second factor that speaks against a merely nutrient intake driven genetic adaptation refers to 
the starch digestive activity of pancreatic amylase. As early as 1995 it was shown that 
pancreatic alpha-amylase extensively covers the digestive needs of starch intake (47). 
Pancreatic postprandial amylase enzyme output varies from 50 U/min to 2,000 U/min (69) 




The significant difference in AMY1-GCN between populations with low and high starch 
intakes and between humans and our nearest evolutionary counterpart, the chimpanzee, is 
likely related to factors in or on starch-rich foods. High alpha-amylase facilitates breakdown 
of starch, liberating various monosaccharides, including glucose. The latter is present in roots 
and tubers eaten by the people belonging to the high AMY1-GCN tribes in Africa (49). Recent 
research with the Hadza, the last authentic hunter-gatherer population in Tanzania, shows 
that tubers and roots are an important part of daily food, varying from 18-38 en% of total 
caloric intake through the year (50).  It is nevertheless their non-preferred food (50) and 
should be considered part of the fallback nutritional sources. Fallback nutritional sources 
normally provide energy when food is scarce. Given the importance of fallback food, it might 
be beneficial to optimize starch digestion efficiency. However, even if starch rich foods would 
exceed 38 en% of total intake, it would make no sense to increase salivary amylase level. 
Salivary and pancreatic amylase in combination with four other starch-digesting enzymes in 
the small gut would cover the starch digestion needs extensively (51).  
 
2.4. AMY1 and the immune system: domestic dog adaptations as introduction 
to our hypothesis 
It was recently found that domestic dogs exhibit several genetic changes suggesting 
adaptation to the intake of starch (52). The three genes showing intense selective pressure 
related with starch digestion in this study, are AMY2B, MGAM and SGLT1, which are 
responsible for the production of respectively amylase, maltase-glucoamylase and the 
sodium-dependent glucose co-transporter 1 (SGLT1).  The difference in gene copy number, 
enzyme production and enzyme activity in dogs is highly significant compared with their 
most closely related counterpart, the wolf (52). The authors concluded that dogs have adapted 
to starch intake during domestication, suggesting that a change of ecological niche was the 
driving force behind that domestication and the novel niche could have induced scavenging 
behaviour in waste dumps. However, waste dumps do not only contain starch, but also other 
food wastes like meat, while all waste products come together with microbes, including 
Escherichia coli, Salmonella (both meat born microbes) and fungi such as Aspergillus growing 
on foul starch (53). These pathogens produce severe symptoms like vomiting, entero-
hemorrhagic enteritis, renal damage and failure, and death in humans, but especially among 
children, although adults are not spared (54).  
 
The three genetic changes found in domesticated dogs and related with starch digestion, also 
have important effects on metabolism, systemic homeostasis and especially the immune 
system. We contend that the effects on the immune system have been the genuine 
background for the very high selective pressure on the above-mentioned genes in dogs and 
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that the same could hold for the AMY1-GCN in humans.  
 
2.5. Evolutionary selective pressure aspects of the consumption of starch-rich 
foods; our hypotheses 
2.5.1. Toxins in starch-rich foods 
Starch-rich foods (SRF) contain, like most plants, a series of proteins and anti-nutrients with 
certain toxic effects. The mostly consumed SRF in non-African populations are cereals and 
legumes, whereas African tribes eat substantial amounts of tubers and roots, although cereals 
such as corn are rapidly replacing these ancient food sources (55). Whole grain cereals and 
legumes contain both toxic and non-toxic compounds and all of these substances contribute 
to the possible net toxic (nettox) effect of these SRF. It is important to consider only 
constituents present in whole grains as possible selective factor, because refined cereal 
products entered our diet only very recently. Candidate substances are gluten and its main 
component gliadin, certain digestive enzyme inhibitors such as amylase-inhibitors in wheat 
and lectins. A review was recently published on the potentially toxic impact of grains on 
human health (56).  
 
2.5.2. Did gluten-toxicity exert sufficient selective pressure to cause augmented AMY1-GCN? 
Gluten can cause a wide range of disorders, varying from celiac disease (57), autoimmune 
disorders (58), increased intestinal permeability syndrome (59) and types 1 and 2 diabetes 
mellitus (60) and gluten burden is not restricted to gluten intolerant individuals (61). 
 
All of these disorders usually evolve with gastro-intestinal problems and often diarrhoea (62) 
The majority of mentioned disorders are negatively correlated with fertility and reproductive 
success (63). Diarrhoea can cause severe dehydration and sodium deficiency and both lead to 
increased mortality in both genders and at any age, but they affect children the most. Thus, at 
least theoretically, it seems possible that gluten intake affected reproduction and mortality by 
dehydration and severe sodium deficiency, causing selective pressure on cereal-eating 
populations. Improved digestion of starch might increase glucose levels in the gut, facilitating 
water, sodium and glucose transport by the sodium-dependent-glucose co transporter 
(SGLT1) and thereby protect against lethal dehydration, hyponatraemia and multiple organ 
failure because of energy deficiency, supporting our basic hypothesis and knowing that 
higher glucose levels in the gut activate SGLT1, whereas normal levels do not (64). 
Identification of gluten as a trigger of severe gastro-intestinal complaints, including 
uncontrollable diarrhoea, vomiting and abdominal pain, occurred after World War II, when 
the Dutch paediatrician Willem-Karel Dicke noticed that the war-related shortage of bread in 
The Netherlands caused a significant drop in death rate among children affected by celiac 
disease—from greater than 35% to essentially zero. He also reported that once wheat was again 
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available after the war, mortality soared to previous levels. Following up on Dicke’s 
observation, other scientists looked at the different components of wheat, discovering that the 
major protein in that grain, gluten, was the culprit (65).  
 
Celiac disease is the best-known disorder related with gluten intake and is caused by a 
combined impact of environmental factors on perhaps more than one hundred genes (66). 
Several genes seem to play major roles in subjects who are susceptible to celiac disease. They 
include genes for the production of human lymphocyte antigen (HLA) molecules and non-
HLA genes for the production of interleukins and their receptors (66). The whole group of 
genes relates to the immune system and therefore it could well be that these genes originally 
protected against pathogens and that celiac disease only occurred after the incorporation of 
cereals into the human diet. In this direction, it has recently been shown that several 
interleukin/interleukin receptor genes involved in the pathogenesis of celiac disease have 
been subjected to pathogen-driven selective pressure. Specifically, celiac disease alleles of 
IL18RAP, IL18R1, IL23, IL18R1 and the intergenic region between IL2 and IL21 display higher 
frequencies in populations exposed to high microbial/viral loads, suggesting that these 
variants play a role in the response to these organisms (67). People with these genotypes are 
probably better protected against pathogens, but at the expense of celiac and other 
autoimmune diseases,  
 
Gluten intolerance further produces secondary lactose intolerance, because of its damaging 
effect on enterocytes, which form the outermost layer of the gut (68). The combined effects of 
damage inflicted by the immunological response against gluten and the secondary lactose 
intolerance only increases the possibility of developing severe intestinal trouble including the 
typical lactose malabsorption symptoms, abdominal pain, diarrhoea, nausea, bloating, and/or 
flatulence (69). 
 
The only plausible explanation for the positive selection or the preservation of genes that 
confer higher susceptibility to toxic-gluten, has to be related with something even more 
dangerous. People living in a highly infectious environment maintained or developed the 
need for increased immune reactivity against pathogens (4). When they incorporated gluten 
rich foods into their diets, the consequences of diarrhoea and vomiting could and 
undoubtedly have killed a countless number of people, demanding another 
phenotypical/genotypical adaptation to survive this novel selective pressure factor and this 
risk only increases when facing secondary lactose intolerance. And for this, why not employ 
another nutrient present in the same food to overcome the deleterious effect of the toxic part 
of this altogether important energy-providing nutritional source? Increased breakdown of 
starch in gluten-sensitive people would provide sufficient glucose to activate SGLT1 and 
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facilitate glucose, sodium and water transport and thereby prevent the severe burden of 
gluten intake. Increased amylase production through higher AMY1-GCN could serve this 
purpose. 
 
The previously mentioned study of Axelsson et al. (52) shows that domesticated dogs carry an 
increased number of pancreatic amylase genes (AMY2B) and a special SGLT1 haplotype with 
structural (better function but not more enzyme) benefits compared with wolves. Dogs suffer 
from food allergies, just as humans, with almost identical symptomatology, including 
gastroenteritis-caused vomiting and diarrhoea, while canine gastroenteritis seems related 
with intestinal bacterial overgrowth with E. coli as main pathogen (70) and gluten intolerance.  
It has even been shown that gliadin, the main protein in gluten, produces the most severe 
allergic response in dogs (71), while dogs are used to investigate the pathways leading to 
clinical celiac disease because of the spontaneous development of celiac disease when fed 
with gluten-rich foods (72). This provides evidence for a parallel evolution of humans and 
domesticated dogs through increased starch digestion by amylase and improved glucose 
transport, protecting the host against possible toxicosis by a novel nutrient, such as gluten. 
and/or certain pathogens, such as enterotoxic E. coli. Higher AMY1-GCN and amylase 
expression can serve this purpose perfectly and it were both Perry et al. (10) in their first 
publication on augmented AMY1-GCN and Mandel et al. in 2012 (44) who already pointed at 
the possible beneficial effects of augmented AMY1-GCN for the protection against intestinal 
toxicity.  
 
2.5.3. Can starch itself be sufficiently toxic to produce important selective pressure? 
Starch is the storable form of energy produced by all green plants.  
A part of dietary starch escapes digestion by all enzymes, reaching the colon as resistant 
starch, ranging from approximately 1% following the consumption of white rice and 6% after 
eating beans (73). Incompletely digested starch has significant impact on the gut microflora in 
cattle and humans. Cows fed cereals can have a 1,000 times higher level of Escherichia coli in 
their gut and gut E. coli corresponds with higher detectable E. coli levels in their meat (74). 
Escherichia coli O157:H7, one of its most toxic mutants, can live undetected in the gut of food 
animals and can be spread to humans directly and indirectly. E. coli is a normal inhabitant of 
the gastrointestinal tract of mammals. Most E. coli strains do not cause disease, but can release 
lipopolysaccharide complexes from their cell walls (including lipid A) upon disintegration. 
These endotoxins can cause fever, and even death, but mostly if E. coli translocates from the 
gut into the blood. Traditional models of E. coli pathogenesis were based on the ability of 





Cattle born pathogens are considered zoonoses (transferable to humans) and they include E. 
coli, but also Salmonella, Campylobacter and Clostridium dificile (75). Salmonella can be 
highly toxic as evidenced by various severe Salmonella outbreaks through ancient and recent 
history (76). Salmonella grows, just like E. coli on meat, and Salmonella/E. Coli infected meat 
and poultry are still considered the most important sources of food born illness (76). Survival 
of the pathogenic form of these microbes is facilitated by the intake of resistant starch that 
escapes total digestion in cattle (74). Recent research shows that this also holds for humans 
and that pathogenic growth of gut damaging microbes is substantially enhanced by 
maltodextrin, a derivate of incomplete digested starch (77).  
 
It seems obvious that the combination of direct exposure to food born pathogens (E. Coli, 
Salmonella) and the nourishing effect of digestion-resistant starch has benefitted the growth 
of these microbes and thereby caused severe gastro-intestinal disorders in humans 
consuming infected meat and starch rich food. Macronutrient uptake is greatly dependent on 
gut surface, passage time and hydrolysis. Complete digestion of starch could have prevented 
bacterial overgrowth of pathogenic bacteria, offered protection against possibly severe 
gastroenteritis and even death. Augmented AMY1-GCN could have served this purpose, by 
causing a more rapid and thereby more complete digestion and uptake in combination with 
the other starch-digesting sacharidases. 
 
2.5.4. Fungi growing on starch rich food; a largely ignored global health issue at present and 
definitely in the past 
Starch provides the major food source for a wide range of fungi, including Fusarium species, 
Aspergillus flavus, Penicillum viridicatum and Acremonium coenophialum (78), whereas 
another fungus, Claviceps purpurea, parasites on starch rich cereals such as barley, rye and 
wheat (79). All of these fungi produce various types of highly toxic mycotoxins, including 
aflatoxins, tricothecenes, fumonisins, T-2 toxin, zearalenone, deoxynivalenol and ochratocin 
A (80). Among these, Claviceps purpurea is a special fungus, because it has historically often 
been looked at as a part of the cereal plant although it produces the most severe mycotoxins 
named ergopeptines, including ergometrine (81).  
 
When present in foods in sufficiently high quantities, mycotoxins can produce symptoms 
ranging from acute liver or kidney deterioration, severe gastroenteritis, vomiting, anorexia, 
reduced weight gain, neuroendocrine changes, immunological effects, diarrhoea, 
leukocytosis, haemorrhage or circulatory shock, and acute death, to chronic liver cancer, 
mutagenic, and teratogenic effects, skin irritation, immunosuppression, birth defects, 




Acute mycotoxicosis belongs to the most devastating infections, affecting human being as 
evidenced by several recent outbreaks including the one in Kenya in 2004, that affected 317 
individuals, killed 125, and was caused by the ingestion of aflatoxin-infected maize (84). 
Another fatal outbreak in 1974 killed 100 persons in India because of the consumption of 
aflatoxin-infected corn (83). Not only cereals are a rich source of mycotoxins. Other starch 
rich foods such as dried fruits (83,), beans, peanuts (83) and underground bulbs (84) are also 
frequently affected by fungi, producing different types and amounts of mycotoxins. The 
actual economic burden of affected crops is enormous, because of the difficulties to control 
fungal growth on SRF (85) and the estimated economic losses are $1.4 billion every year only 
in the USA (83). In the European Union, regulations limit the amount of total aflatoxins to 4 
ng/g, whereas guidelines in a few developing countries and the US limit total aflatoxins to no 
more than 20 ng/g in foodstuffs intended for human consumption (86). In Nigeria, the 
National Agency for Food, Drug Administration and Control has set 20 ng/g as the maximum 
permissible limit for total aflatoxin in foodstuff (86).  
 
Even though preventive methods are very well defined, mycotoxins keep affecting 25% of 
world crops (87). When people started eating SRF thousands of years ago, logical reasoning 
informs us that those crops must have been affected by fungal infections and that the 
consumers are likely to have suffered from acute and/or chronic mycotoxicosis. The group of 
Lesley investigated how mycotoxin growth and fatal doses of mycotoxins could be prevented 
in non-industrialized countries, which were basically all countries of the world 10-30,000 
years ago (88). 
 
These methods are nowadays likely to be well known in the majority of SRF eating 
populations, but it is unlikely that ancient populations knew how to deal with fungal growth 
on SRF, while even if they did, it does not imply that they avoided consumption of the affected 
foods. ‘Even today situations of relative scarcity of food often forces consumers in many 
regions to distressing decisions, such as ‘to eat contaminated grain today and worry about the 
consequences tomorrow (or some other time in the future) or starve today and perhaps not 
even have a tomorrow’ as stated by Bandyopadhyay (89). This behaviour is not a unique 
‘characteristic’ of modern humans, it is the way most individuals think and have thought 
when starving to death.  
 
Several data suggest that people have suffered from more or less fatal mycotoxicosis for 
hundreds of generations and mycotoxin intoxication has without doubt killed thousands of 
people. The mortality rate ranges from 10-60% of the infected people and embryos and 
children are among the most affected individuals (90). Important proof for the devastating 
effects of mycotoxins comes from data related with ergotism. Ergotamine and other 
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ergopeptines from the fungus Claviceps purpurea are highly toxic to humans and can cause 
different types of ‘ergotism’. Convulsive, gangrenous and entero/hyperthermic ergotism 
cause respectively epileptic convulsions, confusion and death (convulsive), vasoconstriction, 
cold/hot feeling, abortion and gangrene (gangrenous) and nausea, vomiting, diarrhoea, 
increased metabolic rate and excessive salivation (entero/hyperthermic, 80). Convincing 
historical data for the existence of epidemics of mycotoxicosis are as old as 600 BC, when 
people in Assyria suffered from ‘madness’ caused by ‘the noxious pustule in the ear of grain’ 
(91) and this seems to be the same disease that affected many parts of Europe in the tenth 
century referred to as St. Anthony’s or Holy fire, and is considered to have been caused by the 
consumption of rye contaminated with ergot alkaloids from Claviceps purpurea. Further 
accounts suggest that other contaminated grains have been responsible for major outbreaks 
of disease (e.g., the Ten Plagues of Egypt, 83). 
 
Mycotoxins can produce chronic diarrhoea and vomiting. At the same time they highly 
influence the functionality of SGLT1 and GLUT5. Very low doses of mycotoxins inhibit 
nutrient transport in the gut, especially affecting SGLT1 (50% inhibition with a 10 µmol/L 
solution in vitro) and the fructose transporter GLUT5 (42% inhibition, 92). Later studies in 
animals confirmed these findings (93). Mycotoxins produced by Aspergillus further inhibit 
alpha-amylase activity, which has been evidenced several times in vivo, although mostly in 
chickens (94). The combination of these targets and their effects can be considered the perfect 
cocktail to die because of dehydration, hyponatraemia and MOF.  
 
Aspergillus and its toxins are definitely highly toxic and have killed thousands of individuals, 
including children and adolescents (95).  
The described pathways, by which mycotoxins can have affected human health and even 
mortality rate, could, and probably have, served as important selective pressure factors for the 
observed augmentation of oral AMY1-GCN in populations with high starch intakes. Complete 
starch digestion would have provided enough glucose to augment SGLT1 activity, improving 
the transport of glucose, water and sodium, preventing dehydration, multiple organ failure 
and possibly lethal hyponatraemia in infected individuals. 
 
Of all the pathogens described in this paper and considered as possible cause of selective 
pressure on the number of AMY1 gene copies, fungi producing mycotoxins seem to be the 
most appropriate candidates.  
 
2.6. Conclusions so far 
The entrance of SRF in the human diet introduced several positive and negative factors. 
Gluten in SRF can be highly toxic and the incomplete digestion of resistant starch in SRF 
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provides an optimal substrate for the growth of possibly lethal pathogens including food 
borne toxic E. coli strains and Salmonella. Dehydration, hyponatraemia and MOF are the most 
damaging effect of gluten-toxicity and food borne pathogens due to chronic diarrhoea and 
vomiting. The same holds for fungi living on SRF, producing highly toxic mycotoxins that can 
be fatal. Higher salivary alpha-amylase activity through augented AMY1-GCN can increase 
glucose level in the gut, facilitating water, sodium and glucose uptake and protect against the 
above mentioned effects. The observation that people with higher AMY1-GCN have lower 
blood glucose levels after starch intake supports the latter conclusion, suggesting that this 





3. Rotavirus, lactose intolerance and AMY1-GCN 
Rotavirus is one of the most important causes of gastro-enteritis, malnutrition, and diarrhoea 
in young children and animals. Rotavirus can be extremely dangerous, evidenced by the fact 
that more than 550,000 children die every year from this infectious disease (96).  Rotavirus 
induces diarrhoea and rotavirus-diarrhoea can be lethal because of reduced uptake of sodium 
and subsequent systemic hyponatraemia through a direct inhibiting effect of rotavirus on the 
SGLT1 mechanism (97). Rotavirus further induces lactose intolerance by inhibiting lactase 
production (98) and dairy intake in people suffering from rotavirus diarrhoea seems to 
augment the diarrhoea duration (99). As mentioned before, rotavirus is extremely dangerous 
for children and newborn and is the mayor death cause in children younger than 5 years old 
(96). Newborns produce lactase to break down the lactose in their mother’s own milk, 
converting it into glucose and galactose, providing energy and enough glucose to transport 
water, sodium and glucose through activation of SGLT1. Newborns hardly produce 
endogenous amylase up to 6 months and even after 2 years still show some dependency on 
breast-milk amylase to support normal starch breakdown (100).  Nothing in breast-milk needs 
amylase to become digested, so why would breast-milk contain substantial amylase activity?  
 
It has been proposed that breast-milk amylase could serve as a compensation for low salivary 
and pancreatic amylase activities in newborns and aid in the digestion of complex 
carbohydrates from the time that complementary foods are introduced in close proximity to 
breastfeeding (101). We suggest that the substantial amylase level in breast-milk has become 
needed to digest complex starch rich food, at times that pathogens, but especially rotavirus, 
cause diarrhea through their combined disturbance of lactase activity, damage to enterocytes 
and inhibition of sodium transport (102).  
 
Rotavirus might be considered an important selective pressure factor (103). It has probably 
entered the human environment as a zoonose from domestic animals (104). The majority of 
individuals dying from rotavirus infections live in developing countries; countries where 
domestic animals and novel zoonoses are relatively new. We suggest that augmented AMY1-
GCN has been selected for the protection against lactose intolerance in the newborn caused 
by pathogens in general but more specifically by Rotavirus. High amylase level in breast-milk 
facilitates starch digesting in newborns that suffer from Rotavirus-induced lactose-
intolerance. Improved starch break down increases glucose level in the newborn gut, activates 
SGLT1 and guarantees a minimum of sodium, water and glucose transport into the 
bloodstream and thereby protects against possibly lethal hyponatraemia, dehydration and 
MOF. This is exactly the rationale behind oral rehydration in individuals suffering from 
Rotavirus diarrhoea (105). Rotavirus is nowadays hardly fatal in North European countries. 
Augmentation of AMY1-GCN could be at the basis of the lack of virulence of Rotavirus in this 
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part of the world, whereas Rotavirus in Africa is still a major cause of childhood and overall 





4. Discussion of our hypotheses and final conclusions 
Table 1 shows an overview of the different environmental factors that might have caused 
selection for lactase persistence and augmented AMY1-GCN. We suggest that these factors are 
not mutually exclusive, but should be viewed upon as complementary and logical in the scene 
of evolutionary biology. Lactase persistence and augmented AMY1-GCN are two genetic 
adaptations showing intense positive selection (lactase persistence > AMY1-GCN) in humans. 
Lactose and starch have deleterious effects on human health when digesting is incomplete 
and this occurs when lactase and amylase do not reach sufficiently high activities. Lactose 
intolerance (not treated in this review) itself can be detrimental to human health, through 
causing symptoms like irritable bowel syndrome, watery stool and excessive flatus (106). 
Lactose intolerance can nevertheless hardly have served as the only factor in the observed 
highly positive selection of lactase persistence, because of the lack of sufficient influence on 
mortality (107), while lactose intolerance also does not seem to affect fertility (108). A recent 
publication (109) also challenges the rather simple ‘fresh milk intake’ hypothesis as the driving 
force behind lactase persistence. . 
 
Incomplete starch digestion also affects human health, but without bacterial overgrowth of for 
instance Escherichia coli, symptoms would be troubling, but mortality rate and reproduction 
are less affected. Looking at both genetic adaptations in a broader perspective suggests that 
they might protect against the severe deleterious effects of several pathogens and the 
damaging effects of gluten. Pathogens like Rotavirus affect lactose digestion directly, whereas 
incomplete starch digestion facilitates the growth of possibly lethal cholera like E. Coli strains. 
Humans have explored new environments more than any other animal and novel 
environments challenge the immune system with new climatological conditions, food and, 
most of all, pathogens.  
 
The last big revolution in the human evolutionary history has been the development of 
agriculture: somewhat like 10 thousand years ago someone started to exploit the observation 
that a plant growths from a seed and agriculture started. With agriculture came the 
domestication of cattle and with cattle came new pathogens. The evidence we have given in 
this article supports our hypotheses that it are these factors that have driven the highly 
positive selection of lactase persistence and augmented AMY1-GCN: both adaptations provide 
enough glucose to activate SGLT1, which is the most important glucose, sodium and water 
transporter in the gastro-intestinal tract. The increased capacity of water, sodium and glucose 
transport from the gut into the blood stream, has probably saved thousand of individuals 
infected with pathogenic E. Coli, Rotavirus and TB, but most of all from highly lethal fungi 
living on starch rich food. The adaptations also protected them against the highly damaging 
effects of gluten intake. We therefore contend that lactase persistence and augmented AMY-
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GCN are not merely adaptations to nutrients in novel foods; they were needed to protect 
humans against novel pathogens that arose with agriculture and the domestication of cattle. 
Food born pathogens, living on meat and starch rich foods are still serious threats to human 
health and it is therefore necessary to further investigate how we can limit the presence of 




Table 1. Overview of the proposed mechanisms for the strong positive selection of lactase 
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In recent years, it has become clear that chronic systemic low-grade inflammation is at the 
root of many, if not all, typically Western diseases associated with the metabolic syndrome. 
While much focus has been given to sedentary lifestyle as a cause of chronic inflammation, it 
is less often appreciated that chronic inflammation may also promote a sedentary lifestyle, 
which in turn causes chronic inflammation. Given that even minor increases in chronic 
inflammation reduce brain volume in otherwise healthy individuals, the bidirectional 
relationship between inflammation and sedentary behaviourmay explain why humans have 
lost brain volume in the last 30,000 years and also intelligence in the last 30 years. We review 
evidence that lack of physical activity induces chronic low-grade inflammation and, 
consequently, an energy conflict between the selfish immune system and the selfish brain. 
 
Although the notion that increased physical activity would improve health in the modern 
world is widespread, here we provide a novel perspective on this truism by providing 
evidence that recovery of normal human behaviour, such as spontaneous physical activity, 
would calm proinflammatory activity, thereby allocating more energy to the brain and other 





Chronic inflammatory diseases are a major cause of morbidity and impaired work and social 
functioning and are responsable for 35 million to 52 million annual deaths Worldwide (WHO 
2014) [1]. A state of low-grade inflammation might be considered the “cause of causes” for 
these deadly and disparate conditions. In contrast to inflammatory patterns observed in 
hunter-gatherer groups living more in accord with lifestyles that were prototypical across 
human evolution and in which inflammatory responses are brisk and time limited (i.e., 
resolving within a maximum of 42 days), in the modern world chronic proinflammatory 
activity can last for weeks, months, or even years [2]. Many of the inflammatory diseases that 
plague modern societies were uncommon until some 200 years ago [3] but are nowadays 
increasingly prevalent. However, treatment is still in its infancy [4], and interventions 
addressing the genuine etiologies of the diseases have typically been less than fully 
satisfactory [5]. 
 
Although the abnormalities that promote allergy, asthma, autoimmunity, and othermore 
systemic inflammatory states, such as cardiovascular disease, are usually characterized in 
terms of their immune effects, it is less appreciated that the underlying activation of both 
innate and adaptive immune inflammatory pathways has costly consequences in terms of 
resource use of energy, proteins, and minerals such as calcium [6] andmagnesium [7–9]. In 
addition, chronic activation of the immune system produces a constant flux of energy and 
blood to the immune system itself, which leads to metabolic stress on other organs and, in 
certain circumstances, also the brain. Stress on the brain is unexpected in light of the brain’s 
selfish character and humans’ high encephalization quotient, which is the highest of all 
mammals and provides evidence of how evolution prioritized energy allocation to the human 
brain [10]. 
 
Thus, as we discuss in this paper, these metabolic and nutrient imbalances have wide ranging 
effects on health-relevant physiological functioning that go beyond the straightforward costs 
of immune activation per se. One of the major risk factors for chronic low-grade activity of 
the immune systemis frequent and abundant food intake. Postprandial inflammation can put 
a high burden on energy availability for the whole body, including the brain, as shown by the 
typical “post-lunch dip” in energy and mental activity observed after high-fat and high-
glycemic load meals [11]. Postprandial inflammation increases withmeal size, meal frequency, 
and consumption of foul food, and these factors reduce brain growth in mammals, illustrating 
the metabolic conflict between the immune system and the brain [12]. 
 
Our ancestors experienced rapid and consistent brain growth for 2.5 million years, despite the 
likelihood that they frequently consumed spoiled food in the absence of food preservation 
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technology [13]. This pattern of rapid and sustained brain growth despite consumptive 
patterns known to activate postprandial inflammation suggests that other mechanisms 
inhibited chronic inflammation—and by extension also attenuated postprandial immune 
activation. While a number of factors may have contributed to this inhibition, in this review 
we will focus on evidence suggesting that preprandial physical activity attenuates 
postprandial inflammatory activity while simultaneously protecting from infection via the 
induction of immunoglobulins, including lysozymes, and especially, lactoferrin. 
 
In human adults, lactoferrin is produced during and after exercise independent of sex, age, 
and menstrual cycle [14]. In infants, lactoferrin is obtained through breast milk, consumed 6 to 
7 times daily by newborns. Newborns allocate 74%of their energy intake to brain growth and 
differentiation [15–17]; an energy allocation that would be impossible if they experienced a 
high-cost bout of postprandial inflammation after every meal. Fortunately, constituents found 
in breast milk are capable of downregulating the newborn’s immune system, while they also 
protect against possible pathogens. Lactoferrin is probably the most abundant 
immunologically active constituent of breast milk that reaches concentrations as high as 8 
mg/g in colostrum and 1.5 to 4 mg/g in mature milk [18]. A breastfed newborn who consumes 
600 mL of breast milk daily can ingest up to 2.4 grams of lactoferrin daily, an amount that is 
probably more than enough to protect against infection, while simultaneously inhibiting 
postprandial inflammatory activity of adipocytes and the immune system, thereby saving 
energy for constant brain growth. 
 
The hominin brain experienced unprecedented growth despite the challenges that the 
immune system faced as our ancestors sought novel experiences and colonized the world. 
 
However, in the last 30,000 years, brain size has shrunk from 1,490mL to 1,350 mL, a loss of 
11% [19]. Here we suggest that this reduction in brain size happened because of new 
environmental inflammatory factors such as novel pathogens, 
high meal frequency, food abundance, and lack of solar radiation but most of all because of 





2. Energy and Energy Conflict as the Driving Force behind 
Evolution 
In all animals, energy conflicts shaped physiology during evolution. These conflicts seem to 
have caused changes in energy allocation among organs. Nowhere have these conflicts been 
more relevant than in the rapid expansion of the brain during hominin evolution [20, 21]. In 
principle, a proportionally larger and metabolically expensive brain could have been 
supported through an increase in the basal metabolic rate, but no evidence of such a 
relationship has been found in humans or other primates [22]. Because of this, several ideas 
have been advanced to explain how this larger brain might have been metabolically 
supported. For example, the expensive tissue hypothesis [20] and, more recently, various 
energy-allocation scenarios [16, 22] propose that the development of the metabolically 
expensive human brain must have had consequences for other organs, leading to lower 
energy allocation to those organs in favour of the brain. 
 
Navarrete et al. [23] examined evidence for the expensive tissue hypothesis in 100 different 
mammalian species, including 23 primates. They found that, controlling for fat free body 
mass, brain size is not inversely correlated with the mass of the digestive tract or any other 
expensive organ, thus refuting the expensive tissue hypothesis. However, they did find 
evidence for a negative correlation between brain size  and fat depots in mammals, raising the 
intriguing possibility that encephalization and fat storage both evolved as compensatory 
strategies to buffer against starvation.When these two strategies are combined, fat might 
provide extra energy for the brain during starvation, but only if this fat storage did not 
negatively impact locomotor efficiency. Central fat storage (which does not hamper 
locomotion efficiency) has probably favoured encephalization, redirecting energy allocation 
from growth, reproduction, and high-energy locomotion to brain development and more 
efficient locomotion, including during starvation [23]. 
The observation that human bipedal locomotion and foot anatomy lead to less energy use 
than the bipedal or quadrupedal locomotion of chimpanzees is supporting this theory [24]. 
Bipedal locomotion in humans also facilitates higher central fat depots without major energy 
demands during movement [23].  
 
A recent study provides new evidence for the expensive tissue hypothesis [25]. The study 
shows that guppies with a bigger brain have smaller guts and produce fewer offspring. This is 
in line with the expensive tissue hypothesis and adds a second factor to this hypothesis 
relating brain size, gut length, and reproductive capacity [25]. Humans are “under-muscled” 
compared with other primates, although this difference is too small to provide sufficient 
energy for brain growth [22]. Nevertheless, it is the energy consumed by human muscles 
during locomotion which is almost twice as low compared with, for instance, in chimpanzees 
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(332 versus 564 kcal/day) [22] providing enough energy for brain development and 
function.The consequence is that humans’ brains are three times bigger than the brains of 
chimpanzees, and brain metabolism accounts for 25% of the basal metabolic rate in humans 
and only 7 to 8% in other primate species [26].  
 
Overall, there seems to be sufficient scientific support to suggest that the increase of human 
brain size and metabolism has been possible because of a change of locomotion, higher 
central fat depot storage [27], and (although not addressed in this review) a change of food 
intake (see review [24]). In addition, the human brain may have benefitted from a change in 
the expression of glucose transporters [28] and the same holds for the immune system. Higher 
expression of GLUT1, supporting high and constant glucose uptake, is seen in activated 
immune cells, where energy is needed to protect against pathogens and other immune 
challenges [29]. This occurs at the expense of GLUT4 that needs insulin for glucose uptake and 
is notably expressed in muscles and adipocytes [30–33]. Thus, immune function may have 
benefitted from a smaller gut, reduced energy needs for locomotion, increased fat mass, and 
tissue specific differences in the expression of glucose transporters. 
 
The work of Fedrigo et al. [28] provides a new explanation for this intriguing “mystery,” that is, 
the evidence that during human evolution energy allocation has been directed to brain and 
immune system development. They showed that human brain cells express more activity of 
the SLC2A1 gene responsible for the production of GLUT1 glucose transporters compared with 
the chimpanzee and macaque (human > chimpanzee > macaque). At the same time, SLC2A4 
expression (i.e., GLUT4) in muscle is significantly higher in chimpanzee > human >macaque. 
Given a certain circulating glucose concentration, an increase in the amount of SLC2A1 or 
SLC2A4 protein per gram tissue results in more glucose being captured by that tissue and less 
by others. It is important to note that GLUT1 transporters are insulin-independent whereas 
GLUT4 in muscles depends on insulin for glucose uptake. An increase in SLC2A1 expression 
in the brain and a decrease in SLC2A4 in skeletal muscle would work synergistically to change 
the distribution of glucose between these two most energy-demanding tissues in the human 





3. Glucose to the Immune System: Prioritizing Energy Guidance 
A similar line of reasoning explains glucose allocation to the immune system. The energy 
demands of lymphocytes and leukocytes increase dramatically upon activation [3, 5] and all 
activated immune cells express GLUT1 glucose transporters [29, 34]. Not surprisingly, several 
signals and stimuli such as pathogen associated molecular patterns (PAMP), including 
lipopolysaccharide (LPS), can promote GLUT1 expression, giving rise to an increase of insulin-
independent glucose transport into all immune cells that supports T-cell receptor stimulation, 
immune cell migration, and inflammation [35, 36]. Thus, higher expression of GLUT1 
promotes energy allocation to the immune system, which could be considered an “energy 
demand reaction,”mobilizing fuel stocks and suppressing the resource demand of other 
organs/systems with the overall purpose of preferentially allocating fuels to activated immune 
cells [37]. Glucose allocation to the immune system maintains its function even under strong 
energy restriction [38]. 
 
Metabolic mechanisms and immune control coevolved, conceivably because both processes 
are interrelated and essential to survival [39], and both seem to have originated in a single fat 
body organ, as can still be seen in  Drosophila melanogaster [40, 41]. The integration of 
metabolism and immunology persists in higher organisms, in which lymph nodes are 
embedded in perinodal adipose tissue that may influence immune responses. In humans, 
adipose tissue is well infiltrated with macrophages, and the production of inflammatory 
cytokines by both adipocytes and macrophages contributes to systemic inflammation [42]. 
Activation of the immune system through danger signals utilizes and redistributes energy in a 
manner that favours the brain and the immune system. However, prolonged activation of the 
immune system, as observed in people with chronic inflammatory states, allocates glucose 
chronically to the immune system through immune-controlled down regulation of GLUT1 
transporters at the level of the blood-brain barrier and a reduction of GLUT4 transporters at 
the level of muscle and adipose tissue [43–45]. This selfish behaviour of the immune system is 
responsible for the majority of chronic diseases, if not all [46].  
 
Our hypothesis is that chronic exercise reallocates energy primarily to the brain and muscles, 






4. Muscle as a Defence Mechanism in Humans 
Muscle is a “forgotten” organ of the immune system. Indeed, the physical activity permitted by 
muscles changes the phenotype of immune function from proinflammatory to 
antiinflammatory, while maintaining protection against possible lethal pathogens. 
Interestingly, chronic exercise is only seen in humans and allowed us to discover and inhabit 
widely divergent habitats around the world, while remaining able to survive and reproduce. 
Hominins in general and humans in particular tended to seek novelty in their environments, 
and this practice would have led them to encounter new pathogens, climatological 
challenges, and food scarcity, all of which would have threatened survival and prompted 
activation of the immune system. If proinflammatory activity had dominated the biology of 
our ancestors when they were challenged with pathogens such as  Plasmodium falciparum 
malaria, tuberculosis,  Salmonella, or pathogenic  Escherichia coli, brain growth from 450mL 
in early  Homo erectus to the current 1,350mL in modern humans would unlikely have been 
possible. The energy costs of a consistently active immune system would have been 
enormous and would probably have impeded the growth of the brain as well as the body. An 
overly active immune system would also have harmed reproduction [47], as evidenced in 
modern fertility issues among autoimmune patients [48]. 
 
Hominins are not the only organisms in which such a trade-off occurs. Green plants and 
hominins probably share one and the same ancestor [49]. The difference is that plants have 
chosen an evolutionary path in which locomotion had low or no priority, which implies that 
they have not learned to escape from danger in a physical manner [50]. Animals’ ability to 
physically flee prevents them from being wounded and thereby from experiencing the 
ensuing cytotoxic and self-damaging reaction of the highly expensive innate immune system 
[51]. Without the means to physically escape from predators or other direct threats, plants 
employ toxins to defend themselves against predators. These toxins {e.g., perforin} are defence 
substances similar to those used by animals to kill invading pathogens and are  part of the 
immune system of the plant [52]. Plants do not have the “migrating” immune cells found in 
animals and are therefore dependent on an immune system in each individual cell [53], which 
has the potential to be very robust. As a result, in plants a chronic pathogenic load can lead to 
overactivity in their equivalent of an immune system causing a change in energy distribution 
that favours immune functions at the expense of functions related to growth and 
reproduction [54]. 
 
Similar to plants, humans and other mammals may experience damage following a robust 
reaction of their immune system, such as in sepsis. Long-term and very intense activation of 
the immune system in individuals with sepsis can cause loss of lean body mass, tissue 
breakdown for use as a source of amino acids and energy, growth impairment, and 
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reproductive disturbances [48, 55]. Even motor and mental functions in later life may be 
affected [55, 56]. In addition, a robust inflammatory reaction following acute trauma, such as a 
stroke or any other neuro-trauma, often produces severe secondary damage [57]. The strength 
of the immune reaction results from the complexity of the human immune system, which has 
high receptor diversity that greatly enhances the efficiency of microbial detection. However, 
these same qualities also make humans uniquely vulnerable to autoimmune disease (AID) 
[58], as high receptor diversity increases the risk of misinterpretation of self-molecules as 
foreign, potentially provoking autoimmune responses [59]. 
 
4.1. The Sedentary Death Syndrome: The Immune System Takes Over.  
The prevalence of autoimmunity is markedly increased in sedentary people [60], who, by 
definition, infrequently engage in physical activity. It is interesting to consider whether the 
expensive immune reaction seen in sedentary individuals can be considered adaptive in a 
manner similar to the strategy plants use to defend against invaders and danger, given that—
like plants—sedentary individuals are less able than others to flee danger. 
 
Exercise has powerful immune effects. Even nonstrenuous exercise, when engaged in 
regularly, promotes better health and increases life expectancy [61]. Nonstrenuous exercise 
also induces the expression of anti-inflammatory molecules such as lactoferrin and 
lysozymes, which provide defence against a large number of invaders, including bacteria, 
viruses, and other microbes [62]. A bout of forty five minutes of running at 75% of VO2 max 
increases the production of lysozyme and lactoferrin in saliva significantly, independent of 
sex and menstrual phase [14]. Serum lactoferrin concentrations also increase immediately 
after strenuous exercise, such as running, and may play an antibacterial role in host defences 
prior to the mobilization of neutrophils into the circulating pool, thereby attenuating the need 
for a possible inflammatory response with high-energy demand [63, 64]. Sedentary 
individuals, obese people, and patients with diabetes mellitus type 2 exhibit lower lactoferrin 
levels [65, 66], while suffering froman energy-demanding, chronic low-grade inflammation 
[10]. All organisms share a need for food intake, and food intake produces postprandial 
immune activation as a result of the possible presence of danger signals. This immune 
reaction is normally based on the production of inflammation-preventing defence molecules 
such as lactoferrin, immunoglobulin A (IgA), and lysozyme, which prevent the high-energy 
demands incurred from activation of innate immune cells [65]. However, when this 
mechanism fails or is inadequate, as often happens in obese/sedentary individuals, an 
inflammatory response ensues [67]. Increasing evidence suggests that this type of 
postprandial inflammatory response may contribute to the development of metabolic 
syndrome,endothelial dysfunction, cardiovascular diseases, obesity, insulin resistance, and 




Just as postprandial inflammation is more common in those who are sedentary or obese, 
postprandial inflammation is also observed after consumption of a meal that is high in fat, 
consists of refined carbohydrates, or contains sugar, fructose, linoleic acid, or other high-
caloric nutrients. Interestingly, a postprandial inflammatory reaction may occur after an even 
modestly sized meal that contains cereal-fed meat which should be considered “new” on an 
evolutionary time scale [68–70]. The same holds for consumption of a new form of hybridized 
beef. The postprandial immune response after ingestion of “new” wagyu beef is significantly 
higher than when humans ingest “old” kangaroo meat [70]. All these data raise the intriguing 
possibility that the increased immune activity against new nutrients reflects a “borrowed” 
ancient immune reaction against evolutionary unknown danger signals, causing low-grade, 
systemic, inflammation [70, 71]. Another factor increasing inflammatory activity of the 
immune system is chronic food availability.The relationship between food availability and 
development of the metabolic syndrome has been investigated in mice [72, 73] and more 
recently in humans.  
Hatori et al. [72] showed that obesity and metabolic syndrome are caused not only by caloric 
content, but also by food being constantly available. Koopman et al. [73] showed that meal 
frequency impacts development of fatty liver. Using a 40% hypercaloric diet, they showed that 
a high meal frequency (6/day) as compared to a lower frequency (3/day) increases 
intrahepatic triglycerides and abdominal fat, independent of caloric content and body weight 
gain. Constant food availability further decreases overall physical activity and especially 
spontaneous physical activity [74]. In contrast, starvation upregulates glucose transport 
through the blood-brain barrier by increasing the number of insulin-independent glucose 
transporters 






5. Exercise Protects the Body against the Expensive and Damaging 
Postprandial Inflammatory Response: Our Hypothesis and Its 
Putative Mechanism 
Interestingly, exercise prior to meal consumption markedly lowers the postprandial 
inflammatory reaction [77]. Evidence suggests that this effect may result from muscle 
contraction inducing anti-inflammatory myocytokines (i.e., myokines), including IL-6, IL-15, 
and IL-8, that subsequently stimulate production and release of anti-inflammatory molecules 
such as lysozyme and lactoferrin by the immune system [64, 78]. The previously mentioned 
anti-inflammatory myokines are increased up to 100-fold during exercise [79] and thereby are 
responsible for the production of anti-inflammatory molecules such as lactoferrin during and 
after physical activity [80]. Elevated concentrations of lactoferrin in serum have been reported 
30 minutes after intense running and are associated with elevated serum antibacterial activity 
to viable Micrococcus luteus [62]. Furthermore, higher levels of serum lactoferrin have also 
been observed two hours after submaximal cycling followed by a bout of eccentric resistance 
exercise [81]. The lactoferrin increase appears to be related to intense exercise and eccentric 
contraction, which has also been observed in relation to the production of anti-inflammatory 
myokines [82]. There seems to be a direct relationship between glycogen depletion and the 
production of muscle-derived IL-6, which, despite its inflammatory activities, also 
demonstrates anti-inflammatory and metabolic-sensing and regulating properties when 
expressed as a muscle myokine [82]. Lactoferrin stimulates the expression of a protein in 
adipocytes and in newly identified cells of the innate immune system called six-
transmembrane protein of prostate 2 (STAMP-2) [83]. 
 
STAMP-2 links obesity, inflammation, and insulin resistance. When STAMP-2 is activated, the 
production of proinflammatory cytokines is inhibited through down regulation of nuclear 
factor kappa B {NFkB}, the key transcription factor for activation of genes responsible for the 
production of proinflammatory cytokines and enzymes such as IL-1-beta, TNF-alpha, COX2, 
and LOX5 [84]. STAMP-2 deficiency can lead to several disorders, including atherosclerosis, 
metabolic syndrome, and diabetes [85]. NFkB contributes to the development of insulin 
resistance, and STAMP-2 restores insulin sensitivity by inhibiting NFkB [86]. All members of 
the STAMP family possess both ferric and cupric reducing activities, which indicate that 
STAMP-2 might regulate iron or copper entry into cells [87]. STAMP-2 requires iron or copper 
as cofactors, suggesting that STAMP-2 is needed to maintain metabolic homeostasis. STAMP-
2 further protects against atherosclerosis and stabilizes plaques in diabetic mice [88]. 
Decreased activity of STAMP-2 and similar proteins creates a signalling bottleneck that leads 
to insulin resistance [86, 88]. Lactoferrin is an “iron” carrying protein, which could explain its 
activating function on STAMP-2 [89]. Considering all these factors, it seems plausible that 
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preprandial (before meal intake) exercise induces the production of anti-inflammatory 
myokines and that these myokines stimulate neutrophils to produce lactoferrin [89]. 
 
The release of lactoferrin into the circulation activates visceral adipocytes, which 
subsequently react with increased expression of STAMP-2 [83]. STAMP-2, in turn, inhibits 





6. Physical Activity Was Spontaneous during Evolution and Causes 
a Phenotypical Shift of the Immune Response during Immune 
Challenges 
That exercise prevents postprandial inflammation makes good sense from an evolutionary 
perspective. From 2 million years ago until approximately 200 years ago, common threats to 
human health included starvation, dehydration, predation, climate, accidents, violence, and 
infectious disease [90]. With the exception of infectious disease, all these threats induced 
spontaneous activity (SPA) through activation of dopaminergic neuroanatomic nuclei in the 
brain, including the ventral tegmentum and the striatum [75]. The major neuropeptide 
systems that have been studied relative to spontaneous physical activity include 
cholecystokinin, corticotropin-releasing hormone, neuromedin U, neuropeptide Y, leptin, 
agouti-related protein, orexins, and ghrelin. All these systems influence dopaminergic 
signalling [91]. SPA stimulates the production of anti-inflammatory myokines by energy 
depletion of the contracting muscles. As mentioned earlier, these myokines drive neutrophils 
to produce antimicrobial/anti-inflammatory molecules {e.g., lactoferrin} and STAMP-2 in 
adipocytes and cells of the innate immune system, thus preventing over-activation of NFkB 
and the subsequent proinflammatory/insulin resistance response. The cascade of 
neurochemical reactions in the brain, when faced with old danger factors such as starvation, 
prompted patterns of SPA that reflected the daily lives of our ancestors.  
 
To starve off hunger and obtain food, both men and women often engaged in fishing, while 
men also engaged in leg-based long-term hunting and women employed arm based 
gathering. Our ancestor’s use of the upper body during physical activity is an important factor 
in stimulating an anti-inflammatory reaction. Upper body muscles are energetically more 
efficient than lower body muscles and are normally conserved even during severe metabolic 
conflicts, as observed in people suffering from chronic obstructive pulmonary disorders 
(COPD) [92, 93]. Preservation of upper body muscles may seem counterintuitive considering 
that scientists unequivocally recognize horizontal running as the evolutionarily conserved 
flight direction and considering that the maximum running speed of predators such as lions, 
tigers, and jaguars is by far much higher than the maximum speed of the fastest human. 
Conceivably, conserving upper body muscles during metabolically stressful situations may 
have occurred because humans could more easily escape threats by climbing/fighting than by 
running, making maintenance of the upper body muscles a priority. This view is supported by 
the observation that energy is first allocated to arm muscles during fear situations, 
manifesting in warm, sweating hands and an instantaneous increase of circulation [94–96].  
 
Palm sweating has a surprising benefit; hands are important parts of the body to eliminate 
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excessive body heat during exercise and increased heat elimination through palm sweating 
augments exercise resistance and prevents fatigue. Use of the upper body is also likely to have 
led to optimal levels of IL-6, which is anti-inflammatory only when produced in small 
amounts. These amounts depend on the amount of metabolic stress on contracting muscles 
during exercise, which is significantly less when using the upper body for fishing, digging, 
and other gathering functions. Our ancestors were merely gatherers/fishers and part-time 
hunters, and they therefore often relied on their upper body, thus producing the optimal anti-
inflammatory cocktail of myokines to cause an anti-inflammatory postprandial response. 
As a result, although our ancestors suffered from stress, these patterns of activity made them 
less likely than most modern humans to experience a metabolically expensive inflammatory 
response of the innate immune system and subsequent low-grade inflammation-based 
disorders. The energy thereby conserved would have been used to feed the metabolically 
expensive brain, and the absence of immune stress induced insulin resistance would prevent 
the development of neurodegenerative diseases and other maladies affecting the central 





7. Spontaneous Physical Activity and the Immune System 
Evidence that SPA is caused by ancient stress factors such as food scarceness comes from 
research with people suffering from anorexia nervosa and individuals with obesity, that is, the 
opposite phenotype [74]. However, SPA and even hyperactivity in periods of reduced food 
availability are not unique to humans: animals need to be active to search for more food if the 
food supply is limited, as is commonly the case in the natural habitat. Already in 1922, the 
psychologist Curt Richter observed that if food is served for a limited period of time, the meal 
is preceded by an increase in physical activity [98]. This phenomenon is referred to as “food 
anticipatory activity” {FAA}, and the biological explanation for FAA preceding meals is similar 
to the above-mentioned evolutionary approach to human SPA in starvation. 
 
The SPA pathway, activated through food restriction, seems to be dependent on orexin and 
dopamine [74]. Activation of orexin receptors leads to an increase in physical activity, while 
orexin is released in response to food restriction [99]. Orexin-producing hypothalamic 
neurons project on dopaminergic neurons in the ventral tegmentum, which are highly 
involved in SPA [100]. The same is true for the gut-derived orexigenic hormone ghrelin, which 
also activates dopaminergic pathways in the ventral tegmentum and induces SPA [101]. 
Dopaminergic pathways responsible for spontaneous physical activity have gained 
importance during evolution. These dopaminergic neurons belong to the group of the so-
called emotional motor neurons [102–104] and these neurons are part of the behavioural 
column.  
The behavioural column and its emotional motor neurons literally facilitate muscle 
contraction through “gain setting” pathways and motivation. It can be concluded that 
motivated activity is energetically less costly (“cheap”) than voluntary exercise and motivated 
activity is dopamine dependent [105]. Comparison of the human substantia nigra and ventral 
tegmentum with those of other mammals or vertebrates revealed tremendous differences in 
the number of dopaminergic neurons.  
 
For example, lizards { Gekko} have about 2,000 dopaminergic neurons and turtles ( 
Pseudemys) about 5,500, while rats have 45,000 dopaminergic neurons, macaques 165,000, 
and humans 590,000 in the first four decades of their lives [106]. Vernier states: “The large 
number of dopaminergic neurons in humans is remarkable given that the human brain is 
only three times larger than that of the macaque. Normally, the number of dopaminergic 
neurons correlates closely with body weight, but humans are a clear exception. This 
peculiarity is even more striking because a single dopaminergic neuron of the substantia 
nigra or ventral tegmental area (VTA) sends many collaterals with large arborization trees to 
several areas of the forebrain. The projections of these neurons are essentially similar among 
the different vertebrate species, though they tend to abundantly innervate the striatal areas 
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and, less abundantly, pallial {cortical} areas, under-scoring their role in the control of incentive 
and sensorimotor behaviours. Details of these connections are well described only in 
mammals and especially in humans [107]”. As mentioned before, the dopaminergic motor 
system belongs to the behavioural column defined by Swanson [103], and this system 
facilitates and permits behaviour [51].  
 
The opposite response is observed in people with a variety of diseases such as fibromyalgia 
syndrome, multiple sclerosis, panic disorder, obesity, and Parkinson’s disease, all of whom 
show non-permissive behaviour such as exercise avoidance [108]. Dopamine-induced 
preprandial SPA firstly saves energy for brain function and secondly helps to induce a 
protective anti-inflammatory response of the immune system after food intake through 
upregulation of the production of lactoferrin and its accumulation in dopaminergic neurons 
might protect against neurodegeneration and Parkinson’s disease [109]. As mentioned before, 
several specific aspects of human locomotion have made it possible to save energy for the 
brain [23], but this is not the only way the brain gained access to more resources to grow and 
develop during hominin evolution. Chronic exercise shaped the immune system, creating a 
highly protective anti-inflammatory phenotype that maintains protection against possibly 





8. Physical Activity: Part of the Combined and Coordinated 
Neuroendocrine-Immunological Stress Response 
Another intriguing effect of spontaneous or voluntary exercise is related to its ability to 
convert dopamine to codeine and morphine, although in low amounts [110]. Codeine and 
morphine are known for their analgesic effects, but much less is known about their influence 
on the immune system. Endogenous codeine and morphine induce constitutive nitric oxide 
synthetase (cNOS) in immune cells. The resulting NO inhibits mitochondrial energy (ATP) 
production in white blood cells and thereby immune inflammatory activity [111]. Voluntary 
motivated exercise also produces the immunoregulatory/anti-inflammatory cytokine IL-10, 
which may further elicit anti-inflammatory effects through dopamine-regulated physical 
activity [112, 113]. This anti-inflammatory response might be dangerous when the bacterial 
load is so high that the host would be in serious infectious danger when the immune system 
would maintain an anti-inflammatory activity. It is in this context not surprising that recent 
research showed that when the pathogenic load is high, the immune response will maintain 
proinflammatory capacity and drive sickness behaviour and thereby outweigh the anti-
inflammatory potential of voluntary exercise [114]. This observation in mice further supports 
the selfish character of the immune system.  
 
Taken together, both the emergence and function of dopamine, morphine, and nitric oxide 
seem to be related to evolutionary pressures to maintain chronic physical activity (for an 
excellent review see [115]). The combined production of lactoferrin, anti-inflammatory 
myokines, and IL-10 and also the dopamine/morphine/NO triad through motivated and 
spontaneous exercise make it at least plausible that SPA has driven the immune system to an 
anti-inflammatory phenotype, thereby saving energy for the brain and the muscles, which is 




9. Physical Activity Protects against the Damaging Effect of the 
Proinflammatory Activity of the Selfish Immune System: Clinical 
Evidence 
Clinical research in patients suffering from different disorders of the central nervous system 
supports the notion that physical activity protects against proinflammatory activity. Patients 
with neuroinflammatory diseases such as amyotrophic lateral sclerosis (ALS) react positively 
to exercise [116], probably through down regulation of the immune response directed against 
brain tissue. Patients with Parkinson’s disease who engage in “forced” exercise show 
significant improvement of typical Parkinson symptomatology and less progression of the 
disease [117]. These and other neurodegenerative and many other diseases seem to be related 
to disturbances in energy metabolism in the brain [118] and also to energy distribution 
between the central nervous system and the peripheral organs [119], all caused, at least in part, 
by a chronically activated immune system [10, 120]. 
 
In summary, SPA and recreational voluntary exercise seems to override the chronically active 
immune system [121] and reduce its selfish behaviour. Strenuous obligatory exercise produces 
immune suppression, possibly leading to increased susceptibility to infection [114, 122], 
although recent human research shows that the immune system reactivates when challenged 
with a high load of pathogens in people engaging in strenuous exercise. Physical activity 
{ancestors = SPA, contemporary = voluntary} induces anti-inflammatory myokines which 
inform the immune system and literally relax it. A relaxed immune system (which is distinct 
from “suppressed”) only reacts to the danger signals it was designed to respond to, such as 
bacteria and viruses, which conserves energy for the benefit of phylogenetically younger 
organs such as the liver, kidneys, and brain and gives rise to normal behaviour and a so-called 
permissive brain phenotype. A subject’s permissive brain literally facilitates free will, as 
opposed to those suffering from a non-permissive brain syndrome [51, 123–126]. 
 
Behavioural changes have high energetic cost and lack of brain energy prevents flexibility and 
loss of free will. Spontaneous and voluntary activity can also be considered a strategy 
belonging to the proactive behavioural immune system. Avoiding danger, psycho-emotional 
problems, social contact with infected individuals, dirt, and other unknown, possibly 
dangerous, triggers relax the expensive reactive immune system, once again providing 
energy for the human brain. Recent research in insects shows that an acute flight/fight 
reconfigures the type of immune reaction from a pro- to an anti-inflammatory phenotype, 
just as in humans. Once more, it is this low-cost anti-inflammatory immunological response 
that protects against infection and saves energy for brain development and function. In 
contrast, the sedentary lifestyle, a disease in itself, demands a proinflammatory response of 
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the immune system and chronic allocation of energy/resources to this system. Low-grade 
inflammation is the ultimate consequence and the cause of causes of most, if not all, 






Because regular muscle contraction diminishes the need for proinflammatory activity of the 
innate immune system [127], we suggest that muscles should be considered part of the 
immune system [128].The phylogenetic development of muscles, together with that of human 
locomotion, increased fat storage. Differences in glucose transporters between muscle and 
the brain have been responsible for patterns of energy allocation that enabled the brain to 
grow to its evolutionary maximum of 1,490mL approximately 30,000 years ago. 
 
Throughout hominin evolution, our ancestors encountered dangerous situations, such as 
violence and dehydration, that threatened the survival of the individual or the species and 
usually triggered a survival response in which more ancient systems tend to dominate 
younger ones [129], although brain functions and anatomy seem to maintain the highest 
priority. 
 
The normal response to survival threats is SPA, and SPA is capable of controlling the immune 
system by saving energy for the brain during stressful situations [130]. The absence of SPA or 
voluntary exercise, as is occurring in sedentary people living modern lifestyles, provides a 
framework in which the immune system overrides the interests of the normally selfish brain, 
which could be the reason why brain size shrank in the last 30,000 years from the maximum 
of 1,490mL to the current average of 1,350 mL. 
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The evolution of human kind has taken millions of years in which environmental factors 
gradually shaped the actual genome adapted to those circumstances. One of the most vital 
behavioural adaptations of mammals in general and especially humans is their capability of 
self-sufficiency through physical activity. Physical activity abilities, including long distance 
running, jumping, climbing and carrying things have probably been necessary to outrun wild 
animals, search for food and hide for danger. In contrast, individuals physically or 
psychologically unable to “take care of themselves” were more susceptible for early death and 
therefore for genetic extinction.  
 
The actual society is characterized by sedentary instead of “moving” individuals. Physical 
inactivity is not just a possible factor related with chronic disease, but should be considered 
the actual cause of the majority of human illness.  Individuals know that exercise is necessary 
and beneficial. Nevertheless almost 75% of the actual population doesn’t reach the estimated 
minimum of necessary activity. Physical inactivity belongs to the characteristics of sickness 
behaviour; the latter which probably is protective for the organism. Sickness behaviour, 
including depressive mood, seems to protect against infection, injury, social conflict and 
facilitates energy conservation. Sickness behaviour is based on immune-brain mechanisms 
and can be defined as non-permissive behaviour. Long-term non-permissive behaviour can 
lead to chronic disease because of reduction of physical activity and self-defeating coping 
styles, converting non-permissive behaviour in a non-permissive brain disorder. We propose 
that physical inactivity disease is synonymous for a non-permissive brain disorder and that 
NPBD produces a so called “reptile phenotype”, characterized by hypothermia, poor hair 
growth, decreased fertility and low basal metabolic rate. 
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Physical inactivity is related to almost every type of chronic disease including heart 
insufficiency, diabetes type II, metabolic syndrome, obesity, gall stones depression, early 
aging, neurodegeneration and even early death (1). Clinical research about the effect of 
exercise on parameters such as blood flow, energy metabolism and immune system 
activation is not conclusive because of a basic mistake; the use of “healthy sedentary” 
individuals as the control group (2). The human genome has been shaped through several 
evolutionary pressure factors including the need of self-sufficiency. Self-sufficiency is 
defined sociologically as each human or small group of humans being responsible for their 
own food, water, defence, and shelter (3, 4). The self-sufficient phase has dominated human 
behaviour for almost 2 million years and only perhaps the last 100 years individuals are 
“served” dinner, warmth, drinks and shelter. This non-self-sufficiency is defined here as 
humans obtaining a constant supply of food until reproductive age through a distribution 
network composed generally of farmers to transporters to sellers to buyers to consumers. 
 
Homo sapiens is the most resistant being to long term exercise, capable of outrunning 
animals such as wildebeest and other big mammals, which have been part of the natural 
nutritional sources of humans till very recently (5, 6). The capability of outrunning other 
animals demands the following unique characteristics of human physiology and morphology 
(7): 
• Thermoregulation in homo sapiens is unique through the absence of body hair and the 
presence of more than 2 million eccrine sweat glands (8, 9) 
• Short toes, reducing the energetic cost of running (10, 11) 
• The capability of producing great amounts of glucose out glycogen, amino acids and 
glycerol; gluconeogenesis 
• Expensive organs such as the heart muscle and the brain can use different energy sources 
when necessary; the so-called metabolic flexibility (12). This metabolic flexibility 
facilitates endurance running, climbing, jumping, swimming, throwing, crawling, 






Table 1 The relationship between evolutionary based life threatening danger factors, the 
developed survival reaction, the benefit and the contemporary consequence of disease. 
 A = adrenalin; AVP = arginine vasopressin; HIF-1 = hypoxia inducible factor 1; HSR = hypoxia stress reaction; IIS = innate 
immune system; IR = insulin resistance; LR = leptin resistance; NA = noradrenalin; SER = serotonin (adapted from 4) 
 
Homo sapiens “is made for walking”, so inactivity is a disease 
As it seems that homo sapiens is “made for walking”, it is very strange that so few people 
engage in physical activity nowadays. Troiano et al (14) using an accelerometer showed that 
only 5% of the adults and 8% of the adolescents reach the minimal amount of recommended 
physical activity (figure 1). Nevertheless, looking at Haile Gebreselassi finishing the Berlin 
marathon and breaking the world record with a big smile on his face makes it plausible that 
exercise, although intense, has to be fun. So knowing why people fail to engage in regular 
exercise, leading to possibly severe damage to their body, is of mayor clinical importance. We 
state that the background of choosing for a sedentary life is based on a so-called non-
permissive brain syndrome (NPBS, our hypothesis, see further, 17). This syndrome protects the 
individual for a certain period (a disorder), while long lasting NPBS is a disease itself (defined 
as such by Heskha and Allison, 18), related with increased mortality risk. NPBS is characterized 




Figure 1 The actual percentage of individuals reaching the minimal physical activity level 
(adapted from 14) 
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The burden of physical inactivity 
The systemic changes caused by physical inactivity occur fast and are specific for a disease. In 
response to excessive inactivity (continuous bed rest or go into the microgravity environment 
of space) individuals exhibit a rapid loss of tissue mass and disruption of normal function in 
many cells and tissues. Within weeks of the onset of continuous bed rest by humans, 
numerous adaptations occur, including 25% decreases in maximal stroke volume, maximal 
cardiac output, and peak consumption of O2 during maximal aerobic exercise. Orthostatic 
intolerance occurs due to attenuated baroreflex-mediated sympatho-excitation in response to 
incremental declines in arterial blood pressures. Bones lose mass at 10 times their normal rate. 
Skeletal muscles become weaker with less endurance for light physical effort. In addition, 
metabolic pathways adapt to inactivity by decreasing mitochondrial concentration in skeletal 
muscles, lowering the capacity to oxidize fatty acids, affecting metabolic flexibility. Whole 
body insulin sensitivity declines within the first 3 days of inactivity, whether it is sedentary or 
active individuals stopping daily exercise. Constipation ensues. Deep vein thrombosis can 
occur within a time frame as short as an international flight with possible pulmonary 
thrombo-embolism in susceptible individuals. In summary, the body’s reaction to physical 
inactivity result in a loss of many structural and physiological processes, which often lead to 
unhealthy, in some cases life-threatening, conditions (3, 19, 20, 21). Another consequence of 
inactivity is the loss of strength of respiratory muscles (22). This effect can cause severe loss of 
muscle strength of peripheral muscles through more severe inactivity, oxygen deficiency and 
higher insulin resistance (23). On cellular level, changes are even more dramatic. Inactivity 
decreases neurogenesis in specific parts of the brain responsible for memory, motor learning 
and programs and need-catering factors (food, water, no-drugs, no-alcohol abuse, etc.). Parts 
included are the cerebellum (motor programs), the olfactory bulb (need – catering) and the 
hippocampus (24). On the contrary, exercise combined with enriched environment is able to 
recover earlier lost neurons also in elder animals and humans (25, 26). Decision-making can 
be considered the most important trait of Homo sapiens. The actual environment demands 
self-control and discipline to make the right decision regarding food choice, physical activity, 
smoking, alcohol and other factors that affect hedonic choices. The hippocampus is essential 
for decision-making together with other parts of the brain such as the striatum and the frontal 
cortex (27, 28). Loss of hippocampus volume (and the subsequence increased susceptibility for 
developing inactive behaviour) can further be produced by stress, sleep disruption, smoking, 
alcohol abuse and inflammation (26, 29, 30). Another consequence of physical inactivity is its 
resistance-inducing effect on insulin, leptin, serotonin, dopamine, thyroxin and cortisol 
signalling, affecting the function of the immune system, the endocrinological system and 
distribution of energy (50, 53, 54, 55, 56).  Resistance to the mentioned hormones is part of the 
development of sterile chronic inflammatory diseases (65). Inactivity can also affect the 
expression of glucose transporter 4 (GLUT4). GLUT4 is responsible for muscular glucose 
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trafficking in rest (insulin dependent) and activity (insulin independent, 19, 20, 62). GLUT4 is 
decreased in sedentary individuals, increased in active ones and persons with high GLUT4 are 
more engaged in exercise (62, 63, 64, 65, 66). Increase of GLUT4 expression enables muscle to 
uptake more than 80% of the daily glucose load. This would make our high glycemic society 
less toxic and therefore less pathological. In resume, the great amount of literature supports 
the overall necessity of increase of physical activity as a normal way of living and in one way 
or another people have to get conscious about the severe deleterious effects of sedentary 
lifestyle on health and life expectation (67, 68).  
 
Possible explanations for the “lazy phenotype” 
Chronic intake of food (high meal frequency and abundant meals) can have an important 
influence on various forms of physical activity (32), including spontaneous and voluntary 
exercise. Spontaneous physical activity, the activity related with daily life, plays a mayor role 
in maintaining body weight, caloric intake and overall health (33, 34, 35, 36). Spontaneous 
physical activity (SPA) is not chosen and bypasses higher cortical regions while voluntary 
exercise is a choice and therefore dependent on neocortical activity and “free will” (36, 37, 38, 
39). Brain stem and spinal centres responsible for the maintenance and recovery of 
homeostatic balances regulate SPA. Hunger, thirst, cold, warmth, itch, libido, curiosity and 
pain are homeostatic feelings inducing movement beyond any doubt. The problem in 
modern society is just that the refrigerator, air conditioner and heating are very nearby and 
eliminate the SPA stimulus within seconds, whereas our ancestors were obliged to move till 
they would find food, water, a place to hide or would have produced so much body heat that 
they could survive in the cold (the self-sufficiency period). Homeostatic feelings are related 
with the production of certain neuromodulators, including orexin and cholecystokinine (CCK, 
for a excellent review see 34). Orexin, related with appetite and environmental food and liquid 
exploration, favours SPA (40,41, 42). On the contrary, CCK, produces postprandial satiety, 
inhibits SPA and induces sleep (43). Postprandial CCK production influences the body arousal 
system probably by inhibiting the sympathetic nervous system and by activating the non-
myelinated vagus nerve (44, 45, 46, 47). This appetite-satiety/exercise-rest rhythm has 
probably been developed through evolutionary mechanisms, giving raise to the so-called 
feast-rest/famine-exercise hypothesis of Chakravarthy and Booth (3, 47, 48). Several 
interventions to promote SPA have failed so far; although something so simple as less 
sedentary behaviour and reduction of television hours could already be effective (49).  
 
Human evolution has shaped the genome in such a way that the majority of genes are 
selected against physical inactivity (3, 70, 71, 72, 73). Current scientific research shows that a 
few genes seem to play a mayor role in engagement in physical activity, including dopamine 
receptor 1 (Drd1) and the so-called nescient helix loop helix (Nhlh2, 82). The involvement of a 
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dopamine-signalling pathway in physical activity should not be surprising. Dopamine is 
involved in several locomotor disorders such as Parkinson, attention deficit hyperactive 
disorder, Tourette syndrome and restless legs. Quite a few studies have been carried out 
relating Drd1 expression with activity-level in animals and humans (see review 74). Dopamine 
is the key-player in functions such as drive, motivation, “cheap movement”, decision-making, 
future thinking, reward searching and control of emotional-obsessive behaviour (7).  
 
Dopamine is fun, but an overload can be responsible for hyperkinetic disorders, paranoia, 
fanatic religious behaviour and even uncontrollable aggressive behaviour (75, 76). Dopamine 
receptors 1and 2 are the most studied in humans. Theoretically, Drd2 receptor binding signals 
the presence of important (often reward-based) information and allows the prefrontal cortex 
(PFC) network to respond to this new information by updating its working memory system. 
Drd1 receptor stimulation, on the other hand, plays a gating role by controlling the threshold 
of significance above which information may pass before it can be admitted to working 
memory and processed by the PFC. Drd1 receptor activation stabilizes the pattern of activity 
within the PFC neural network and protects the system from distracters until the appropriate 
behavioural response is generated (77). Different research groups have found that animals and 
humans with a lower expression of Drd1 in the nucleus accumbens belong to the high-active 
sample while high expression of Drd1 produces a more inactive phenotype (77, 78, 79, 80, 81). 
Dopamine signalling in the brain is very much dependent on the intra-uterine environment 
and especially of the presence of enough iodine, L-tyrosine and omega 3 fatty acids (82, 83, 
84, 85, 86, 8, 88, 89, 90). Chronic inflammation is especially important in dopamine signalling 
and therefore will be considered separately proposing our hypothesis. 
 
Our Hypothesis: “The non-permissive brain disorder; laziness as a 
protection?” 
We hypothesize that physical inactivity is part of a non-permissive brain syndrome caused by 
(adaptive?) disorders of dopamine signalling; not only genes will be involved but also 
environmental factors including a lack of brain nutrients during brain development and 
maturation (iodine, DHA, L-tyrosine, Cunnane 2005), vitamin D deficiency, increased protein 
turn-over and energy distribution disturbances (17). The pathways leading to insufficient 
dopamine signalling include hyper activation of indoleamine 2,3 dioxygenase pathway in 
chronic inflammation (for an excellent review see 61) and decrease of the conversion of the 
amino acid l-tyrosine in dopamine (75). Chronic disease is characterized by higher energy 
demand of the immune system and dramatically increased protein turnover (60). The 
increased protein/energy demand can be so severe that multiple organs could suffer 
functional disorders and even failure, leading to acute death (59). Chronic immune activation 




• Exercise avoidance  
• Thermoregulation disorders  
• Social isolation  
• Reduction of libido  
• Gluttony or 
• Lack of appetite  
• Increased pain sensitivity  
• Fatigue  
• Concentration deficiency 
• Attention disorders 
• Memory problems 
• Change of body composition (muscle atrophy and increased fat deposits) 
• Decreased fertility  
• Impaired hair growth and boldness 
• Decrease of top-down decision making 
• Self-defeating behaviour 
• Depressive mood 
 
The physical characteristics lined up belong to a species with low basal metabolism such as a 
reptile (51). Low activity belonging to sickness behaviour and NPBS could help to defend the 
organism against infection, conflict, injury, exhaustion and perhaps the most important 
factor, low activity conserves energy for the immune system to combat infection, although it 
would be a sterile one (96, 97, 98). Certain depressive states are part of the non-permissive 
brain disorder (NPBS) and therefore depression and low activity should probably be 
considered protective at start. Long-term inactivity is deleterious per sé because of the 
tremendous damage at physical and mental level.  We define NPBS as a behavioural strategy 
to prevent more severe damage, conserve energy and proteins to support immune function 
and provide protection of the most expensive organs of the human body at start.  NPBS can 
also protect people against repeated physical abuse (social withdrawal in people who have 
suffered childhood abuse, 119) and severe loss of lean body mass during chronic immune 
system activity (52, 58, 59). Long lasting NPBS is severely deleterious to the host and should be 
treated as one of the most important clinical identities in modern medicine.Humans have the 
highest encephalisation quotient of all living animals on earth. Big brains need more energy.  
The development of bigger brains, mostly in mammals, has changed the morphology of these 
mammals in such a way that more central energy allocation was needed in stead of high 
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allocation to “dismissible” organs such as guts and muscles (99, 100). Possible threat to brain 
energy supply will lead to NPBS. 
 
The “selfish brain” will continuously scan energy status in the peripheral body through 
neurological and endocrinological communication, including sympathetic interoceptors and 
hormones such as insulin (informing about muscle energy) and leptin (informing about the 
amount of stored fat. Peters et al (101, 102) showed that the brain would always give priority to 
its own energy need although others organs could suffer. Even in insulin resistant states, in 
which energy allocation is disturbed, the brain will cover its needs through up regulation of 
alternative substrate usage such as creatine and fatty acids (103, 104). NPBS will therefore 
protect primarily the brain on behalf of muscle tissue. Muscle tissue uses an average of 13 
kcal/24 hours in rest and up to 10 times more during exercise (table 2, 107). Muscle waisting 
and physical inactivity conserves a substantial amount of energy and provide proteins to be 
used by the immune system. 
 
Chronic immune system activation is just one possibility of energy and protein deficiency 
(105). Hepatic overload (through chronic fructose intake, environmental toxins, hormonal 
stress) demands a higher energy turnover in the liver. Situations in which an expensive organ 
demands more energy and protein, other organs will have to reduce their metabolic rate, 
conserving energy and proteins for the demanding organ (103, 106). 
 
 
Table 2 The energy rate/24 hours of different human organs and tissues.  
Muscle, contributing to more than 40% of the body mass, uses approximately 13 kcal/24 hours. Fat tissue and bones belong 
to the cheapest tissues and demand 4,6 kcal/24 hours and 2,2 kcal/24 hours respectively (107) 
 
An excellent example of a NPBS is chronic fatigue. The majority of people suffering from 
chronic fatigue syndrome (CFS) show symptoms, which should be considered as 
consequence of the huge energy and protein demand of the chronic activated immune 
system. Another topic in CFS is the high incidence of people suffering from fatty liver disease, 
low thyroid hormone function and insulin resistance (108, 109, 110, 111). Impaired thyroid 
hormone function induces low basal metabolism and inactivity (¿??). 
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Resuming, it seems plausible to state that physical inactivity as part of NPBD could actually be 
a protective strategy against severe or more damage and infection, an energy conservation 
strategy and an avoidance strategy against possible psycho-emotional conflicts. If so, 
treatment for people with physical inactivity disease (PID) should be based upon inhibition of 
the immune system, improvement of energy distribution, recovery of insulin sensitivity and 
reduction of psychosocial stress. Even other factors such as shame coping style (117), socio-
demographic conditions (118), childhood abuse (119) and lack of employment (120), causing an 
inactive phenotype should be considered just part of the etiological factors leading to NPBS. 
 
NPBS and engaging in physical activity; discussion 
As it is stated in this article, physical inactivity disease should be considered a non-permissive 
brain syndrome, based on multiple factors but all related with a possible threat for brain 
energy deficiency. Our hypothesis can be easily tested through measurement of biomarkers 
such as basal metabolic rate, acute phase proteins, the use of validated questionnaires and the 
influence of integrative “motivational” treatment and the measurement of engaging in 
spontaneous and voluntary exercise after intervention. Basic part of the treatment of people 
suffering from NPBS is in depth information about the pathways leading to it and the 
subsequence physical inactivity.  
 
Physical inactivity is a disease and should be considered one of the most damaging 
behavioural traits not only in developed but also in developing countries. Multiple etiological 
factors have been identified to explain this rather strange way of living (without exercise). 
Strange because of the fact that exercise has saved Homo sapiens during thousands of 
generations and is therefore programmed against inactivity. The impact of physical inactivity 
on systemic, metabolic, cellular, molecular en genetic level is so diverse and severe that the 
effort to find a so called “exercise pill” will probably will be too good to be true (121). Engaging 
people in physical activity needs an integrative intervention based upon deep learning, 
immune system regulation, recovery of insulin sensitivity and normalizing of energy and 
energy distribution (50). Part of the optimal treatment is based on motivation, increase of 
inevitable spontaneous exercise (absence of elevators) and on promoting evolutionary 
biorhythm, including a feast/famine rest/exercise rhythm (51).  Education in the need of 
engagement in physical activity should probably begin when the next generation starts; at 
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Background: Chronic low-grade inflammation and insulin resistance are intimately related 
entities that are common to most, if not all, chronic diseases of affluence. We hypothesized 
that a short-term intervention based on ‘ancient stress factors’ may improve anthropometrics 
and clinical chemical indices. 
 
Objective 
Study whether a 10-day-mimic of a hunter-gatherer lifestyle favorably affects 
anthropometrics and clinical chemical indices. 
 
Methods 
Fifty-three apparently healthy subjects and two patients with fibromyalgia (22–69 years, 28 
women), in 5 groups, engaged in a 10-day trip through the Pyrenees. They walked 14 km/day 
on average, carrying an 8-kilo backpack. Raw food was provided, self-prepared and water was 
obtained from waterholes. They slept outside in sleeping bags and were exposed to 
temperatures ranging from 12-42 °C. Anthropometric data and fasting blood samples were 
collected at baseline and the study end.  
 
Results 
We observed median decreases (p≤0.002) of body weight (-3.5 kg), BMI (-1.1 kg/m2), hip (-3 
cm) and waist (-5 cm) circumferences, glucose (-0.6 mmol/L), HbA1c (-0.1%), insulin  
(-4.7 pmol/L), HOMA-IR (-1.2 mmol*mU/L2), triglycerides (-0.14 mmol/L), total cholesterol (-
0.7 mmol/L), LDL-cholesterol (-0.6 mmol/L), triglycerides/HDL-cholesterol (-0.55 mol/mol) 
and FT3 (-0.8 pmol/L). Changes in anthropometrics were unrelated to changes in clinical 
chemical indices, except for FT4 and FT3. ASAT (11 IU/L), ALAT (6 IU/L), ASAT/ALAT ratio 
(0.14) and CRP (0.56 mg/L) increased, and their changes were interrelated. 
 
Conclusion 
Coping with ‘ancient mild stress factors’, including physical exercise, thirst, hunger and 
climate, may influence immune status and improve anthropometrics and metabolic indices 





Chronic non-communicable diseases (CNCD), including diabetes type 2, cardiovascular 
diseases, autoimmune diseases, chronic fatigue, depression and neurodegenerative diseases, 
are the major causes of morbidity, work absence and invalidity. They may be responsible for 
35 million out of 52 million annual deaths worldwide (1). CNCD has recently become the 
major topic for the World Health Assembly. In 2013, the Lancet issued a special on CNCD (2, 3). 
Treating patients with CNDC is complex and of limited availability in many countries because 
of costs, while its proximate treatment has many side effects. Compliance is often low (e.g. 
lipid lowering drugs, anti-hypertensives) and many interventions have proven unsuccessful 
(4). 
 
The vast majority of CNCD are caused by unhealthy lifestyle and other anthropogenic factors. 
It seems that none of us is immune for the damaging effects of modern lifestyle (5, 6). Not 
surprisingly, many of these diseases are preventable by changes in behavior, including 
nutrition, physical activity and coping strategies (7, 8, 9, 10). The anthropogenic factors 
responsible for the CNCD pandemic include physical inactivity, unhealthy diet (e.g. high 
energy density refined food, too low vegetables, fruits and fish), chronic psycho-emotional 
stress, insufficient sleep (loss of biorhythm) and environmental toxins, including smoking (5, 
11, 12, 13, 14, 15, 16, 17, 18). All of these may be considered ‘danger signals’ that activate central 
stress axes [sympathetic nervous system (SNS) and hypothalamus-pituitary-adrenal gland axis 
(HPA)] and the immune system (19, 20).  
 
Inflammation is characterized by the five classical symptoms of rubor, dolor, calor, tumor and 
torpor. Inflammation requires metabolic adaptations (12). Overt injury and infection bring 
about short-term allostatic responses aiming at the removal of the infectious agent, engaging 
in repair, and, ultimately, recovering homeostasis in a highly coordinated fashion (21). While 
ancient infectious challenges induce optimal responses with self-resolving capacity, 
anthropogenic inflammatory stimuli deriving from modern society provide us with weak and 
long-lasting immunological responses that take us to a condition of chronic systemic low-
grade inflammation with accompanying chronic hypometabolic adaptations (22, 12, 23). It has 
become clear that many, if not all, CNCD are characterized by a state of low-grade 
inflammation (LGI, 24, 25) that comes along with (e.g.) insulin resistance, hyperleptinemia, 
cortisol resistance, subclinical hypothyroidism and nerve-driven immunity. Jointly, they are 
responsible for the gradual development of multiple comorbidities together referred to as the 




The absence of ancient immune challenges in current Western societies inspired us to 
hypothesize that acute stress from ancient danger signals causes redistribution of the 
immune system towards its evolutionary preferred locations, and thereby favorably affects the 
state of chronic systemic low-grade inflammation, normalizes stress axes activities, recovers 
rhythmic function and restores insulin-insensitive pathways.  Mild stress factors may activate 
resolution responses based on survival mechanisms that originate from millions of years of 
evolutionary pressure. In this study we investigated whether such ‘ancient stressors’, provided 
by a 10-day trip through the Pyrenees, improved anthropometrics and various clinical 
chemical parameters of low-grade inflammation, stress and metabolic control in 53 
apparently healthy adults and two patients with fibromyalgia. The objective was to provide 
proof of principle that humans can influence their immune and metabolic systems by 
exposure to ancient mild acute stress factors. Our intervention mimicked, to some extent, the 
‘conditions of existence’ of ancestral and current hunting/fishing-gathering populations.  
 
2. Subjects and methods 
Study group 
The participants were students, scientists, physicians and other health professionals who were 
engaged in clinical Psycho-Neuro-Immunology (PNI) courses throughout Europe. They were 
interested to experience the impact of ancient lifestyle on their own health and well-being 
and therefore jointly decided to engage in this study. No consent from a medical ethical 
committee was deemed necessary, for which we refer to the constitutional law of self-
determination, in which people have a basic right to decide what they want to do with their 
health (included in the patients self-determination act, United States 1991 and the Council of 
Europe 2009). The participants were part of their own team, united in a research consortium 
(see acknowledgments). They covered their own expenses and there were no grants. They 
appointed one of us (LP) as the study coordinator. All volunteers signed an informed consent 
and all were informed about the trip details. The Catalan Government and the local 
government of Tremp (Spain) gave permission to execute our study without any restrictions. 
 
We included apparently healthy adults and two patients with fibromyalgia. The fibromyalgia 
syndrome was diagnosed by medical specialists. Exclusion criteria were cardiovascular 
diseases, psychiatric diseases and chronic use of medication for serious illnesses. 
 
Study design 
Groups of 11 subjects, at most, participated in this 10-day trip through the Spanish Pyrenees 
during the summers of 2011 (n=10), 2012 (n=32) and 2013 (n=11). The participants lived 
outdoors and walked from one water-source to another. Food was provided by the 
organization and with help of forest-guards from official institutes of the Catalan county. 
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Food intake was planned before the trip, based on the average daily food intake by the 
traditionally living Hadzabe people in Tanzania (Supplementary Tables 1 and 2). The use of 
mobile phones or other electronic devices was not allowed. 
 
The detailed activities and condition during the 10-day study were as follows: 
• First day, arrival at the hospital of Tremp (Catalonia, Spain) with an air-conditioned bus 
from Barcelona (2.5 h drive). Participants were once again informed about the trip. 
Anthropometric data and blood samples were collected in the fasting state. 
• Daily walking trips from waterhole to waterhole, with an average walking distance of 
about 14 km/day, including altitude differences up to approximately 1,000 m. The 
participants carried their own backpacks with an average weight of 8 kg. The trip took 
place in the part of the pre-Pyrenees with a maximum altitude of 1,900 meters above sea 
level.  
• Participants consumed two meals daily. The first was provided by the organization 
halfway and the second on arrival at the camping site. Animals, including ducks, 
chickens, turkeys, rabbits and fish, were delivered alive and killed by the participants. Fish 
were caught with nets in the Noguera river. All foods were prepared on the spot by the 
participants. Nutritional details are in Supplemental Table 2. 
• The participants slept outside in sleeping bags on small inflatable mattresses. Outside 
temperatures varied from 22 to 42 °C during daylight, whereas night  temperatures varied 
from 12 to 21°C. One group experienced a day of snow in the middle of July, which 
prompted the organization to provide hotel accommodations for a single night. 
• Bulk (intermittent) drinking behavior was recommended by drinking as much as possible 
(up to satiety) after reaching a waterhole. The waterholes contained non-chloritized 
drinking water. 
• Some manual work was done to clean mountain trails as agreed upon with the Catalan 
Government. 
 
Anthropometric data, sample collection and analyses 
Sixteen anthropometric and clinical chemical parameters were measured before departure to 
the Pyrenees and after return. Anthropometric measurements were measured by one of us 
(LP) at the hospital of Tremp. The subgroup of two participants with fibromyalgia syndrome 
was followed for more than two years. Fasting heparin-, oxalate- and EDTA- anti-coagulated 
blood samples were collected by venipuncture in the first morning and the morning of the 
10th day at the study end. All samples were transported at 5 °C and processed within 1 h. 
Analyses were done in the clinical laboratory of the hospital of Tremp. 
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HbA1c, total-cholesterol, HDL-cholesterol, aspartate aminotransferase (ASAT), alanine 
aminotransferase (ALAT) and glucose were determined with a Cobas c-501 analyzer (Roche, 
Madrid, Spain). Serum insulin was measured by chemo-luminescent assays, using Dxi-600 
(Beckman, Barcelona, Spain) and Liaison XL (Diasorin, Madrid, Spain), respectively. High 
sensitivity C-reactive protein (CRP) was measured with a Behring Nephelometer II Analyzer 
System. HOMA-IR (mmol*mU/L2) was calculated by glucose (in mmol/L)*insulin/22.5 (in 
mU/L) (Hill 2013) 
 
Statistics 
Statistical analyses were performed with IBM SPSS statistics version 23.0 (IBM Corp). Changes 
during the intervention were analyzed with the Wilcoxon signed rank test at p<0.05. 





There were 55 participants. Their median age was 38 years (range 22-67). The number of 
women was 28 (50.9%). Baseline anthropometrics are in Table 1.  
 
Course of the trip 
The 10-day trip went through the low and middle-high part of the Pyrenees. The majority of 
participants did very well. If one of them got too tired, LP or JA carried his/her backpack for as 
long needed. Trips were made from one waterhole to another, with a consistent midday pause 
of 1-1.5 h. The Mountainside of the Pyrenees is composed of hard soil and many of its 
vegetation carries thorns. Most participants suffered from small wounds on arms and legs, 
caused by the thorns of the aliaga, a plant belonging to the original vegetation of the Pyrenees. 
None of them suffered from infected wounds and most appeared fully cured at the end of the 
trip. Participants suffered from hunger feelings during the first three days, but gradually got 
used to eating only twice daily. Only one participant discontinued the trip, because she had 
different expectations. The local organization arranged transport and she left. The other 
participants enjoyed the trip for the full 10 days, without exceptions. Interestingly, the 
majority, including LP, wanted to go home after 7 days (see discussion).  
 
Feelings of thirst were moderate at the beginning, but ameliorated after 3 days. Participants 
noticed that they could drink increasingly more water upon arrival at a waterhole and 
gradually experienced less needs for ‘in-between water stops’. Three participants suffered 
from what might have been neuroglycopenic periods, feeling weak, hungry, cold, dizzy and 
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trembling. However, measurement of their blood glucose level by finger prick did not reveal 
hypoglycemia. One of these participants was grossly overweight and exhibited fasting 
glucoses highly surpassing the normal range. He was not able to carry his backpack during 
the first three days, but managed surprisingly well during the last. At night, some participants 
were affected by the cold. They needed a thicker sleeping bag, which was supplied. 
Participants went asleep at sunset and rose at sunrise. Overall, participants felt good, 
occasionally tired, but not at all overloaded. Mosquitoes were a nuisance at night and 
therefore a liquid mosquito repellent was provided by the organization. Several participants 
suffered from diarrhea at the trip’s end, probably from drinking water from the non-
chloritized waterholes. Taken together, the vast majority of the participants enjoyed the trip 
and recognized the benefits by feeling more healthy and recovered from Western stressful life. 
 
Anthropometrics and clinical chemical indices   
Anthropometric and clinical chemical data collected before and after the excursion were 
available from 23-53 participants (Table 1). The missing values were attributable to the 2012 
groups. Probably because of procedural imperfections in the Tremp lab, the outcome of the 
insulin assay could not be performed in various series.  
 
We found (Table 1) that body weight decreased with a median (range) of -3.4 kg (-7.5 to -0.7), 
BMI with -1.2 kg/m2 (-4.4 to -0.2), hip circumference with -3 cm (-17 to +5), waist 
circumference with -5 cm (-18 to +9) and waist/hip ratio with -0.02 (-0.14 to +0.10).  
 
We also observed decreases (median; range; Table 1) of: glucose (-0.6; -1.7 to +0.5 mmol/L), 
HbA1c (-0.1; -0,4 to +0.2 %), insulin (-4.7; -31.4 to -0.2 pmol/L), HOMA-IR (-1.2; -7.0 to -0.4 
mmol*mU/L2), triglycerides (-0.14; -6.12 to +2.18 mmol/L), total cholesterol (-0.7; -2.8 to +0.4 
mmol/L), LDL-cholesterol (-0.6; -3.1 to +0.6 mmol/L), triglycerides/HDL-cholesterol ratio (-
0.55; -8.98 to 1.34 mol/mol), and FT3 (-0.8; -3.4 to +3.1 pmol/L).  
 
On the other hand we found that ASAT and ALAT activities increased with 11 IU/L (-8 to 54) 
and 6 IU/L (-13 to 52), respectively, while CRP increased with 0.56 mg/L (-15.72 to +41.07). 
Figure 1 shows the median and individual changes of ASAT (panel A), ALAT (panel B) and CRP 
(panel C). The ASAT/ALAT ratio before the intervention was 1.23 (0.68–2.00) and increased 
with 0.08 to 1.31 (0.48–2.06).  
Figure 2 shows the medians of the percentage change for the anthropometric and clinical 







Two subjects with fibromyalgia 
The two female participants (ages 37 and 38 years) were part of the 2011 group. Both managed 
surprisingly well. The first three days they still suffered from overall pain, but these gradually 
disappeared after 7 days. From the start, they preferred to carry their own backpacks but were 
in too much pain. LP and one of the others carried their backpacks most of time during the 
first three days. They were able to carry their own backpacks from then. Fatigue symptoms 
were severe during the first 4 days but diminished substantially after the fifth. Sleeping 
problems vanished almost immediately. Bowel movement was compromised at start, but 
improved during the trip to become almost normal in one of them at the end. The second 
patient kept complaining about abdominal pain, but stool consistency and frequency were 
normal. No notable differences were observed in the changes of their clinical chemical 
indices when compared with other participants. Both showed increases of ASAT (from 26 to 
48; and 36 to 53 IU/L), ALAT (18 to 30; 25 to 39 IU/L) and CRP (0.37 to 2.71; 0.17 to 0.64 mg/L). 
while their HOMA-IR decreased (0.48 to 0.31; 1.04 to 0.52 mmol*mU/L2). Their ASAT, ALAT 
and CRP values decreased during the months after the trip. Three months after the trip her 
ASAT had decreased from 48 to 22 IU/L in one of them, while ALAT decreased from 30 to 19 
IU/L, and CRP from 2.71 to 0.5 mg/L. The other showed changes from 53 to 18 IU/L for ASAT, 
39 to 16 IU/L for ALAT and 0.64 to 0.2 mg/L for CRP. Follow-up of both patients occurred 
during three years. At present both women are healthy. One became pregnant and mother of 
a healthy child. She started her own clinical PNI institute, while the other is completing an 
University master.  
 
One subject with arrhythmia. 
One of the participants suffered from cardiac arrhythmia since 2000, following a sternum 
fracture in a car accident. He was on medication since then. During the trip he stopped taking 
treatment and did not suffer from arrhythmic periods during the 36-month-period that 
passed since the study end. 
 
Interrelationships 
Relationships between changes of the anthropometric and clinical chemical indices are 
presented in Supplemental Table 3. Importantly, we found that the changes in weight, BMI, 
hip circumference, waist circumference and waist/hip ratio were generally unrelated to the 
changes of clinical chemical indices. Exceptions were the negative associations (p<0.05) 
between waist circumference and FT3 (r= -0.359), and waist/hip ratio and FT4 (r= -0.360). The 
change in HOMA-IR was negatively related to changes in total cholesterol (r= -0.457) and 
LDL-cholesterol (r= -0.436). Finally, we found that the changes in ASAT, ALAT and CRP were 
positively interrelated (ASAT vs. ALAT r= 0.777; ASAT vs. CRP r=0.508; and ALAT vs. CRP 
293 	
 
r=0.440). Age proved positively related to the change of ASAT (r= 0.371), but was unrelated to 
the changes of ALAT and CRP. 
Discussion 
The aim of this study was to investigate whether a 10-day trip through the Pyrenees favorably 
affects anthropometric-, metabolic- and inflammatory-parameters in apparently healthy 
subjects and two patients with the fibromyalgia syndrome. The trip mimicked to some extent 
the ‘conditions of existence’ of ancient and contemporary hunting-gathering populations. We 
found that the intervention was well tolerated and that all participants, except for one dropout, 
experienced a better subjective feeling of health following its completion. Also the two 
patients with fibromyalgia experienced improvements: they were able to meet the needed 
physical activity after 7 days. The pain vanished and favorable effects seemed to remain 
during a subsequent follow up of three years. The trip caused decreases in body weight and 
BMI (median change 4.8%), hip circumference (3%), waist circumference (5.6%) and waist/hip 
ratio (2.5%)(Table 1; Figure 2). Among the clinical chemical indices we found decreases of 
glucose (12.5%), insulin (55%), HOMA-IR (58.1%), HbA1c (1.8%), triglycerides (20%), total-
cholesterol (13.7%), LDL-cholesterol (21.9%) and triglycerides/HDL-cholesterol ratio (19.3%). On 
the other hand, the medians of ASAT and ALAT increased with 48.0% and 35.7%, respectively, 
while CRP increased with 110.1%. 
 
Favorable effects 
Altogether we found that 3 features of the metabolic syndrome improved, i.e. body mass, 
glucose homeostasis and circulating lipids. The fourth, i.e. blood pressure, was not recorded. 
The metabolic syndrome, also named the insulin resistance syndrome, is a well-established 
risk factor for various diseases of affluence, including type 2 diabetes, cardiovascular disease, 
essential hypertension, polycystic ovary syndrome, non-alcoholic fatty liver disease, certain 
types of cancer (colon, breast, pancreas), sleep apnea and pregnancy complications, such as 
preeclampsia and gestational diabetes (32). Although we did not aim at hard endpoints, our 
results suggest that the 10-day intervention could be of value to both primary and secondary 
prevention of the ‘typically Western diseases of affluence’. 
 
Potential mechanisms 
Our intervention is based on causing ‘mild acute stress’ in humans who in their usual daily 
lives are exposed to the chronic stress commensurate with our modern lifestyle. Acute stress 
promotes release of stress hormones, including adrenaline, noradrenaline and cortisol, that 
each cause profound metabolic and immunologic adaptations (33). For instance, a recent 
study by the group of Pickkers (34), showed that extreme cold exposure, combined with 
breathing exercise (producing intermittent hypoxia), profoundly increases adrenaline 
secretion. This study and others (35, 33) show that acute stress factors increase autonomic 
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activity, accelerate immune cell proliferation and differentiation, and also stimulate the anti-
inflammatory component of the immune system (i.e. production of IL10, lactoferrin, 
lysozymes) (26). Nevertheless, mild stress initially produces a pro-inflammatory response, 
which may subsequently give rise to recovery from the reigning state of chronic low grade 
inflammation and the return to homeostasis (36, 37).  
In line with the above, we found that the observed changes in HOMA-IR and lipids were 
independent of weight loss, suggesting that a combination of lifestyle factors might be at 
stake. Major, highly interacting, lifestyle factors contributing to typically Western diseases are 
poor diet, insufficient physical activity, chronic stress, insufficient sleep, abnormal microbial 
flora and environmental pollution (smoking included) (38, 11). However, other mismatches 
with our ancient lifestyle are less appreciated. For instance, the participants suffered from 
thirst. Thirst relates to oxytocin production and the inhibition of stress axis activity (39, 40). 
The participants were also disconnected from daily trouble and ‘self-made’ stress, which 
reduced the number of anthropogenic stress factors and possibly other inflammatory ‘danger 
signals’ (16). Another factor might be the prohibited use of mobile telephones and other 
electronic devices. Although controversial, chronic mobile telephone usage may activate 
stress systems as evidenced by a recent study of Hamzany et al. (41). Chronic use of mobile 
telephones also negatively affects the production of anti-inflammatory substances in saliva 
(42). Absence of artificial light might be another factor. The trip forced the participants to 
adopt a ’natural day-night rhythm’ in which the sleep-wake cycle was not dominated by social 
life, but rather by sunlight (43, 44, 45).  
 
Spontaneous physical activity prior to food and water intake might be another beneficial 
factor. The postprandial inflammatory response has been identified as an independent risk 
factor for cardiovascular, metabolic and other non-communicable disorders (26, 46, 47, 48). 
Pre-prandial exercise did not only blunt the pro-inflammatory response after food intake, but 
also produced a shift towards the production of anti-inflammatory mediators by the immune 
system and adipose tissue, conferring protection against possible pathogens present in food 
(49, 50). Another important difference between Western life and the 10-day trip in the 
Pyrenees might be the presence of ‘cutaneous- and other body surface- directed danger 
signals’. All participants suffered from little wounds on hands, arm and legs because of small 
injuries inflicted by sharp thorns and other natural obstacles. In addition, several participants 
suffered from mild gastrointestinal disorders and diarrhea. Fiuza-Luces et al. (51) attributed 
positive health effects to so-called hormetic triggers, including small external wounds and 
light muscle damage. Although speculative, the immune system might have migrated to sites 
that have been most susceptible to the damaging effects of the environment during evolution, 
including those affecting the skin, the gastrointestinal tract and the lungs, jointly being the 





Taken together, we propose that we are dealing with complex interacting lifestyle factors (5, 
11) and that the current tendency to perform interventions aiming at single components, 
whether or not designed as RCTs, might suffer from a reductionist approach.  
 
Possible adverse effects 
We found increases of ASAT, ALAT and CRP, which at first glance might be regarded as 
genuine adverse effects. Increases of ASAT and the ASAT/ALAT  ratio are related to cardiac 
muscle damage (52), while those of ALAT (53) and CRP (54) are intimately related to liver 
damage and infection, respectively.  
 
Extreme sports, such as marathon and triathlon, are well known to elicit increases of lactate 
dehydrogenase, creatine kinase, ALAT, ASAT, ASAT/ALAT ratio, CRP and cardiac troponins 
(55, 56, 57, 58). The responses may easily exceed the upper limit of the reference range into the 
myocardial infarction area. The increases of cardiac troponins were similar when exercise was 
performed under controlled normoxic or hypoxic conditions, but proved dependent on 
exercise duration and intensity, possibly aggravated by hypoxic conditions (56). Noakes et al. 
(59) also observed that novice runners had much higher responses than experienced runners 
and these results where confirmed in a later study (60). We found that the augmentation of 
ASAT increased with age, as previously reported by Jastrzebski et al. (57). Increases of cardiac 
markers under these conditions have not been firmly associated with irreversible cardiac 
muscle damage and are at present considered benign, at least in well-trained subjects. On the 
other hand, there are currently no data from long-term follow-ups (61).  
 
The increases of both ALAT and CRP might also point at moderate liver damage and 
inflammation due to environmental exposure, the latter causing mild gastrointestinal 
infections from drinking water from waterholes, and small injuries on legs and arms inflicted 
by thorns and falls. Although the aforementioned plausible adverse effects will definitely 
require more attention in future interventions, they are not unexpected in the light of hunter-
gatherer populations. For instance, the Pygmies exhibit huge gamma-globulin bands in the 
classical electrophoretic profiling of serum proteins, pointing at exposure to a host of different 
microorganisms and parasites (62). Therefore, apart from the effects of intensive physical 
activity, the current findings remind us of the super-hygienic conditions of our current 
lifestyle. Hygiene is a major factor in longevity, but may, as a trade-off, also be at the basis of 
e.g. autoimmune disease; the so-called ´hygiene hypothesis´ (63, 64, 65). For instance, a 
recent study in pregnant and newborn mice revealed that helminth colonization exerts 
beneficial effects on the infectious response of the offspring brain and also on microglial 
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sensitization and cognitive dysfunction at adult life (66).   
 
Comparison with previous studies 
Our study is not the first to suggest that mimicking the lifestyles of traditional hunter-gatherer 
populations may be beneficial to our health. Already in 1984, O’Dea et al. showed that 
overweight Australian Aborigines with type 2 diabetes who reverted to their original lifestyle 
for 7 weeks, were able to improve, or even normalize, the characteristic abnormalities of 
diabetes, including improvements of body weight and fasting glucose, insulin and 
triglycerides. The favorable changes were attributed to weight loss, low-fat diet and increased 
physical activity (67). Another example of the protective effects of our ‘ancient conditions of 
existence’ against modern lifestyle and ‘Western diseases of affluence’, may be compiled from 
the studies of the Kitava people in Papua New Guinea  (68, 69). Lindeberg et al. showed that 
these people, living a traditional lifestyle (e.g. consuming wild foods with profound physical 
activity) showed low rates of cardiovascular disease, obesity and other modern diseases, 




Our study has many limitations. There was no control group and we also did not employ a 
cross-over or RCT-like design. The investigated group was relatively small and we only 
measured a small number of ‘soft’ parameters. Hard endpoints can obviously not be expected 
in short-term interventions in small groups with good general health. The findings of the two 
patients with fibromyalgia and the single subject with arrhythmia should be regarded as 
‘anecdotal’. However, whether a placebo effect or not, the subjective feeling of better health is 
certainly important and so are the observed changes in anthropometric and clinical chemical 
parameters. Our primary objective was to provide a proof of principle. More studies with more 
participants are certainly needed, including the recording of more parameters to objectivize 
e.g. the feeling of improved health. Also the minimum duration and intensity needed to 
demonstrate favorable effects are uncertain as yet.   
 
Conclusions 
The outcome of this 10-day ‘Study of Origin’ suggests that a short period of return to the 
‘conditions of existence’ similar to those on which our genome is based may improve 
anthropometrics and metabolism by favorably challenging the immune system in apparently 
healthy subjects and possibly patients with fibromyalgia. The ‘return’ may come with some 
costs in more active infection, as a trade-off for the ‘chronic systemic low grade inflammation’ 
typical of our current lifestyle of affluence. We may increasingly appreciate that we cannot 
have it all, while the evolutionary lessons of Darwin and intervention studies (71) teach us that 
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Figure 1. Median and individual changes of ASAT (panel A), ALAT (panel B) and CRP (panel C) 





Figure 2. Medians of the percentage changes of anthropometric and clinical chemical 
parameters during the 10 days trip through the Pyrenees.  





Table 1. Anthropometrics and clinical chemical indices at baseline and at the study end 
Data are medians (range). Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; BMI, body mass 
index; CRP, C-reactive protein; FT3, free triiodothyronine; FT4, free thyroxine; HbA1c, hemoglobin A1c; HDL, high-density-
lipoprotein; HOMA-IR, homeostasis model assessment-estimated insulin resistance; LDL, low-density lipoprotein; N.M. Not 
measured; TG, triglycerides; TSH, thyroid-stimulating hormone. *, Significant difference between the values before and after 




Food consumed Hadza en% kcal 
Meat 25 625 
Tubers 17 425 
Wild Berries 25 625 
Fruits   
Eggs   
Fish   




Baobab 11 275 
   
Honey 22 550 
   
   
   
Total 100 2500 
   
 
Supplemental Table 1.  Average food intake of Hadzabe hunter-gatherers   
Data derive from Pontzer 2012, Murray 2001, IDF 2012, www.philosophy.dept.shef.ac.uk/culture&mind/people/crittendena/ 
1. Murray, S. S., Schoeninger, M. J., Bunn, H. T., Pickering, T. R. & Marlett, J. A. Nutritional Composition of Some 
Wild Plant Foods and Honey Used by Hadza Foragers of Tanzania. Journal of Food Composition and Analysis 
14, 3-13 (2001). 
2. Pontzer, H., Raichlen, D. A., Wood, B. M., Mabulla, A. Z., et al. Hunter-gatherer energetics and human obesity. 




Nutrient Average amount kcal /unit total kcal kcal/part/10 days 
     
Banana 80 105 8400 840 
Apple 70 20 1400 140 
Melon 10 kilo 300 3000 300 
Mangos 4,5 kilo 645 2900 290 
Pineapple 3 kilo 460 1380 138 
Watermelon 8 kilo 280 2260 226 
Dates 1,1 kilo 2760 3036 304 
Onions 12 kilo 400 4800 480 
Lettuce (6 types) 3 kilo 160 480 48 
Cucumber 3 kilo 112 336 33 
Garlic 2 kilo 132 264 26 
Olives 1,5 kilo 1660 2500 250 
Carrots 2,4 kilo 410 985 99 
Mushrooms 1,1 kilo 225 250 25 
Zucchini 1,5 kilo 160 240 24 
Asparagus 1 kilo 220 220 22 
Avocado 6 kilo 1650 10100 1010 
Pumpkin 2 kilo 200 400 40 
Leek 2 kilo 550 1100 110 
Sweet potato 1,5 kilo 720 1080 108 
Coconut 5 kilo 3180 15900 159 
Raisins 1 kilo 2860 2860 286 
Berries 3 kilo 480 1440 144 
   Subtotal 6532 
     
Mayonaise 1 kilo 6300 6300 630 
Olive oil 3 liters 8400 25200 2520 
Honey 2 kilo 7000 14000 140 
   Subtotal 3290 
     
Deer 11 kilo 1480 26280 2628 
Chicken 9 kilo 2140 19260 1920 
Rabbit 2 kilo 2764 5528 553 
Sweat water fish 8 kilo 1590 12720 1272 
Tuna in olive oil 5 kilo 4030 20150 2015 
Duck 6 kilo 2016 12096 1209 
Eggs 5,5 kilo 1400 7700 770 
Nuts 3,7 kilo 575 20275 2027 
   Subtotal 12394 
     
   Total/pp/trip 22216 
   Total/pp/day 2222 
Supplemental  Table 2. Average food intake of participants during the ten days trip through the 




Supplemental  Table 3. Spearman's correlation coefficients for the relations between the 
changes in anthropometric and clinical chemical indices during the study 
Changes refer to the difference between pre- and post-intervention data. Abbreviations: ALAT, alanine aminotransferase; 
ASAT, aspartate aminotransferase; CRP, C-reactive protein; FT3, free triiodothyronine; FT4, free thyroxine; HBA1c, 
hemoglobin A1c; HDL, high-density-lipoprotein; HDL-C, high-density-lipoprotein-cholesterol; LDL, low-density lipoprotein; 




Summary and Future perspectives 
This thesis describes the multiple ways by which the human immune system can react upon 
direct and indirect challenges, such as infection and wounds on the one hand, and chronic 
multi metabolic stress factors on the other. The immune system exhibits a type of selfish 
behaviour during both acute- and chronic activity states. Acute activation of the immune 
system is normally finalized in a short time through multiple mechanisms exerting immune 
inhibiting effects. Several of these mechanisms are intrinsic to the immune system itself, such 
as the negative biofeedback function of lactic acid produced by the anaerobic metabolism of 
an activated immune system (Hoque 2014, Fischer 2007). Systemic inhibitors include cortisol, 
testosterone and adrenalin and all these have protective short-lasting immune suppressive 
roles. An immune suppressive period serves four purposes. First of all it facilitates the recovery 
of energy sources and energy distribution to those organs and systems disposed-of during the 
inflammatory phase. Second, wound healing can only start when the inflammation has been 
finalized. The third purpose is to prevent the development of lymphocytes with sensitivity 
against auto-antigens, which could cause autoimmune disease. Finally, since the opposite 
also occurs, increased self-tolerance through long-term contact between activated 
lymphocytes and auto-antigens, the immune suppressive state also decreases the chance of 
developing cancer. Short-term immune suppression prevents self-tolerance against cancer 
cells, which implies that when tumour cells develop they will be recognized as non-self. 
 
A state of chronic activity of the immune system can only be achieved when this state 
becomes supported by reactivation and gluconeogenic strategies, of which the development 
of insulin resistance with compensatory hyperinsulinemia is an example. Chronic activity of 
the immune system is caused by the total number of so-called anthropogenes, which include 
proximal lifestyle factors, such as overeating, sitting time, and insufficient sleep, but also 
economy, environmental toxins and politics, the latter as examples of distal factors. The sum 
of risk factors produces chronic activation of stress axes and endotoxaemia, causing a chronic 
infectious state that is referred to as chronic low-grade inflammation. This low-grade 
inflammation should be considered as the cause of most, if not all, chronic non-




Chapter 1. Chronic systemic low-grade inflammation 
Paragraph 1.1 
The brain and the immune system are the only two systems of the human body capable of 
dominating all other organs and systems with respect to the use of resources, including 
glucose. The brain dominates during daytime hours and stressful situations, whereas the 
immune system protects us during the night, infectious periods and wound healing. Both 
systems exhibit similar capacities to pull on energy and other essential resources, using 
strategies favouring their own functional and anatomical benefits. Human evolution has put 
the brain on top of the body’s systems, resulting in a shift from strong to smart. However, the 
immune system is very old and robust. If necessary, it is activated through a variety of non-
specific factors and most often when problems are not solved in an appropriate time frame. If 
chronically activated the immune system demonstrates an even more selfish behaviour than 
the selfish brain, inducing chronic low-grade inflammation and multiple related diseases. But 
before castigating the immune system for this behaviour it is crucial to recognize that it is 
only doing what it is made for: trying to protect us. 
 
Paragraph 1.2 
In this paragraph, we focus on lifestyle changes, especially dietary habits, that are at the basis 
of chronic systemic low-grade inflammation, insulin resistance and ‘typically Western’ 
diseases. Our sensitivity to develop insulin resistance traces back to our rapid brain growth in 
the past 2.5 million years. An inflammatory reaction jeopardizes the high glucose needs of our 
brain, causing various adaptations, including insulin resistance, functional reallocation of 
energy-rich nutrients and by changing the serum lipoprotein composition. The latter aims at 
redistribution of lipids, modulation of the immune reaction, and active inhibition of reverse 
cholesterol transport for damage repair. With the advent of the agricultural and industrial 
revolutions, we have introduced numerous false inflammatory triggers in our lifestyle, driving 
us to a state of chronic systemic low grade inflammation that eventually leads to ‘typically 
Western’ diseases via an evolutionary-conserved interaction between our immune system 
and metabolism. The underlying triggers are an abnormal dietary composition and microbial 
flora, insufficient physical activity and sleep, chronic stress and environmental pollution. The 
disturbance of our inflammatory/anti-inflammatory balance is illustrated by dietary fatty acids 
and antioxidants. The current decrease in years without chronic disease is rather due to 
‘nurture’ than ‘nature’, since less than 5% of the ‘typically Western’ diseases are primary 
attributable to genetic factors. Resolution of the conflict between environment and our 
ancient genome might be the only effective manner for ‘healthy aging’, and to achieve this we 





Paragraph 1.3  
In 1996, Serhan and colleagues introduced the term ‘Resoleomics’ as the mechanistic process 
of inflammation resolution. Their major discovery is that the onset to the conclusion of an 
inflammatory reaction is a highly controlled process orchestrated by the immune system  
itself, and not simply the consequence of an ‘extinguished’ or ‘exhausted’ immune reaction. 
Resoleomics can be considered as the evolutionary conserved mechanism of restoring 
homeostatic balances after injury, inflammation and infection. Under normal circumstances, 
Resoleomics should be able to conclude inflammatory responses. However, considering the 
modern pandemic increase of chronic somatic and psychiatric illnesses involving chronic 
inflammation, it has become apparent that Resoleomics is currently not fulfilling its 
potentially resolving capacity. We suggest that recent drastic changes in lifestyle, including 
diet and psycho-emotional stress, are responsible for inflammation and for disturbances in 
Resoleomics. In addition, current treatments, chronic use of anti-inflammatory medication 
included, suppress Resoleomics. These, from an evolutionary point of view, new lifestyle 
factors should be considered health hazards, as they are capable of causing long-term or 
chronic activation of the central stress axes. The immune system is designed to provide 
solutions for fast, intensive, hazards and not to cope with long-term, chronic, stimulation. The 
never-ending stress factors of recent lifestyle changes have pushed the immune system and 
the central stress system into a constant state of activity, leading to chronically unresolved 
inflammation and increased vulnerability for chronic disease. Our hypothesis is that modern 
diet, increased psycho-emotional stress and chronic use of anti-inflammatory medication 
disrupt the natural process of inflammation resolution, i.e. Resoleomics. 
 
Paragraph 1.4 
Nowadays, CNCDs are the leading causes of work absence, disability and mortality worldwide. 
Most of these diseases are associated with low-grade inflammation. Here we hypothesize that 
stresses (defined as homeostatic disturbances) can induce low-grade inflammation, which 
augments the need of water, sodium and energy-rich substances to meet the increased 
metabolic demand induced by the stressor. One way of triggering low-grade inflammation is 
by augmented intestinal barrier permeability through activation of various components of the 
stress system. Although beneficial to meet the demands necessary during stress, increased 
intestinal barrier permeability also raises the chance of translocation of bacteria and their 
toxins, i.e. their passage from the intestinal lumen into the blood circulation. In combination 
with modern life-style factors, increased bacteria/bacterial toxin translocation, arising from a 
more permeable intestinal wall, causes a low-grade inflammatory state. We support this 
hypothesis with numerous studies, showing associations with CNCDs and markers of 
endotoxaemia, and thereby suggest that this mechanism plays a pivotal, and perhaps even 




Wheat is one of the mostly consumed cereal grains worldwide and makes up a substantial part 
of the human diet. Although government-supported dietary guidelines in Europe and USA 
advise individuals to eat ample amounts of (whole) grain products per day, cereal grains 
contain ‘anti-nutrients’, such as wheat gluten and wheat lectin, that in humans can elicit 
dysfunction and disease. In this review we discuss evidence from in vitro, in vivo and human 
intervention studies that describe how the consumption of wheat, but also other cereal grains, 
may contribute to the manifestation of chronic inflammation and auto-immune diseases by 
increasing intestinal permeability and initiating a pro-inflammatory immune response.     
 
Paragraph 1.6 
Various recent, positively selected, adaptations to new nutrients have been identified. Lactase 
persistence is among the best known, enabling exposed populations to drink milk, notably to 
digest lactose, at post-weaning age. An augmented number of amylase gene (AMY1) copies, 
giving rise to higher salivary amylase activity, has been implicated in the consumption of 
starch-rich foods. Higher AMY1 copy numbers has been demonstrated in populations with 
recent histories of starchy diets. It is, however, questionable whether the resulting 
polymorphisms have merely exerted positive selection pressure by providing easily-available 
sources of macro- and micronutrients. Humans have explored new environments more than 
any other animal. Novel environments challenge the host, but especially its immune system 
with new climatic conditions, foods and especially pathogens. With the advent of the 
agricultural revolution and the concurrent domestication of cattle came new pathogens and 
diseases (zoonoses). We contend that specific new food ingredients (e.g. gluten) and novel 
pathogens drove selection for lactase persistence and higher AMY gene copy numbers. Both 
adaptations provide ample glucose for activating the sodium glucose-dependent co-
transporter 1 (SGLT1), which is the principal transporter of glucose, together with sodium and 
water, in the small intestine and to a lesser extent the stomach (Chen 2010). Following starch 
ingestion, people with higher AMY1 copy numbers have more rapid increases of insulin and 
concomitantly lower plasma glucose, compared with counterparts with lower AMY1 copies 
(Mandel 2012). Rapid uptake of glucose, sodium and water confers protection against 
potentially lethal dehydration, hyponatraemia and ultimately multiple organ failure, especially 
during infection accompanied by diarrhoea and vomiting. Also oral rehydration therapy aims 
at SGLT1 activity and is the current treatment of choice for these conditions. We hypothesize 
that lifelong lactase activity and rapid starch digestion should be looked at as the evolutionary 





Chapter 2. Physical inactivity 
Paragraph 2.1 
In recent years, it has become clear that chronic systemic low-grade inflammation is at the 
root of many, if not all, ‘typically Western’ diseases associated with the metabolic syndrome. 
While much focus has been given to sedentary lifestyle as a cause of chronic inflammation, it 
is less often appreciated that chronic inflammation may also promote a sedentary lifestyle, 
which in turn causes chronic inflammation. Given that even minor increases in chronic 
inflammation reduce brain volume in otherwise healthy individuals, the bidirectional 
relationship between inflammation and sedentary behaviour may explain why humans have 
lost brain volume in the last 30,000 years and also intelligence in the last 30 years. We review 
evidence that lack of physical activity induces chronic low-grade inflammation and, 
consequently, an energy conflict between the selfish immune system and the selfish brain. 
Although the notion is widespread that increased physical activity would improve health in 
the modern world, we here provide a novel perspective on this truism by providing evidence 
that recovery of normal human behaviour, such as spontaneous physical activity, would calm 
pro-inflammatory immune activity, thereby allocating more energy to the brain and other 
organs, and by doing so would improve human health. 
 
Paragraph 2.2 
The evolution of humankind has taken millions of years, during which environmental  
factors gradually shaped its genome with the aim to adapt to the reigning  circumstances 
(Darwin). One of the most vital behavioural adaptations of mammals in general, and humans 
in particular, is their capacity to be self-sufficient through physical activity.  Physical activity 
abilities, including long distance running, jumping, climbing and carrying things have 
probably been necessary to outrun wild animals, to search for food and to hide from danger. 
In contrast, individuals physically or psychologically unable to ‘take care of themselves’, were 
more susceptible to early death and therefore genetic extinction.  
 
The current society is characterized by sedentary, instead of ‘moving’, individuals. Physical 
inactivity is not just a possible factor related with chronic disease, but should be considered 
the actual cause of the majority of human illness. The majority of people know that exercise is 
necessary and beneficial. Nevertheless, almost 75% of the current population doesn’t reach the 
estimated minimum of the necessary activity. Physical inactivity belongs to the 
characteristics of sickness behaviour; which is probably protective for the organism. Sickness 
behaviour, including depressive mood, seems to protect against infection, injury, social 
conflict and facilitates energy conservation. Sickness behaviour is based on immune-brain 
mechanisms and can be defined as non-permissive behaviour. Long-term non-permissive 
behaviour can lead to chronic disease because of reduced physical activity and self-defeating 
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coping styles, converting non-permissive behaviour into a non-permissive brain disorder. We 
propose that physical inactivity disease is synonymous with a non-permissive brain disorder 
and that this disorder produces a so called ‘reptile phenotype’, characterized by hypothermia, 





Chapter 3. Lifestyle intervention 
Paragraph 3.1 
Chronic low-grade inflammation and insulin resistance are intimately related entities that are 
common to most, if not all, chronic diseases of affluence. We hypothesized that a short-term 
intervention based on ‘ancient stress factors’ may improve anthropometrics and clinical 
chemical indices. In this paragraph we investigated  whether a 10-days-mimic of a hunter-
gatherer lifestyle favourably affects anthropometrics and clinical chemical indices. Fifty-three 
apparently healthy subjects and two patients with fibromyalgia (22–69 years, 28 women), in 5 
groups, engaged in a 10-day trip through the Pyrenees. They walked 14 km/day on average, 
carrying an 8-kilo backpack. Raw food was provided and self-prepared. while water was 
obtained from waterholes. They slept outside in sleeping bags and were exposed to 
temperatures ranging from 12-42 °C. Anthropometric data and fasting blood samples were 
collected at baseline and the study end. We observed median decreases (p≤0.002) of body 
weight (-3.5 kg), BMI (-1.1 kg/m2), hip (-3 cm) and waist (-5 cm) circumferences, glucose (-0.6 
mmol/L), HbA1c (-0.1%), insulin (-4.7 pmol/L), HOMA-IR (-1.2 mmol*mU/L2), triglycerides (-
0.14 mmol/L), total cholesterol (-0.7 mmol/L), LDL-cholesterol (-0.6 mmol/L), 
triglycerides/HDL-cholesterol ratio (-0.55 mol/mol) and FT3 (-0.8 pmol/L). Changes in 
anthropometrics were unrelated to changes in clinical chemical indices, except for FT4 and 
FT3. ASAT (11 IU/L), ALAT (6 IU/L), ASAT/ALAT ratio (0.14) and CRP (0.56 mg/L) increased, and 
their changes were interrelated. We conclude that coping with ‘ancient mild stress factors’, 
including physical exercise, thirst, hunger and climate, may influence immune status and 






Many CNCDs are considered ‘incurable’ because of a reigning ‘one cause’ dogma. This way of 
thinking was inspired by Louis Pasteur (1822–1895), who showed that an infectious disease 
originates from a single causal factor. This factor can be demonstrated and eliminated by 
specific treatments. However, the ‘germ theory of disease’ merely states that some diseases are 
caused by infectious agents. It is our believe that CNCDs will not become cured if we keep 
insisting on mono-etiological backgrounds. We suggest that CNCDs are caused by multi-
metabolic anthropogenic risk factors, which not only include individual lifestyle factors such 
as smoking, lack of exercise and high calorie diets, but also more distant political, economic, 
social, cultural and even evolutionary risk factors. Our view is largely in line with the papers of 
Egger et al. (Egger 2012, Egger 2014a, Egger 2014b). With the exception of diseases with 
primary causes in genetics (‘inborn errors’) it seems theoretically possible that each of us is 
able to enjoy ‘healthy aging’ and to ultimately die from old age.  However, the future does not 
seem favourable: the number of anthropogenic factors is likely to increase. Several of these 
adverse factors seem inevitable and most of us have little ability to influence them in an 
effective manner. We nevertheless believe that prevention remains the most effective manner 
to ‘solve’ CNCDs. These preventive measures may aim at resilience against the toxic triggers 
of modern life. The best choice would be regular exposure to hormetic triggers, as shown in 
our pilot intervention named the ‘Study of origin’ (Chapter 3). It is not difficult, and may even 
be enjoyable, to include some of these intermittent hormetic triggers in daily life. There is 
increasing support for the health effects of ‘intermittent living’, including intermittent fasting 
(Barnosky 2014), intermittent hypoxia (Duennwald 2013), intermittent sitting (Henson 2015) 
and intermittent heat (Laukkanen 2015).  We suggest that future studies may aim at such 
interventions, and that funds will be made available for these aims. There is, however, one 
hesitation: the outcomes of these interventions may at most demonstrate that Darwin was 
right when he coined his view that ‘organisms adapt to the conditions of existence’. Thus 
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Samenvatting en toekomstperspectieven 
In dit proefschrift worden de verschillende wegen beschreven waarlangs het menselijk 
immuunsysteem kan reageren op directe en indirecte uitlokkers, zoals infectie en verwonding 
enerzijds en chronische metabole stressfactoren anderzijds. Het immuunsysteem vertoont 
een soort zelfzuchtig gedrag, zowel gedurende acute, als chronische activiteit. Een acuut 
geactiveerd immuunsysteem wordt normaal gesproken binnen korte tijd weer uitgezet via 
diverse mechanismen met immuunremmende effecten. Verschillende van deze 
mechanismen zijn intrinsiek aan het immuunsysteem zelf, zoals de negatieve 
feedbackfunctie van melkzuur dat geproduceerd wordt door de anaerobe stofwisseling van 
een geactiveerd immuunsysteem (Hoque 2014, Fischer 2007). Systemische remmers zijn 
onder meer cortisol, testosteron en adrenaline; deze hebben allemaal een beschermende, 
kortdurende, immuunonderdrukkende rol.  
 
Een periode van immuunonderdrukking heeft vier doelen. Ten eerste faciliteert het de 
wedertoevoer van energiebronnen en het herstel van de energiedistributie naar de organen 
en systemen die tijdens de ontstekingsreactie ‘verwaarloosd’ zijn. Ten tweede kan wondheling 
slechts dan van start gaan, wanneer de ontstekingsfase is afgerond. Het derde doel is het 
voorkómen van de ontwikkeling van lymfocyten die gevoelig zijn voor auto-antigenen, 
waardoor auto-immuunziekten zouden kunnen ontstaan. Tot slot, aangezien het 
tegenovergestelde ook voorkomt – i.e. verhoogde zelftolerantie door langdurig contact tussen 
geactiveerde lymfocyten en auto-antigenen – verlaagt de toestand van 
immuunonderdrukking ook de kans op het ontwikkelen van kanker. Kortdurende 
immuunonderdrukking voorkòmt zelftolerantie tegen kankercellen, hetgeen impliceert dat, 
wanneer tumorcellen zich ontwikkelen, ze worden herkend als niet eigen. 
 
Een toestand van chronische immuunactiviteit kan alleen worden bereikt indien deze 
toestand ondersteuning krijgt middels reactivatie- en gluconeogenesestrategieën. De 
ontwikkeling van insulineresistentie met compenserende hyperinsulinemie is daarvan een 
voorbeeld. Chronische activatie van het immuunsysteem wordt veroorzaakt door het totaal 
van zogenaamde antropogene factoren, waaronder proximale leefstijlfactoren, zoals overeten, 
langdurig zitten en onvoldoende slaap, maar ook economie, toxinen in het milieu en politiek. 
Deze laatste zijn voorbeelden van distale factoren. De som van de risicofactoren leidt tot 
chronische activatie van de stressassen en endotoxemie, waardoor een chronische toestand 
van infectie ontstaat waarnaar verwezen wordt als chronische laaggradige ontsteking. Deze 
chronische laaggradige ontsteking zou gezien moeten worden als de oorzaak van de meeste, 
zo niet alle, chronische niet-overdraagbare aandoeningen (CNCD’s – chronic non-




Hoofdstuk 1. Chronische systemische lage graad ontsteking 
Paragraaf 1.1 
De hersenen en het immuunsysteem zijn de enige twee systemen van het menselijk lichaam 
die in staat zijn alle andere organen en systemen te domineren op het gebied van 
bronnengebruik, waaronder glucose. De hersenen domineren overdag en in stressvolle 
situaties, terwijl het immuunsysteem ons vooral beschermt tijdens de nacht, bij infecties en bij 
het wondhelingsproces. Beide systemen vertonen een vergelijkbare capaciteit  om energie en 
andere essentiële bronnen aan te trekken, waarbij ze strategieën gebruiken ten voordele van 
hun eigen anatomie en functie. De menselijke evolutie heeft de hersenen in de koppositie 
geplaatst ten opzichte van de andere lichaamssystemen, waardoor er een verschuiving heeft 
plaatsgevonden van sterk naar slim. Het immuunsysteem is echter zeer oud en robuust. 
Indien nodig, wordt het geactiveerd door een keur aan aspecifieke risico factoren, zoals 
psychoemotionele stress en meestal wanneer risico factoren die het immuunsysteem 
activeren  niet binnen een passend tijdsbestek zijn opgelost. Indien chronisch geactiveerd, 
laat het immuunsysteem zelfs nog zelfzuchtiger gedrag zien dan het zelfzuchtige brein, 
waarbij het chronische laaggradige ontsteking en verschillende daaraan gerelateerde ziekten 
veroorzaakt. Maar voordat we het immuunsysteem alle schuld in de schoenen schuiven, is het 
van het grootste belang om te erkennen dat het alleen maar doet waar het voor gemaakt is: 
proberen ons te beschermen. 
 
Paragraaf 1.2 
In deze paragraaf richten we ons op veranderingen in de leefstijl, met name eetgewoonten, 
die aan de basis staan van chronische laaggradige ontsteking, insulineresistentie en ‘typisch 
westerse’ ziekten. Onze gevoeligheid voor de ontwikkeling van insulineresistentie is terug te 
voeren op de snelle hersengroei die in de afgelopen 2,5 miljoen jaar bij onze soort heeft 
plaatsgevonden. Een ontstekingsreactie brengt de grote glucosevraag van onze hersenen in 
gevaar, waardoor verschillende aanpassingen ontstaan, waaronder insulineresistentie, 
functionele herverdeling van energierijke nutriënten en een veranderde samenstelling van 
het serumlipoproteïne. Dit laatste heeft als doel het herverdelen van vetten, modulatie van de 
immuunreactie en actieve remming van omgekeerd cholesteroltransport om schade te 
herstellen.  
 
Met de komst van de landbouw- en industriële revolutie, hebben we verschillende valse 
ontstekingsuitlokkers in onze leefstijl geïntroduceerd, waardoor we in de richting worden 
geduwd van een toestand van chronische laaggradige ontsteking die uiteindelijk leidt tot 
‘typisch westerse’ ziekten via een evolutionair geconserveerde interactie tussen ons 
immuunsysteem en onze stofwisseling. De onderliggende uitlokkers zijn een abnormale 
voedingssamenstelling en microbiële flora, onvoldoende lichaamsbeweging en slaap, 
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chronische stress en milieuvervuiling. De verstoring van de ontstekings-/anti-
ontstekingsbalans wordt geïllustreerd door voedingsvetzuren en antioxidanten. De huidige 
afname in jaren dat men vrij is van chronische ziekte, wordt eerder veroorzaakt door ‘nurture’ 
dan ‘nature’, aangezien minder dan 5% van de ‘typisch westerse’ ziektebeelden primair zijn toe 
te wijzen aan genetische factoren. De oplossing van het conflict tussen de huidige omgeving 
en ons oude genoom zou wel eens de enige effectieve manier kunnen zijn om gezond oud te 
worden. Om dit te bereiken, zouden we wellicht terug moeten naar de leefstijl van het 
paleolithicum, vertaald naar de cultuur van de 21e eeuw. 
 
Paragraaf 1.3  
In 1996 introduceerden Serhan en zijn collega’s de term ‘resoleomics’ als benaming voor het 
mechanistische proces waarlangs ontstekingen opgelost worden. Hun grootste ontdekking is 
dat de beëindiging van een ontstekingsreactie een hoogst gecontroleerd proces is dat door 
het immuunsysteem zelf geleid wordt, en dus niet simpelweg het gevolg is van een 
‘uitgedoofde’ of ‘uitgeputte’ immuunreactie. Resoleomics kan worden gezien als het 
evolutionair bewaard gebleven mechanisme waarmee homeostatische balansen worden 
hersteld na verwonding, ontsteking en infectie. Onder normale omstandigheden zou 
resoleomics in staat moeten zijn om ontstekingsreacties te beëindigen. Echter, met de 
pandemische toename van chronische somatische en psychiatrische ziekten waarbij 
chronische ontsteking een rol speelt, is het duidelijk geworden dat resoleomics zijn oplossend 
potentieel momenteel niet vervult. We stellen daarom dat recente drastische veranderingen in 
leefstijl, waaronder in de voeding en psycho-emotionele stress, verantwoordelijk zijn voor 
ontstekingen en verstoringen van resoleomics. Daarbij wordt resoleomics door de huidige 
behandelingswijzen onderdrukt, waaronder door chronisch gebruik van ontstekingsremmers. 
Deze, vanuit een evolutionair oogpunt bezien, nieuwe leefstijlfactoren zouden gezien moeten 
worden als bedreigingen voor de gezondheid, aangezien ze in staat zijn om de stressassen 
langdurig of chronisch te activeren. Het immuunsysteem is ontworpen om oplossingen aan 
te dragen bij snel optredend en intensief gevaar en niet om opgewassen te zijn tegen 
langdurige, chronische stimulatie. De stressfactoren die inherent zijn aan onze recente leefstijl 
hebben het immuunsysteem en de centrale stresssystemen in een toestand van voortdurende 
activiteit gebracht, waardoor chronisch onopgeloste ontstekingen ontstaan, alsmede een 
verhoogde bevattelijkheid voor chronische ziekte. Het is onze hypothese dat de moderne 
voeding, verhoogde psycho-emotionele stress en chronisch gebruik van ontstekingsremmers 
het natuurlijke proces van ontstekingsremming, ofwel resoleomics, verstoren. 
 
Paragraaf 1.4 
Tegenwoordig zijn CNCD’s wereldwijd de voornaamste oorzaak van werkverzuim, invaliditeit 
en sterfte. De meeste van deze ziekten worden in verband gebracht met laaggradige 
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ontsteking. Hier presenteren we de hypothese dat stress (gedefinieerd als homeostatische 
verstoringen) laaggradige ontsteking kan induceren, waardoor de behoefte aan water, 
natrium en energierijke stoffen toeneemt, zodat voldaan kan worden aan de verhoogde 
metabole vraag die veroorzaakt wordt door de stressor. Eén manier om een laaggradige 
ontsteking uit te lokken is door een verhoogde permeabiliteit van de darmwand langs 
activatie van verschillende componenten van het stresssysteem. Hoewel het een voordeel 
oplevert bij het voorzien in de vraag tijdens stress, verhoogt een toegenomen permeabiliteit 
van de darmwand ook de kans op translocatie van bacteriën en hun toxinen van het 
darmlumen naar de bloedsomloop. Samen met moderne leefstijlfactoren veroorzaakt een 
verhoogde translocatie van bacteriën en bacteriële toxinen, als gevolg van een meer 
permeabele darmwand, een toestand van laaggradige ontsteking. We ondersteunen deze 
hypothese met talloze studies, en tonen verschillende verbanden tussen CNCD’s en markers 
van endotoxemie, waarmee we suggereren dat dit mechanisme een cruciale – misschien zelfs 




Tarwe is één van de meest gegeten granen ter wereld en maakt een substantieel onderdeel uit 
van de menselijke voeding. Hoewel door de overheid gesteunde voedingsrichtlijnen in 
Europa en de VS adviseren om dagelijks voldoende (volkoren) graanproducten te eten, 
bevatten granen ‘antinutriënten’, zoals gluten en lectinen, die bij mensen tot disfunctie en 
ziekte kunnen leiden. In deze review behandelen we bewijs uit in vitro, in vivo en menselijke 
interventiestudies die beschrijven hoe de consumptie van tarwe, maar ook andere granen, 
kunnen bijdragen aan het manifesteren van chronische ontsteking en auto-immuunziekten 
door de permeabiliteit van de darm te verhogen en door een ontstekingsbevorderende 
immuunreactie te initiëren. 
 
Paragraaf 1.6 
Diverse recente, positief geselecteerde aanpassingen aan nieuwe nutriënten zijn 
geïdentificeerd. Lactasepersistentie is één van de bekendste, hetgeen populaties die eraan 
worden blootgesteld in staat stelt om melk te drinken, in het bijzonder om lactose te verteren 
na de zoogtijd. Een verhoogd aantal kopieën van amylasegenen (AMY1), welke zorgen voor 
een grotere activiteit van amylase in het speeksel, is in verband gebracht met de consumptie 
van zetmeelrijke voedingsmiddelen. Hogere aantallen AMY1 genen zijn aangetoond in 
populaties met een recente geschiedenis van zetmeelrijke voeding. Het is echter twijfelachtig 
of de resulterende polymorfismen positieve selectiedruk hebben uitgeoefend door louter de 




De mens heeft meer nieuwe omgevingen verkend dan welk ander dier dan ook. Nieuwe 
omgevingen bieden nieuwe uitdagingen aan de gastheer, maar confronteren in het bijzonder 
het immuunsysteem met nieuwe klimaatomstandigheden, voeding en in het bijzonder 
pathogenen. Met de komst van de landbouwrevolutie en de daarop volgende domesticatie van 
vee werden nieuwe pathogenen en ziekten geïntroduceerd (zoönosen). We beweren dat 
specifieke nieuwe voedingsingrediënten (bijvoorbeeld gluten) en nieuwe pathogenen de 
selectie hebben gestuurd richting lactasepersistentie en een groter aantal kopieën van het 
AMY-gen. Beide aanpassingen leveren ruim voldoende glucose voor het activeren van de 
natrium/glucose-afhankelijke cotransporters 1 (SGLT1), welke de voornaamste transporter is 
voor glucose, samen met natrium en water, in de dunne darm en in mindere mate de maag 
(Chen 2010). Na inname van zetmeel, hebben mensen met hogere aantallen AMY1-kopieën 
een snellere toename van insuline en daarmee gepaard gaande lagere plasmaglucose, 
vergeleken met personen met lagere aantallen AMY1-kopieën (Mandel 2012). Snelle opname 
van glucose, natrium en water levert bescherming tegen potentieel dodelijke uitdroging, 
hyponatremie en uiteindelijk meervoudig orgaanfalen, in het bijzonder tijdens infectie 
gecombineerd met diarree en braken. Ook orale rehydratietherapie is gericht op SGLT1-
activiteit en is momenteel de eerste keus behandeling bij deze aandoeningen. Het is onze 
hypothese dat levenslange lactase-activiteit en snelle zetmeelvertering gezien moeten worden 
als de evolutionaire voorloper van de huidige orale rehydratietherapie.  
 
Hoofdstuk 2. Fysieke inactiviteit 
Paragraaf 2.1 
De afgelopen jaren is het duidelijk geworden dat chronische systemische laaggradige 
ontsteking aan de basis staat van veel, zo niet alle ‘typisch westerse’ aandoeningen die 
samenvallen met het metabool syndroom. Hoewel er veel nadruk is gelegd op de zittende 
leefstijl als oorzaak van chronische ontsteking, wordt het minder vaak ingezien dat 
chronische ontsteking ook een zittende leefstijl kan bevorderen, wat op zijn beurt chronische 
ontsteking veroorzaakt. Gegeven dat zelfs kleine toenames in chronische ontsteking het 
hersenvolume verkleinen bij anderszins gezonde personen, kan de tweezijdige relatie tussen 
ontsteking en een zittende leefstijl wellicht verklaren waarom mensen hersenvolume hebben 
verloren in de afgelopen 30.000 jaar en ook intelligentie in de afgelopen 30 jaar. We geven een 
overzicht van het bewijs dat gebrek aan lichaamsbeweging chronische laaggradige ontsteking 
veroorzaakt en, ten gevolge daarvan, een energieconflict veroorzaakt tussen het zelfzuchtige 
immuunsysteem en het zelfzuchtige brein. Hoewel de notie in de hedendaagse wereld 
wijdverbreid is dat meer lichaamsbeweging goed is voor de gezondheid, geven we hier een 
nieuw perspectief op deze gemeenplaats door bewijs te leveren dat het herstel van normaal 
menselijk gedrag, zoals spontane lichaamsbeweging, de ontstekingsbevorderende 
immuunactiviteit zou kalmeren, waardoor er meer energie aan de hersenen en andere 
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organen wordt toebedeeld en op deze manier de menselijke gezondheid bevordert. 
 
Paragraaf 2.2 
De evolutie van de mens heeft miljoenen jaren in beslag genomen, gedurende welke periode 
omgevingsfactoren gaandeweg het genoom hebben gevormd met als doel zich aan te passen 
aan de heersende omstandigheden (Darwin). Eén van de meest vitale gedragsmatige 
aanpassingen van zoogdieren in het algemeen – en mensen in het bijzonder – is hun 
vermogen om in hun levensonderhoud te voorzien middels lichaamsbeweging. 
Lichaamsbeweging, zoals rennen, springen, klimmen en dragen, zijn waarschijnlijk nodig 
geweest om wilde dieren te snel af te zijn, om naar voedsel te zoeken en om voor gevaar te 
schuilen. Aan de andere kant waren individuen die lichamelijk of psychologisch niet in staat 
waren om voor zichzelf te zorgen, vatbaarder voor een vroegtijdige dood en daardoor 
genetisch uitsterven.  
 
De huidige maatschappij wordt gekenmerkt door locatiegebonden individuen, in plaats van 
individuen die ‘in beweging’ zijn. Een gebrek aan lichaamsbeweging is niet slechts een 
mogelijke factor die gerelateerd is aan chronische ziekte, maar moet gezien worden als de 
eigenlijke oorzaak van vrijwel de gehele menselijke ziektelast. Het overgrote deel van de 
mensen weet dat lichaamsbeweging nodig is en voordeel oplevert. Desalniettemin haalt 
nagenoeg 75 procent van de huidige populatie niet het geschatte minimale niveau van 
lichaamsbeweging. Lichamelijke inactiviteit behoort tot de kenmerken van ziektegedrag, 
hetgeen waarschijnlijk een beschermende functie heeft voor het organisme. Ziektegedrag, 
waaronder een depressieve stemming, lijkt te beschermen tegen infectie, letsel en sociaal 
conflict en bevordert het behoud van energie. Ziektegedrag is gebaseerd op immuun-
hersenmechanismen en kan worden gedefinieerd als niet-permissief gedrag. Langdurig niet-
permissief gedrag kan leiden tot chronische ziekte vanwege verminderde lichaamsbeweging 
en zichzelf hinderende copingstrategieën, waarmee niet-permissief gedrag wordt omgezet in 
een niet-permissieve hersenaandoening. We stellen voor dat de lichamelijke 
inactiviteitsziekte een synoniem is van een niet-permissieve hersenaandoening en dat deze 
aandoening leidt tot een zogenaamd ‘reptielenfenotype’, dat wordt gekenmerkt door 
hypothermie, slechte haargroei, afgenomen vruchtbaarheid en een laag basaalmetabolisme. 
 
Hoofdstuk 3. Leefstijl interventie 
Paragraaf 3.1  
Chronische laaggradige ontsteking en insulineresistentie zijn nauw aan elkaar verwante 
entiteiten die de meeste, zo niet alle, chronische welvaartsziekten met elkaar gemeen hebben. 
Het is onze hypothese dat een kortermijn interventie gebaseerd op ‘oude stressfactoren’ een 
verbetering kan geven op antropometrische resultaten en klinisch-chemische indices. In deze 
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paragraaf onderzochten we of een tiendaagse nabootsing van een jager-verzamelaarsleefstijl 
een gunstig effect heeft op antropometrische resultaten en klinisch-chemische indices. In 
totaal 53 op het oog gezonde deelnemers en twee patiënten met fibromyalgie (22–69 jaar, 28 
vrouwen), verdeeld in vijf groepen, deden mee aan een tiendaagse reis door de Pyreneeën. 
Gemiddeld wandelden ze 14 kilometer per dag, waarbij een 8 kilogram zware rugzak werd 
gedragen. Men werd voorzien van natuurlijke voedingsbronnen en bereidde dit zelf tot 
voeding, terwijl water werd verkregen uit waterputten. Ze sliepen buiten in slaapzakken en 
stonden bloot aan temperaturen tussen de 12°C en 42°C. Antropometrische gegevens en 
bloedmonsters tijdens vasten werden verzameld aan het begin en eind van het onderzoek. We 
zagen mediaandalingen (p≤0.002) in lichaamsgewicht (-3,5 kg), BMI (-1,1 kg/m2), heup- (-3 
cm) en middelomtrek (-5 cm), glucose (-0,6 mmol/L), HbA1c (-0,1%), insuline (-4,7 pmol/L), 
HOMA-IR (-1,2 mmol*mU/L2), triglyceriden (-0,14 mmol/L), totaalcholesterol (-0,7 mmol/L), 
LDL-cholesterol (-0,6 mmol/L), verhouding triglyceriden/HDL-cholesterol (-0,55 mol/mol) en 
FT3 (-0,8 pmol/L). Veranderingen in antropometrische resultaten hielden geen verband met 
veranderingen in klinisch-chemische indices, behalve voor FT4 en FT3. ASAT (11 IU/L), ALAT 
(6 IU/L), ASAT/ALAT-verhouding (0,14) en CRP (0,56 mg/L) gingen omhoog en hun 
veranderingen stonden met elkaar in onderling verband. We concluderen dat de omgang met 
‘oude, milde stressfactoren’, waaronder lichaamsbeweging, dorst, honger en klimaat, invloed 
kan hebben op de immuunstatus en antropometrische- , en metabole- indices kunnen 





Veel CNCD’s worden gezien als ‘ongeneeslijk’ vanwege het heersende dogma dat een 
bepaalde ziekte altijd maar één oorzaak heeft. Deze manier van denken is geïnspireerd op het 
werk van Louis Pasteur (1822–1895), die aantoonde dat een infectieziekte zijn oorsprong vindt 
in één causale factor. Deze factor kan worden aangetoond en bestreden met specifieke 
behandelingen. Echter, de ‘kiemtheorie van ziekte’ zegt alleen maar dat sommige ziekten 
worden veroorzaakt door ziekteverwekkers. Wij geloven dat CNCD’s onbehandelbaar blijven 
als we de nadruk blijven leggen op een enkelvoudige etiologie. We stellen daarom dat CNCD’s 
worden veroorzaakt door multi-metabole antropogene risicofactoren, waaronder niet alleen 
leefstijlfactoren zoals roken, bewegingsarmoede en calorierijke voeding, maar ook 
risicofactoren die iets verder weg staan, zoals politieke, economische, sociale, culturele en 
zelfs evolutionaire factoren. Onze visie komt in grote lijnen overeen met de publicaties van 
Egger et al. (Egger 2012, Egger 2014a, Egger 2014b). Met uitzondering van ziekten met een 
primaire oorzaak gelegen in de genetica (‘aangeboren stofwisselingsziekten’) lijkt het 
theoretisch mogelijk dat elk van ons gezond ouder kan worden en kan sterven van ouderdom. 
De toekomst lijkt er echter niet gunstig uit te zien: het lijkt aannemelijk dat het aantal 
antropogene factoren zal toenemen. Diverse van deze nadelige invloeden lijken 
onvermijdelijk en de meesten van ons zijn niet goed in staat om deze factoren op een 
effectieve manier te beïnvloeden.  
 
Desalniettemin geloven we dat preventie de meest effectieve manier blijft om CNCD’s op te 
lossen. Deze preventieve maatregelen kunnen gericht zijn op het bevorderen van de 
weerbaarheid tegen toxische uitlokkers van het moderne leven. De beste optie zou 
regelmatige blootstelling aan hormetische uitlokkers zijn, zoals we hebben aangetoond in 
onze pilot-interventie de ‘Study of origin’ (Hoofdstuk 3). Het is niet moeilijk, en zou zelfs 
aangenaam kunnen zijn, om enkele van deze intermitterende hormetische uitlokkers te 
integreren in het dagelijks leven. Er komst steeds meer bewijs voor de gezondheidseffecten 
van ‘intermittent living’, waaronder intermittent fasting (Barnosky 2014), intermittent hypoxia 
(Duennwald 2013), intermittent sitting (Henson 2015) en intermittent heat (Laukkanen 2015). 
We stellen voor dat toekomstige onderzoeken zich op dit soort interventies richten en dat 
daarvoor geld beschikbaar komt. Er is echter een enkele aarzeling: de uitkomsten van deze 
interventies kunnen op hun hoogst aantonen dat Darwin gelijk had toen hij stelde dat 
“organismen zich aanpassen aan de leefomstomstandigheden”. Dus wat is de zin van het 
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